Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33300.0 | 2018-04-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2018 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-12-2018-2018-04-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2018. A cash dividend payment of $0.28 per share is scheduled to be paid on May 15, 2018. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 5.66% increase over prior dividend payment. At the current stock price of $59.14, the dividend yield is 1.89%.
The previous trading day's last sale of ABT was $59.14, representing a -8.45% decrease from the 52 week high of $64.60 and a 39.78% increase over the 52 week low of $42.31.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and TiGenix ( TIG ). ABT's current earnings per share, an indicator of a company's profitability, is $.26. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 14.37%, compared to an industry average of 10.1%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Healthcare ETF ( IYH )
Vanguard Health Care ETF ( VHT )
Vanguard Div Appreciation ETF ( VIG )
iShares Global Healthcare ETF ( IXJ )
NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ).
The top-performing ETF of this group is VIG with an increase of 3.67% over the last 100 days. IYH has the highest percent weighting of ABT at 3.1%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 14.37%, compared to an industry average of 10.1%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2018. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $.26. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2018. |
33301.0 | 2018-04-10 00:00:00 UTC | Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings? | ABT | https://www.nasdaq.com/articles/will-buyouts-help-quest-diagnostics-dgx-beat-q1-earnings-2018-04-10 | nan | nan | Quest Diagnostics Inc.DGX is scheduled to report first-quarter 2018 earnings performance before the opening bell on Apr 19.
Last quarter, the company's earnings surpassed the Zacks Consensus Estimate by a penny, delivering a positive surprise of 0.73%. Also, the metric outperformed the consensus mark in all the trailing four quarters with an average beat of 6.83%.
Let's take a look at how things are shaping up prior to this announcement.
Factors at Play
On a positive note, Quest Diagnostics seems well-aligned with its two-point growth agenda to accelerate growth and drive operational excellence.Per its new long-term growth outlook (beyond 2017), revenue increase for the period 2017-2020 is expected to be 3-5% with 1-2% growth projected from acquisitions. Earnings for the period are anticipated to rise faster than revenues in the mid-to-high single digit range.
The company estimates revenue growth for the period 2017-2020 at 3-5%. Per the company, its increasing number of partnerships with other health care leaders and strategic acquisitions is creating promising opportunities for the top and bottom-line growth while improving the patient experience and reducing the overall cost of care.
In this regard, we take a note of two recent strategic M&As by Quest Diagnostics. First, the acquisition of Cleveland HeartLab, which should help strengthen the company's position in the New York metropolitan marketplace. Second, the buyout of Mobile Medical Examination Service MedXM, which should fortify Quest Diagnostics' mobile provider capabilities and population health management solutions for health plans. These two transactions should garner favorable results in the yet-to-be-reported quarter.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote
We are also optimistic about the company's successful execution of its strategy to build esoteric testing business as well as boost profitable growth.
Additionally, Quest Diagnostics has recently witnessed a significant improvement via infectious disease testing, prescription drug monitoring and industry-leading wellness business. Therefore we expect these growth drivers to replicate the company's success story in its upcoming quarterly results, having thus remained active throughout. Also, the performance is likely to drive the same primary metrics like the preceding quarter.
We strongly believe all these recent developments to have significantly contributed to the company's top line in the first quarter.
The company expects 2018 revenues in the range of $7.7-$7.77 billion (annualized growth of 4-5%). The Zacks Consensus Estimate for revenues is pegged at $7.94 billion, ahead of the company's projected range.Excluding the impact of special items, amortization expense and ETB (excess tax benefit associated with stock based compensation), adjusted EPS for the full year is projected in the band of $6.50-$6.70. The Zacks Consensus Estimate of $6.10 falls below this guided range.
On the flip side, after a phase of continual drag for several quarters in the company's revenue per requisition performance, the last three quarters saw a slight rebound. However, it still remains to be seen if this upside is here to stay or not.
The company's two Professional Lab Services engagements - WJ Barnabas Health and HealthONE System of HCA Holdings, Inc. (HCA) - also carry lower revenue per requisition due to the nature of work.
Further, we should take into consideration the persistent headwind of unit price, which was moderately down in less than 100 basis points. Excluding the impact of Protecting Access to Medicare Act of 2014 (PAMA), the company expects unit price headwinds in 2018 to remain below 100 basis points with PAMA adding an extra headwind of approximately 50 basis points to it. This should also get reflected in the first-quarter results.
Overall, we believe that lack of employment and slow growth of commercially-insured lives will continuously affect the company's volumes (measured by the number of requisitions) till the economy turns around for better.
What Our Model Suggests
Per the proven Zacks model, a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP .
Quest Diagnostics has a Zacks Rank #3, which increases the predictive power of ESP and an Earnings ESP of +3.19%, which raises confidence about a positive surprise. Together, the combination suggests that the company is likely to beat on earnings this quarter.
Conversely, we caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Other Stocks Worth a Look
Here are a few other medical stocks worth considering with the right combination of elements to surpass estimates this time around:
Abaxis, Inc. ABAX has an Earnings ESP of +1.56% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3.
Henry Schein HSIC has an Earnings ESP of +3.34% and is a Zacks #3 Ranked player.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Abaxis,Inc. (ABAX): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Additionally, Quest Diagnostics has recently witnessed a significant improvement via infectious disease testing, prescription drug monitoring and industry-leading wellness business. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3. Quest Diagnostics Incorporated Price and EPS Surprise Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote We are also optimistic about the company's successful execution of its strategy to build esoteric testing business as well as boost profitable growth. | Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Quest Diagnostics Incorporated Price and EPS Surprise Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote We are also optimistic about the company's successful execution of its strategy to build esoteric testing business as well as boost profitable growth. | Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. The company expects 2018 revenues in the range of $7.7-$7.77 billion (annualized growth of 4-5%). |
33302.0 | 2018-04-04 00:00:00 UTC | Health Care Sector Update for 04/04/2018: SNN,AMRN,GSK,LLY | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04042018-snnamrngsklly-2018-04-04 | nan | nan | Top Health Care Stocks
JNJ +2.05%
PFE +1.42%
ABT +0.86%
MRK +1.03%
AMGN +3.47%
Health care stocks were mostly higher, including a 1.0% gain for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 were up nearly 1.7% as a group while the Nasdaq Biotechnology index was rising almost 3.2%.
Among health care stocks moving on news:
-Smith & Nephew ( SNN ) still was on negative turf late in Wednesday trading, paring most of a 2% decline earlier in the session after the medical device company today named Namal Nawana to be its new chief executive officer, replacing Olivier Bohuon who had announced his retirement plans six months ago. Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. His appointment begins May 7, when Nawana also will join the Smith and Nephew board as Bohuon steps down from the panel ahead of his planned retirement in November.
In other sector news:
+ Amarin ( AMRN ) was sharply higher Wednesday afternoon, climbing over 9%, after trimming its fiscal Q1 revenue guidance, now estimating around $43 million in net product revenue for the three months ended March 30, rising more than 25% over the first three months in 2017. The new outlook compares with its prior forecast expecting between $45 million to $48 million for Q1 and also lags the Capital IQ consenus by at least $2.7 million. The company also continues to see more than $230 million in FY18 revenue. The Street is at $235.5 million.
+ Eli Lilly ( LLY ) has returned to positive ground in recent trading, clawing back from a decline soon after today's opening bell despite the drugmaker reporting positive results from Phase III for its Cyramza drug candidate in patients with liver cancer, meeting the primary endpoint of the trial of a statistically significant increase in overall survival. It also met its secondary goal of delaying progression of the disease.
+ GlaxoSmithKline ( GSK ) has steadily ground higher during Wednesday trading, recently rising more than 1% after announcing a new collaboration agreement with Kymera Therapeutics to develop Kymera's proprietary Pegasus drug discovery platform. The companies will work together on certain protein degradation targets of mutual interest to discover new drugs in addition to also agreeing to collaborate on E3 ligases, which are enzymes that bind and target disease-causing proteins and marking them for degradation.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. Among health care stocks moving on news: -Smith & Nephew ( SNN ) still was on negative turf late in Wednesday trading, paring most of a 2% decline earlier in the session after the medical device company today named Namal Nawana to be its new chief executive officer, replacing Olivier Bohuon who had announced his retirement plans six months ago. His appointment begins May 7, when Nawana also will join the Smith and Nephew board as Bohuon steps down from the panel ahead of his planned retirement in November. | Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. Health care stocks were mostly higher, including a 1.0% gain for the NYSE Health Care Index in recent trade. + GlaxoSmithKline ( GSK ) has steadily ground higher during Wednesday trading, recently rising more than 1% after announcing a new collaboration agreement with Kymera Therapeutics to develop Kymera's proprietary Pegasus drug discovery platform. | Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. Health care stocks were mostly higher, including a 1.0% gain for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: -Smith & Nephew ( SNN ) still was on negative turf late in Wednesday trading, paring most of a 2% decline earlier in the session after the medical device company today named Namal Nawana to be its new chief executive officer, replacing Olivier Bohuon who had announced his retirement plans six months ago. | Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. Health care stocks were mostly higher, including a 1.0% gain for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: -Smith & Nephew ( SNN ) still was on negative turf late in Wednesday trading, paring most of a 2% decline earlier in the session after the medical device company today named Namal Nawana to be its new chief executive officer, replacing Olivier Bohuon who had announced his retirement plans six months ago. |
33303.0 | 2018-04-02 00:00:00 UTC | Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device | ABT | https://www.nasdaq.com/articles/abbott-starts-guide-hf-clinical-trial-for-cardiomems-device-2018-04-02 | nan | nan | In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. The trial will evaluate the effectiveness of CardioMEMS HF System in improving the survival and quality of life for patients with New York Heart Association (NYHA) Class II - IV heart failure.
Per Abbott, positive results from the trial will help the company in expanding its customer base as well as provide additional clinical evidence to expand coverage for the CardioMEMS HF System.
What is CardioMEMS HF System?
Featuring a small pressure-sensing device, the FDA-approved CardioMEMS HF System allows physicians to monitor pressure changes before the patient's condition deteriorates, lowering the possibility of hospitalization. Notably, the CardioMEMS device has already been proven its effectiveness for patients with NYHA Class III heart failure.
GUIDE-HF Cinical Trial in Detail
The GUIDE-HF clinical trial will enroll 3,600 patients at 140 hospitals with stage C, NYHA Class II-IV heart failure along with either elevated brain-type natriuretic peptide (BNP) levels or prior heart failure hospitalizations in the past year across North America. These patients will be enrolled at 140 hospitals.
A Peek in to Heart Failure Business
This business by Abbott has continued to deliver stable top-line performance in recent times. In the last reported quarter, sales within this business improved double-digits.
Notably, the Heart Failure business accounted for 6.3% of total revenues in the broader Medical Device segment. Under the segment, the company made HeartMate 3 commercially available in the United States. Management also informed about working on expanding indications for the product to include destination therapy for patients who are barred from opting for transplants.
Market Prospects
Per a report by GlobalData published on Drug Development & Delivery, the heart failure market is estimated to reach a value of $11.8 billion by 2025, at a CAGR of 13.7% from 2015 to 2025.
Per the company, over 5.7 million people suffer from heart failure in the United States with around 915,000 more people getting diagnosed with the condition each year. Furthermore, the American Heart Association (AHA) estimates more than 8 million heart failure patients in the United Stated by 2030, with around three million hospitalizations annually.
Thus, positive results from the trial will help Abbott cash in on the opportunities in the heart failure market.
Share Price Movement
Over the past six months, Abbott has been outperforming its industry . The stock has gained 11.5% compared with the industry's 4.8%.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO , athenahealth, Inc. ATHN and Edwards Lifesciences Corporation EW .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. It has long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. It has long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank of 2 (Buy).
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Featuring a small pressure-sensing device, the FDA-approved CardioMEMS HF System allows physicians to monitor pressure changes before the patient's condition deteriorates, lowering the possibility of hospitalization. | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. Furthermore, the American Heart Association (AHA) estimates more than 8 million heart failure patients in the United Stated by 2030, with around three million hospitalizations annually. | In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. GUIDE-HF Cinical Trial in Detail The GUIDE-HF clinical trial will enroll 3,600 patients at 140 hospitals with stage C, NYHA Class II-IV heart failure along with either elevated brain-type natriuretic peptide (BNP) levels or prior heart failure hospitalizations in the past year across North America. | In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Furthermore, the American Heart Association (AHA) estimates more than 8 million heart failure patients in the United Stated by 2030, with around three million hospitalizations annually. |
33304.0 | 2018-04-01 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2018-04-01 | nan | nan | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) battle each other in the marketplace every day. But they also are partners. That's not an unusual scenario in the biopharmaceutical world today.
Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. The two companies face different opportunities and challenges in the years ahead than they have in the past, though. So which big pharma stock is the better buy now?
The case for AbbVie
Investors typically fall into one of three categories: growth, income, or value. AbbVie is one of those relatively rare stocks that offer something to each type of investor.
AbbVie's historical growth stemmed primarily from Humira, the top-selling drug in the world. The autoimmune-disease drug continues to generate 65% of AbbVie's total revenue. And sales for Humira keep growing. AbbVie projects the drug's sales will approach $21 billion by 2020.
Future growth, though, will be driven by other products. At the the top of the list is Imbruvica, which AbbVie co-markets with Johnson & Johnson. Sales for the cancer drug jumped 40% last year and peak annual sales could top $7 billion within a few years. AbbVie's new hepatitis C drug, Mavyret, is expected to become the company's next blockbuster.
AbbVie CFO Bill Chase recently stated that the drugmaker's pipeline has "almost an embarrassment of riches." The list of these "riches" includes endometriosis and uterine fibroids drug elagolix, and autoimmune-disease drugs upadacitinib and risankizumab.
For income-seeking investors, AbbVie offers a dividend that currently yields a little under 4%. Since its spinoff from Abbott five years ago, AbbVie has increased its dividend by a whopping 140%.
The stock is also priced attractively, something value investors would like. AbbVie shares trade at less than 11 times expected earnings. Factoring in the company's growth prospects makes the valuation look even better.
The case for Johnson & Johnson
How does Johnson & Johnson measure up in the three areas of growth, income, and value? Pretty well.
Johnson & Johnson hasn't achieved the rate of earnings growth or stock gains that AbbVie has in recent years. Yet the company appears to be positioned for future growth thanks to acquisitions and a strong pipeline.
Several acquisitions over the past couple of years have boosted J&J's top and bottom lines. The company's medical-device segment acquired Megadyne Medical Products, Torax Medical, and Abbott Medical Optics. Johnson & Johnson's biggest recent acquisition, however, was the $30 billion purchase of Swiss drugmaker Actelion last year.
The company claims several drugs with fast-growing sales, including Imbruvica, multiple myeloma drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. J&J's pipeline includes well over 30 late-stage programs. Some target potential new indications for already-approved drugs such as Darzalex, Imbruvica, and Stelara. Others are testing new drugs, notably including prostate cancer drug apalutamide, which market research firm EvaluatePharma ranked as the No. 2 most valuable pipeline asset in the biopharmaceutical industry.
Johnson & Johnson boasts an impeccable track record when it comes to dividends. The company has increased its dividend for a remarkable 55 consecutive years. J&J's dividend currently yields 2.64%.
As for valuation, J&J stock trades at less than 15 times expected earnings. That's well below the S&P 500 index's average forward-earnings multiple of 17. It's also lower than the average for healthcare stocks in the S&P 500.
Better buy
So far I haven't mentioned some of the challenges facing these companies. But challenges exist for both: AbbVie announced a significant pipeline setback recently, when Rova-T failed in a phase 2 study as a third-line treatment for relapsed/refractory small-cell lung cancer. And Johnson & Johnson's top-selling drug, Remicade, is losing market share to biosimilar competition.
These issues are not insignificant, but I think that both AbbVie and Johnson & Johnson should be able to overcome their respective obstacles.
AbbVie clearly boasts a more attractive dividend and valuation than J&J does. The company's growth prospects also appear to be higher, even with the Rova-T setback. On the other hand, Johnson & Johnson's business spans across healthcare, including consumer products, medical devices, and pharmaceuticals. The healthcare giant is certainly more diversified than AbbVie is, and arguably claims a stronger moat .
My view is that both of these stocks will be winners for long-term investors. If I could choose only one of these stocks, though, I'd go with AbbVie. The company has a compelling growth story (again, even with the uncertainty over Rova-T) and a fantastic dividend. The takeaway: AbbVie has something to offer all types of investors.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. AbbVie CFO Bill Chase recently stated that the drugmaker's pipeline has "almost an embarrassment of riches." But challenges exist for both: AbbVie announced a significant pipeline setback recently, when Rova-T failed in a phase 2 study as a third-line treatment for relapsed/refractory small-cell lung cancer. | Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. AbbVie shares trade at less than 11 times expected earnings. The company claims several drugs with fast-growing sales, including Imbruvica, multiple myeloma drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. | Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. The case for Johnson & Johnson How does Johnson & Johnson measure up in the three areas of growth, income, and value? Johnson & Johnson hasn't achieved the rate of earnings growth or stock gains that AbbVie has in recent years. | Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. The company claims several drugs with fast-growing sales, including Imbruvica, multiple myeloma drug Darzalex, and Stelara, which treats psoriasis and psoriatic arthritis. That's right -- they think these 10 stocks are even better buys. |
33305.0 | 2018-03-29 00:00:00 UTC | Sum Up The Pieces: SPLV Could Be Worth $51 | ABT | https://www.nasdaq.com/articles/sum-pieces-splv-could-be-worth-51-2018-03-29 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares S&P 500 Low Volatility Portfolio ETF (Symbol: SPLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.33 per unit.
With SPLV trading at a recent price near $46.48 per unit, that means that analysts see 10.44% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share. Similarly, CTSH has 12.40% upside from the recent share price of $79.67 if the average analyst target price of $89.55/share is reached, and analysts on average are expecting APH to reach a target price of $95.12/share, which is 12.11% above the recent price of $84.85. Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share. Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). | Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share. Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share. | Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share. |
33306.0 | 2018-03-28 00:00:00 UTC | Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire | ABT | https://www.nasdaq.com/articles/trade-war-fears-grip-medtech-3-stocks-line-fire-2018-03-28 | nan | nan | The trade war cacophony has spread far and wide, not sparing the investment world. The conflict between two of the world's biggest economies has led Dow to fall more than 1,100 point in just two days last week. Although it is gradually recovering, the market is still fraught with possibilities of other outbreaks.
The 10 sectors that have been identified by Trump for imposition of higher tariff are now on investors' radar. Healthcare, including medical equipment, is one of the sectors which might face the brunt of the trade dispute.
Current Scenario
Unlike what most economists had initially expected, China is fast adopting stances to square off America's advantage points in this import tariff game.
In response to Trump's proposed imposition of $60 billion in annual tariffs on Chinese products, Beijing has announced the initial $3 billion of reciprocal tariff on 128 (roughly) imports from the United States and is supposedly preparing a bolder counter-attack.
In the wake of the tariff threats, Nobel Prize-winning economist Robert Shiller has warned of an impending economic crisis.
Meanwhile, a Bloomberg report states that the United States will maintain a lead in the trade conflicts with China. This is because the United States, to some extent, is a monopsony market with a large number of buyers. Thus, if the nation stops purchasing Chinese products, China will not be able to channelize that surplus to Canada or Indonesia at the same price. However, China will not be able to adopt a tit-for-tat strategy as it does not import on the same scale from the United States.
Accordingly, following last week's crash, the market is slowly looking up. The news that the nations are likely to resolve the issue mutually is fuelling the recovery. However, whether the talks will extinguish the possibilities of a trade war completely is yet to be seen. Meanwhile, investors are caught in the "America First" and "Made in China 2025" web.
Is Medical Device Caught in the Storm?
As stated earlier, U.S. Trade Representative Robert Lighthizer has identified healthcare as one of the 10 sectors which are subjected to the $60 billion U.S. tariff. More specifically, Trump has considered biomedicine and high-performance medical devices, which include China's advanced chemicals and medical equipment, respectively.
Needless to say, this has triggered a decline in the sector. Following the news and with chances of China's retaliation, losses were widespread in the Medical device sector with bigwigs taking severe blows. We note that, the sector has gained significantly from profits earned by a number of medical device companies from the BRIC nations.
Going by a Market Realist report, companies like Medtronic plc MDT , Becton, Dickinson and Company BDX , Abbott and others saw considerable weakness on Mar 23 as talks of a U.S.-China trade war started doing the rounds.
Although these stocks are gradually reviving on rising chances of the two nations negotiating certain terms, investors consider them still extremely vulnerable and widely exposed to the trade conflict given their huge business network in Mainland China.
We have shortlisted three stocks that are facing the brunt of the tumultuous market conditions.
Zimmer Biomet Holdings, Inc.ZBH : This Zacks Rank #5 (Strong Sell) lost 6.5% on Mar 23. We note that, the company has been investing heavily to cash in on the Chinese Reconstructive and Trauma markets. Strategic investments in these regions over the past several quarters to improve operational and sales performance are yielding results. In the fourth quarter, the company witnessed improvement in its Asia Pacific business on solid distributor orders. China particularly demonstrated strong growth. Thus, any form of retaliation by China will impact the company.
Zimmer Biomet Holdings, Inc. Price
Zimmer Biomet Holdings, Inc. Price | Zimmer Biomet Holdings, Inc. Quote
Medtronic : In the last reported quarter, Medtronic's businesses in China showed strength, growing double digits. According to the company, within the next decade, China is expected to be its biggest health care market. Needless to say, this Zacks Rank #3 (Hold) company is expending large amounts of cash to strengthen its business in this market. The company is focused on developing public and private partnerships as well as executing channel optimization strategies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. This Zacks Rank #3 stock's core Established Pharmaceuticals Division ("EPD") business operates solely in emerging geographies, with leading positions in Chinese pharmaceutical markets for branded generics. In the last reported quarter as well, China demonstrated double-digit growth in EPD.
Trade war or not, these stocks are in an extremely vulnerable position with a broad network and diversified business base in China.
Abbott Laboratories Price
Abbott Laboratories Price | Abbott Laboratories Quote
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion - more than a 3,800% increase in the previous 12 months. They're now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks' has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic PLC Price Medtronic PLC Price | Medtronic PLC Quote Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Current Scenario Unlike what most economists had initially expected, China is fast adopting stances to square off America's advantage points in this import tariff game. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic PLC Price Medtronic PLC Price | Medtronic PLC Quote Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. Zimmer Biomet Holdings, Inc. Price Zimmer Biomet Holdings, Inc. Price | Zimmer Biomet Holdings, Inc. Quote Medtronic : In the last reported quarter, Medtronic's businesses in China showed strength, growing double digits. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic PLC Price Medtronic PLC Price | Medtronic PLC Quote Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. Going by a Market Realist report, companies like Medtronic plc MDT , Becton, Dickinson and Company BDX , Abbott and others saw considerable weakness on Mar 23 as talks of a U.S.-China trade war started doing the rounds. | Medtronic PLC Price Medtronic PLC Price | Medtronic PLC Quote Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. The conflict between two of the world's biggest economies has led Dow to fall more than 1,100 point in just two days last week. |
33307.0 | 2018-03-27 00:00:00 UTC | Notable ETF Inflow Detected - IWD, ABT, MDT, PNC | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-iwd-abt-mdt-pnc-2018-03-27 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $59.9 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 301,350,000 to 301,850,000). Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $59.9 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 301,350,000 to 301,850,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $59.9 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 301,350,000 to 301,850,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78. |
33308.0 | 2018-03-26 00:00:00 UTC | Is Pfizer's Best Option Now a Consumer Healthcare Spinoff? | ABT | https://www.nasdaq.com/articles/pfizers-best-option-now-consumer-healthcare-spinoff-2018-03-26 | nan | nan | More doors are closing than opening for Pfizer (NYSE: PFE) with regard to the big drugmaker's options for its consumer healthcare business. Pfizer announced in October that it was reviewing strategic alternatives for the unit, including the potential for a sale, a spinoff, or keeping the business.
Selling the unit appeared to be Pfizer's preferred option. The company moved forward with an auction in the hopes of generating up to $20 billion in a sale. However, the front-runner for buying Pfizer's consumer healthcare business, GlaxoSmithKline (NYSE: GSK) , dropped out of the bidding on March 23. Is a spinoff of the unit now Pfizer's best option?
Dropping like flies
In 2006, Pfizer sold its consumer healthcare business to Johnson & Johnson (NYSE: JNJ) for $16.6 billion. That sale included products such as Benadryl, Listerine, Neosporin, and Sudafed. A few years later, though, Pfizer rebuilt its consumer healthcare business with its acquisition of Wyeth.
When Pfizer announced it was looking at another potential sale, Johnson & Johnson was naturally considered to be on the short list of top prospective buyers. However, in January J&J decided against attempting to buy Pfizer's consumer healthcare business. One potential factor in the company's decision was the challenges of overcoming regulators' likely antitrust concerns.
Reckitt Benckiser withdrew from bidding on Pfizer's consumer unit only days before GlaxoSmithKline. The British drugmaker stated that it had offered to buy part of Pfizer's consumer business but not all of it. Pfizer wasn't agreeable to only selling off part of the business, so another potential buyer was crossed off the list.
Reckitt's exit left GlaxoSmithKline as the most likely candidate to win Pfizer's consumer unit. However, GSK CEO Emma Walmsley's statement that potential deals "must meet our criteria for returns and not compromise our priorities for capital allocation" hints that the price tag was too high for the company.
Who's left?
In Pfizer's Q3 conference call , CEO Ian Read stated that he expected "broad interest from potential acquirers." But with J&J, GlaxoSmithKline, and Reckitt Benckiser out of the running, who's left?
Nestle is one name that's been mentioned. While Nestle is known primarily as a food company, it has taken steps in recent years to expand into healthcare. The company's Nestle Health Sciences subsidiary develops nutritional products and has invested in other pure-play healthcare organizations. In addition, Nestle CEO Mark Schneider's background is in healthcare. Schneider served as CEO of Fresenius before taking the helm at Nestle.
Procter & Gamble (NYSE: PG) is another prospective acquirer. Pfizer's products, including Advil, Centrum, Nexium, and Robitussin, appear to be solid additions to P&G's current consumer healthcare lineup, which include Metamucil, Nyquil, Pepto-Bismol, and Prilosec.
One other possibility is Abbott Labs (NYSE: ABT) . Abbott's current primary consumer focus is on nutritional products, and Pfizer's consumer healthcare products would bring a different flavor to Abbott's offerings.
And there's still another option for Pfizer -- turning to private equity funds. Although most of the buzz has centered on big names like J&J, GlaxoSmithKline, and others, private equity could very well be on the table.
Spinoff alternative
However, it's entirely possible that Pfizer simply won't get the price it wants for the consumer business. I suspect that's what we're seeing with the GlaxoSmithKline exit. Spinning off the consumer healthcare unit could be the best alternative for Pfizer shareholders.
Pfizer CFO Frank D'Amelio stated a few months ago that this was exactly what happened with the company's animal health business. He noted that Pfizer received offers it considered to be too low and opted to spin off the business as a separate entity, called Zoetis , rather than sell it for a lower price.
That has turned out to be a smart move. Zoetis stock is up more than 150% since the spinoff in 2013. During the same period, Pfizer's share price has increased only 25%.
There's no guarantee, however, that a spinoff of the consumer healthcare business would be as successful as the Zoetis spinoff. It's a totally different ballgame to market consumer products than to sell primarily to veterinarians and livestock producers.
The option no one wants
Of course, there is one other alternative for Pfizer -- keeping the consumer healthcare business. I think it's fair to say that it's the one option no one wants.
Pfizer hasn't really wanted to be in the consumer healthcare business for years. That's why the company sold its consumer unit to J&J more than a decade ago. Shareholders would see it as a negative if Pfizer retained the business after announcing that it was evaluating strategic alternatives.
My view is that Pfizer really would rather sell the consumer unit than spin it off. But the company might not be able to get the $20 billion it wants. Would Pfizer settle for less -- perhaps $18 billion? We'll find out soon enough. It's now past the deadline for bids from potential acquirers.
Pfizer will make a decision this year. If a sale isn't announced within the next few months, a spinoff could be the next best thing.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other possibility is Abbott Labs (NYSE: ABT) . More doors are closing than opening for Pfizer (NYSE: PFE) with regard to the big drugmaker's options for its consumer healthcare business. However, GSK CEO Emma Walmsley's statement that potential deals "must meet our criteria for returns and not compromise our priorities for capital allocation" hints that the price tag was too high for the company. | One other possibility is Abbott Labs (NYSE: ABT) . However, the front-runner for buying Pfizer's consumer healthcare business, GlaxoSmithKline (NYSE: GSK) , dropped out of the bidding on March 23. Dropping like flies In 2006, Pfizer sold its consumer healthcare business to Johnson & Johnson (NYSE: JNJ) for $16.6 billion. | One other possibility is Abbott Labs (NYSE: ABT) . However, the front-runner for buying Pfizer's consumer healthcare business, GlaxoSmithKline (NYSE: GSK) , dropped out of the bidding on March 23. Dropping like flies In 2006, Pfizer sold its consumer healthcare business to Johnson & Johnson (NYSE: JNJ) for $16.6 billion. | One other possibility is Abbott Labs (NYSE: ABT) . The option no one wants Of course, there is one other alternative for Pfizer -- keeping the consumer healthcare business. My view is that Pfizer really would rather sell the consumer unit than spin it off. |
33309.0 | 2018-03-22 00:00:00 UTC | Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK | ABT | https://www.nasdaq.com/articles/baxter-bax-closes-acquisition-of-recothrom-preveleak-2018-03-22 | nan | nan | Baxter International Inc.BAX has completed the acquisition of two hemostat and sealant products from Mallinckrodt plc to widen its existing surgical portfolio of hemostats and sealants, especially for intraoperative bleeding. Notably, the company bought RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant product lines from Mallinckrodt.
Baxter expects the deal to be modestly accretive to its 2018 adjusted earnings. Thereafter, the transaction deal will increasingly add capabilities to Baxter's portfolio, driving its bottom line in turn.
The Deal in Detail
Baxter is buying RECOTHROM and PREVELEAK for an upfront payment of approximately $153 million and potential contingent payments in the near future. The deal was announced earlier in January.
Baxter now gains major traction from RECOTHROM's (only stand-alone recombinant thrombin) buyout, providing more options of innovative hemostatic products to surgeons for dealing with severities of bleeding. PREVELEAK (used in vascular reconstruction) complements the company's existing portfolio of advanced surgical sealants.
Baxter's Surgical Portfolio
Baxter's surgical portfolio includes products like FLOSEAL Hemostatic Matrix, TISSEEL Fibrin Sealant, COSEAL Surgical Sealant and VASCU-GUARD Patch among others. The portfolio is composed of hemostasis (addressing bleeding), tissue sealing and hard tissue regeneration as well as soft tissue repair and microsurgery with products available in nearly 60 countries.
The company consistently endeavors to improve its Advanced Surgery business. For 2018, the company expects advanced surgery business to increase 3-4% on constant currency basis.
Baxter has also announced plans to focus on launching advanced surgery products in Japan in the coming days.
Market Potential
Per a CISION report, the Global Surgical and Medical device market is anticipated to witness a CAGR of 5.93% over the forecast period of 2017-2026, reaching a worth of $828.6 billion by 2026. Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT .
Stock Performance & Estimate Revision
Shares of Baxter have outperformed the industry in the past year. The stock has rallied 28.6%, outperforming the S&P 500's 15.9% gain and the broader industry's 16.4% rise.
The company's estimate revision trend for the current year has been positive. In the past couple of months, nine analysts moved north with no revision in the opposite direction. Earnings estimates rose around 2.9% to $2.78.
Zacks Rank & Other Key Picks
Baxter carries a Zacks Rank #2 (Buy). Two other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO and Varian Medical Systems, Inc. VAR .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank of 2.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company bought RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant product lines from Mallinckrodt. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT . Baxter's Surgical Portfolio Baxter's surgical portfolio includes products like FLOSEAL Hemostatic Matrix, TISSEEL Fibrin Sealant, COSEAL Surgical Sealant and VASCU-GUARD Patch among others. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT . Baxter International Inc.BAX has completed the acquisition of two hemostat and sealant products from Mallinckrodt plc to widen its existing surgical portfolio of hemostats and sealants, especially for intraoperative bleeding. | Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company bought RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant product lines from Mallinckrodt. |
33310.0 | 2018-03-22 00:00:00 UTC | Can Boston Scientific's Pain be a Boon for Edwards & Others? | ABT | https://www.nasdaq.com/articles/can-boston-scientifics-pain-be-boon-edwards-others-2018-03-22 | nan | nan | The transcatheter aortic valve replacement (TAVR) market, which is projected to witness CAGR of 18.3% between 2017 and 2022 (per a report by Azoth Analytics published on ReportsnReports), has been constantly under the radar of market experts, courtesy of the stir caused by one of the forerunners within this space - Boston Scientific Corporation BSX .
Last February, the company voluntarily recalled all its core Lotus Valve devices, including Lotus with Depth Guard. This dragged down its shares by 9.4% in the pre-market trading session (per an article on Medical Device and Diagnostic Industry).
Sadly, again in November, Boston Scientific announced a further delay in the re-launch of the LOTUS Edge Aortic Valve System after it failed to meet the committed timeline, hurting shareholder sentiments even more. Per an article on the Medical Device and Diagnostic Industry, the company had opted out from the Piper Jaffray healthcare conference in New York on the same day, pulling down the stock by 7.5%, which was followed by a decline in its market cap by around $2.9 billion.
Meanwhile, rejoicing at this situation is Edwards Lifesciences Corporation EW , a leading player in the TAVR market. Encouragingly, the company's shares have soared 45.4% since Lotus Valve devices' recall last February.
Let's take a sneak peek into what's brewing in this market for investors who are keen to effectively put in their money in the healthcare space.
The Backdrop
Boston Scientific has been consistently dominating headlines on developments in the Lotus Valve devices, though for all the unpleasant reasons. Last February, the company had to call back all Lotus Valve devices due to issues related with the premature release of a pin which connects Lotus Valve to the delivery system. However, this was not the first time when the company had to face such a situation.
Earlier in 2016, the company had to retract the Lotus Edge Valve system on similar grounds. Even in 2014, it had to face the brunt of the FDA's order and withdraw 278 units of Lotus Valve from circulation in Europe, due to the Lotus Valve getting unlocked from the delivery system during release.
The company has also been disappointing investors by continuously delaying the filing of the premarket approval (PMA) with FDA for the Lotus Edge Valve system.
Currently, the company expects LOTUS Edge to be back in the European market not before 2019. It also intends to roll out the same in the United States in the same year.
Nevertheless, some major market analysts believe such numerous product missteps have always ended up tarnishing the brand image, along with deviated customer and clinician interests.
Edwards Lifesciences -Seizing the Opportunities
While Boston Scientific hit a rough patch on issues surrounding its Lotus Valve devices in 2017, Edwards Lifesciences reaped the maximum benefits from its solid Transcatheter Heart Valve Therapy (THVT) platform. During the company's annual investor conference, its chairman and CEO Michael A. Mussallem noted, "As we come to the end of 2017, our performance and accomplishments this year significantly exceeded our expectations, and we expect 2018 to be another strong year for Edwards Lifesciences." "The primary factor driving the company's global growth is the prospering transcatheter aortic valve therapy business," he further asserted.
In this regard, management currently projects sales of $2.1-$2.4 billion in Transcatheter Heart Valve Therapy in 2018.
Moreover, Edwards Lifesciences expects the global TAVR opportunity to be more than $5 billion by 2021. And to make the most of it, the company has been firing on all cylinders, lately.
In line with this, Edwards Lifesciences has its near-term product pipeline on track. It expects that the new SAPIEN 3 Ultra system, featuring an on-balloon delivery system and next-generation sheath technology, will be launched in the United States and Europe later this year. Also, the company anticipates to begin the U.S. pivotal trial for the CE Marked CENTERA valve system in 2018. Furthermore, Edwards Lifesciences expects results from its PARTNER 3 trial of the SAPIEN 3 valve to be presented at ACC 2019, followed by the FDA's approval later that year.
We note that some market speculators believe Edwards Lifesciences' solid global presence, particularly in high-potential regions like Europe and Japan, along with delay in the comeback of some key competitive products like Boston Scientific's Lotus Valve, will help the company further cement its hold in the highly potential TAVR space.
Other Major Players Riding the Gains
Medtronic plc MDT , with its CoreValve Evolut TAVR platform comprising the CoreValve, CoreValve Evolut R and the CoreValve Evolut PRO systems, has well maintained the company's position as a formidable player in the TAVR space. Per an article by Reuters, shares of Medtronic had inched up 1% on Boston Scientific's announcement of the withdrawal of Lotus Valve devices, last February. Notably, the company recorded TAVR growth in the mid-20s in the United States and low 40s in international markets, in the last reported quarter.
Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space.
Boston Scientific - A Rebound in the Cards?
As Winston Churchill had rightly said,"All men make mistakes, but only wise men learn from their mistakes."
Unwilling to let go of the bountiful opportunities in the TAVR market, Boston Scientific acquired Symetis SA, a structural heart company focused on minimally-invasive TAVR devices, in 2017. The company has started selling ACURATE neo Aortic Valve in Europe. It is also working on designing the ACURATE neo 2 Aortic Valve System equipped with an enhanced outer sealing skirtfeature.
Moreover, Boston Scientific is looking forward to leveraging on its existing LOTUS infrastructure to enhance the ACURATE neo AS Valve system through better field support, geographic expansion and next-generation products. The company plans to invest in the United States and Japan trials as well.
Will ACURATE Replace Lotus?
However, several opinions have been making rounds in the TAVR space, of late. Some market experts believe the company will eventually replace the Lotus Valve devices with the Symetis' portfolio, while others speculate that the deal has been clinched to cushion it from the jitters which might stem from the Lotus Valve devices' withdrawal. A few analysts are also of the opinion that Boston Scientific expended the huge amount on the Symetis buyout deal to use it as a contingency plan in case the Lotus Valve device issue remains unresolved.
Nonetheless, dismissing all such speculations, Boston Scientific has been consistently emphasizing on the Symetis acquisition as a move to broaden its TAVR suite and not a replacement of Lotus Valve devices.
To end all speculations, let's wait and watch to find out whether or not Boston Scientific's Lotus (valve) will find the right weather to bloom again.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Per an article on the Medical Device and Diagnostic Industry, the company had opted out from the Piper Jaffray healthcare conference in New York on the same day, pulling down the stock by 7.5%, which was followed by a decline in its market cap by around $2.9 billion. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space. Other Major Players Riding the Gains Medtronic plc MDT , with its CoreValve Evolut TAVR platform comprising the CoreValve, CoreValve Evolut R and the CoreValve Evolut PRO systems, has well maintained the company's position as a formidable player in the TAVR space. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space. We note that some market speculators believe Edwards Lifesciences' solid global presence, particularly in high-potential regions like Europe and Japan, along with delay in the comeback of some key competitive products like Boston Scientific's Lotus Valve, will help the company further cement its hold in the highly potential TAVR space. | Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, rejoicing at this situation is Edwards Lifesciences Corporation EW , a leading player in the TAVR market. |
33311.0 | 2018-03-20 00:00:00 UTC | Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW | ABT | https://www.nasdaq.com/articles/abbotts-mitraclip-therapy-wins-reimbursement-nod-from-mhlw-2018-03-20 | nan | nan | The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. The move is likely to improve the company's Structural Heart business.
MitraClip is a FDA approved and CE Marked system. Also in nearly 50 countries, more than 50,000 people have been treated with the MitraClip. MHLW approved the MitraClip System in Japan in November 2017.
What is MitraClip?
MitraClip therapy is used to treat patients with mitral regurgitation. The reimbursement will be effective from April 1, 2018 in Japan. This reimbursement will entitle patients to access the therapy through the country's health insurance plans.
Per the company, mitral regurgitation is a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart.
The MitraClip system is approved in Japan for the treatment of both severe degenerative mitral regurgitation ("DMR") and functional mitral regurgitation ("FMR") heart diseases.
A Glimpse of the Structural Heart Business
Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business.
Sales improvement at this segment was driven by double-digit growth in Heart Failure, Electrophysiology, Structural Heart, Neuromodulation and Diabetes Care in the last quarter.
Notably, the Structural Heart business accounted for 9.3% of total revenues in the Medical devices segment. The upside was led by continued double-digit growth of MitraClip. We believe the latest development will boost the company's top line.
Recently, the company announced the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. With the approval, the company has expanded the Masters Series portfolio under the Structural Heart business.
Market Prospects
Per a report by Allied Market Research, Tanscatheter Mitral Valve Repair & Replacement Market is estimated to worth $1,878 million (both repair and replacement valves) by 2023, at a CAGR of 30% from 2017 to 2023. A noteworthy company in this space is Edwards Lifesciences Corporation EW .
Share Price & Estimate Revision Trend
Abbott has been gaining investor confidence on consistent positive results. Over the last three months, the stock has outperformed the industry . The stock has moved up 9.4%, in comparison with the broader industry's 4.1% gain.
The current estimate revision trend is favorable. For the current year, 12 estimates moved north compared with one movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has risen 1.1% to $2.86 per share.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO and Varian Medical Systems, Inc. VAR .
Bio-Rad Laboratories sports a Zacks Rank of 1(Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, the company announced the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. A Glimpse of the Structural Heart Business Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. The MitraClip system is approved in Japan for the treatment of both severe degenerative mitral regurgitation ("DMR") and functional mitral regurgitation ("FMR") heart diseases. | The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. What is MitraClip? |
33312.0 | 2018-03-20 00:00:00 UTC | Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus | ABT | https://www.nasdaq.com/articles/goldman-sachs-backs-emerging-markets-medtech-stocks-focus-2018-03-20 | nan | nan | Emerging market investment has taken a backseat of late, thanks to the nonstop blows to the economy. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States.
Going by the MSCI Emerging Markets Index, the last five-year annualized growth rate was just 5.02%. On the other hand, GDP per capita growth rate over the last five years for the United States was 5.83% (International Monetary Fund World Economic Outlook Database).
In the face of such adversities, Goldman Sachs' statement to Bloomberg last week, addressing emerging market stocks as world's best bet, has created quite a stir in the investment world. According to the report, following the selloff in February and unlike other market corrections, investors are keen to put money in riskier assets of the emerging economy this time around.
Although the MSCI Index has not shown any significant improvement since then, the comment by Sheila Patel, chief executive officer of International GSAM, has forced investors to think all over again before taking their assets out of this market.
Going by the Bloomberg report, Goldman Sachs is particularly betting on Indian healthcare firms, Mexican consumer stocks and Argentine debt. "She expects India's government will boost spending on public health under Prime Minister Narendra Modi. And although political risks can't be ignored investors' pessimism toward Mexico and Argentina is overdone"- the report says.
Emerging Market Healthcare Scenario Way Better Than the United States
While Patel particularly talked about the growing prospects of the Indian healthcare market, data shows that the prospects of the broader emerging market are equally encouraging. On the contrary, the healthcare scenario in the United States is muddled.
A survey report by Gallup Analytics last July revealed that U.S. adults cited healthcare as the second major problem faced by the country under the new presidential administration. Following the new healthcare reform announcement in December, a Gallup poll the next month stated that the past decade marked the biggest increase in the uninsured rate. Whatever the new healthcare reform may bring in, the near-term scenario remains pretty unclear as of now.
Meanwhile, with exploding population, rising middle class and increasing governmental awareness of health issues, emerging geographies are facing huge demand for modern but cheaper healthcare options. Going by a report in The Guardian, International Finance Corp's (IFJ) data shows that developing countries account for 80% of global deaths from chronic diseases indicating enormous market opportunity.
Emerging Market Openings for MedTech
Per a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India, the fifth largest MedTech market in the world, currently records 17% annual growth. At this pace, India may emerge as a strong competitor to Japan and Germany by 2022.
Among other emerging geographical regions, Latin America, even in the face of economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, Central and South American nations significantly increased per capita spending on healthcare between 2008 and 2014.
Given the huge potential in these regions, long back, Johnson & JohnsonJNJ had set up manufacturing and R&D centers in India, China and Brazil. The company's emerging markets medical device segment continues to grow three to four times faster than the developed markets.
AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. In the recent quarters, sales in key emerging markets were up in double digits, driven by strength in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
At MedtronicMDT , in the second quarter of fiscal 2018, businesses in China, Latin America, and Southeast Asia showed sustained strength, growing in double digits. Overall, Medtronic's long-term outlook on emerging markets is encouraging.
Boston Scientific 's BSX emerging markets' business registered 13% organic growth in fourth-quarter 2017, reflecting a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 19% year over year).
Conclusion
The growth pace of the emerging market has declined from the pre-financial crisis years. However, this market has historically played a crucial role for large corporations by hedging their international trade risk. According to a BCG report, going forward, emerging market GDP is projected to grow around 2% faster than that of developed economies. The market will account for around 40% of total consumer spending - more than $20 trillion by 2020. From an investor point of view, it will be imprudent to disregard the immense growth potential of the emerging economy due to the occasional rough spots.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Emerging Market Healthcare Scenario Way Better Than the United States While Patel particularly talked about the growing prospects of the Indian healthcare market, data shows that the prospects of the broader emerging market are equally encouraging. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Emerging Market Healthcare Scenario Way Better Than the United States While Patel particularly talked about the growing prospects of the Indian healthcare market, data shows that the prospects of the broader emerging market are equally encouraging. | AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Emerging Market Healthcare Scenario Way Better Than the United States While Patel particularly talked about the growing prospects of the Indian healthcare market, data shows that the prospects of the broader emerging market are equally encouraging. |
33313.0 | 2018-03-19 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2018-03-19 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on GPC - FREE
Get the latest Zacks research report on ATO - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on GPC - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on GPC - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on GPC - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33314.0 | 2018-03-17 00:00:00 UTC | 2 Stocks That Pay You | ABT | https://www.nasdaq.com/articles/2-stocks-pay-you-2018-03-17 | nan | nan | We sink a lot of money into stocks, so it's nice when they turn around and pay us . These companies are not making random donations to our welfare -- I'm talking, of course, about dividends.
There are many stocks that distribute payouts on a regular basis. Some of the most reliable of these issuers are the Dividend Aristocrats, that small, elite group of S&P 500 stocks that have raised their distributions at least once annually for a minimum of 25 years in a row. Here is a pair of stocks in this regal bunch I think will continue to hike their payouts, while demonstrating strong potential to grow their core fundamentals.
McDonald's
Not long ago, fast-casual restaurant chain operators were all the rage on the stock market -- witness the price appreciation of Chipotle Mexican Grill and Shake Shack at various points earlier this decade. Such companies stole the thunder away from McDonald's (NYSE: MCD) , which many considered to be a faded operator selling unhealthy food that was out of step with the times.
What a difference a few years make. Moves like the introduction of both higher-quality and bargain menu items and the rollout of all-day breakfast have brought diners back into the restaurants. It's also opened their wallets -- global comparable-store sales rose by 5.5% in fiscal 2017, in the midst of a restaurant recession , no less.
Going forward, a refranchising push -- in which company-owned stores are sold to franchisees, in keeping with the company's classic business model -- should save costs while raising profit margins. Another cost-cutting move, the installation of ordering kiosks at restaurants, should also help in this regard.
And the more McDonald's can save while boosting its overall results, the more cash it should have on hand for its quarterly dividend. Which, by the way, pays out nicely, with a yield of 2.6%.
Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a more narrowly focused company than it used to be. In the old days, it was a sprawling pharmaceutical and medical devices maker. Then in 2013, it spun off its research-based pharma operations into a separate, publicly traded company, AbbVie . Abbott Labs held on to the remainder, chiefly the legacy device business.
Abbott Labs might not be as cutting-edge and exciting as its swashbuckling corporate sibling, but it delivers for its shareholders. The company's fiscal 2017 saw it grow its sales by nearly 5% on a year-over-year basis -- even incorporating a top acquisition last year, device maker St. Jude Medical -- to $27.4 billion. Adjusted earnings rose by a healthy 9% to $4.4 billion for a good net profit margin of 16%.
And while Abbott Labs has a lower profile than its spinoff, this doesn't mean it isn't innovative. Late last year the U.S. Food and Drug Administration (FDA) approved its Freestyle Libre Flash , a continuous glucose monitoring system for diabetics that eliminates the need for constant finger pricks to analyze blood sugar. This is a game-changer in the diabetes market, and will certainly help the company's fundamentals.
It'll also help support the quarterly dividend, which has doubled from $0.14 to $0.28 since the 2013 split. At the moment, Abbott Labs' payout yields 1.8%.
A list of winners
Although the future prospects and current yields of the Dividend Aristocrats vary greatly, most of them are steady operators in their fields that emphasize shareholder payouts. As such, they make for an ideal list from which to source income-promising investment ideas like the two aforementioned stocks.
10 stocks we like better than McDonald's
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and McDonald's wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Chipotle Mexican Grill. The Motley Fool is short shares of Shake Shack. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a more narrowly focused company than it used to be. McDonald's Not long ago, fast-casual restaurant chain operators were all the rage on the stock market -- witness the price appreciation of Chipotle Mexican Grill and Shake Shack at various points earlier this decade. Going forward, a refranchising push -- in which company-owned stores are sold to franchisees, in keeping with the company's classic business model -- should save costs while raising profit margins. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a more narrowly focused company than it used to be. McDonald's Not long ago, fast-casual restaurant chain operators were all the rage on the stock market -- witness the price appreciation of Chipotle Mexican Grill and Shake Shack at various points earlier this decade. At the moment, Abbott Labs' payout yields 1.8%. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a more narrowly focused company than it used to be. McDonald's Not long ago, fast-casual restaurant chain operators were all the rage on the stock market -- witness the price appreciation of Chipotle Mexican Grill and Shake Shack at various points earlier this decade. The company's fiscal 2017 saw it grow its sales by nearly 5% on a year-over-year basis -- even incorporating a top acquisition last year, device maker St. Jude Medical -- to $27.4 billion. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a more narrowly focused company than it used to be. At the moment, Abbott Labs' payout yields 1.8%. 10 stocks we like better than McDonald's When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. |
33315.0 | 2018-03-15 00:00:00 UTC | Noteworthy ETF Inflows: IHI, ABT, BDX, SYK | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-ihi-abt-bdx-syk-2018-03-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $85.7 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 9,050,000 to 9,500,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $85.7 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 9,050,000 to 9,500,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $85.7 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 9,050,000 to 9,500,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81. |
33316.0 | 2018-03-13 00:00:00 UTC | 10 Dividend Aristocrats You Never Have to Worry About | ABT | https://www.nasdaq.com/articles/10-dividend-aristocrats-you-never-have-to-worry-about-2018-03-13 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There's nothing more thrilling than being able to tell the tale of an incredible stock trade that dished out massive, short-term gains. Though most of these proverbial "whale hunts" don't pan out as initially hoped, enough of them do to keep investors ever-searching for them.
The fact of the matter is, however, for many investors the bulk of their total investing profits reaped for the long haul will come from dividends… even dividends that are reinvested in the companies paying them. As the old adage goes, slow and steady wins the race.
With that as the backdrop, here's a rundown of the market's highest-quality dividend stocks … dividend payers that could be considered the aristocrats among the market's income-oriented investments.
My 7 Must-Own Stocks to Build Up Your Retirement
They may ebb and flow from one year to the next, and none of them make for splashy headlines. If you're willing to sit back and let time do the work for you though, these are names you'll eventually be glad you own.
Source: Flickr
Dividend Aristocrats to Buy: Abbott Laboratories (ABT)
It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. It also makes a variety of artificial heart valves, stents and catheters . The average investor can't name one of its products, though.
But it doesn't matter. Its mix of products is always in demand, keeping cash flowing nicely in almost any economic environment. That's how the company was able to raise its quarterly dividend for the 46th year in a row … a decision announced late last year .
The yield of 1.8% isn't red hot, but there's a lot to be said for reliability.
Source: Dean Hochman via Flickr (Modified)
Dividend Aristocrats to Buy: 3M Co (MMM)
Name any kind of industrial or consumer product you can think of, and 3M Co (NYSE: MMM ) either makes it or supports the companies that make it. Stethoscopes, Post-Its, army helmets, electrician's supplies and cleaning supplies are just some of the things it sells .
It can always find customers, in good times and bad, despite the fact that nothing it sells is particularly exciting. That's how the company has managed to raise its annual dividend every year since 1977 .
Better still, 3M can afford to dish out what it's paying shareholders. Its payout ratio - the amount of earnings passed along to shareholders as dividend - for the past twelve months has been less than 60% of its profits , and that's actually above the company's typical payout.
10 Bulletproof Blue-Chip Growth Stocks to Invest In
That leaves plenty of room for the company to invest in its own growth.
Source: Shutterstock
Dividend Aristocrats to Buy: Kimberly Clark Corp (KMB)
Most everyone knows Kimberly Clark Corp (NYSE: KMB ) is a paper company. Not everyone fully appreciates the depth of its product base though, nor all the brands under its umbrella . Depends diapers for adults, Kotex tampons, Kleenex and Scott paper towels are just a few of the labels owned by the company.
It's this diversity that's allowed the paper giant to smooth out some of the ebbs and flows other players in and out of its industry have suffered. The end result is a company that's slowly but surely increased its dividend payout going all the way back to the early 70's .
And, with a current yield of 3.6%, newcomers are getting in at a relatively cheap price.
Source: Shutterstock
Dividend Aristocrats to Buy: Visa Inc (V)
Between the advent of Bitcoin and other cryptocurrencies along with the ongoing growth of online payment options like PayPal, it seems credit card middlemen like Visa Inc (NYSE: V ) are approaching obsolescence.
That's not how it works though. Indeed, Visa provides the very connection framework between consumers and merchants that PayPal needs to become even more mainstream . And, though its initial relationship with cryptocurrency players has been a strained one, the fact that Visa is even bothering to experiment with them suggests it's preparing for a future that's very different than the present.
10 Stocks That Are Screaming Buys Right Now
In other words, Visa's going to be fine, and so is its dividend … a dividend that's been paid, and increased, quite consistently going all the way back to 2008 .
Source: VEX Robotics via Flickr
Dividend Aristocrats to Buy: Texas Instruments Incorporated (TXN)
When investors think of technology stocks, game-changing names like Intel Corporation (NASDAQ: INTC ) or NVIDIA Corporation (NASDAQ: NVDA ) tend to come to mind. They're sexy, and they make for splashy headlines.
That's fine, but the volatility pendulum swings in both ways, particularly in the tech world. Income-oriented investors seeking safe, reliable exposure to the technology sector may want to consider Texas Instruments Incorporated (NASDAQ: TXN ), tapping into its current dividend yield of 2.3%.
No, it doesn't make the newest computer processors, nor is it waist-deep into artificial intelligence. It's still the king of calculators and clocks (though they're high-tech industrial and scientific clocks these days). That's the point. The boring stuff always sells. That's how Texas Instruments boasts a string of steady dividend payouts and increases going all the way back to 1971 .
Source: Dawn Via Flickr
Dividend Aristocrats to Buy: Johnson & Johnson (JNJ)
Like Texas Instruments, Johnson & Johnson (NYSE: JNJ ) may be one of the most boring health product companies an investor could think of. And like Texas Instruments, that's the point.
For the record, though the average investor would struggle to name even just one of them, J&J does make and market prescription drugs. (Remicade, for a variety of gastrointestinal problems, is the big one, by the way, driving $6.3 billion worth of revenue last year. Past that, the sales contribution of its other pharmaceutical drops off in a hurry.)
10 Best Stocks Under $10
Its mainstays, however, are the more familiar products like its baby shampoo, Band-Aids and Tylenol … the things people buy over and over again without a second thought. That's how Johnson & Johnson has mustered nearly five straight decades' worth of annual payout increases .
Source: Shutterstock
Dividend Aristocrats to Buy: Consolidated Edison, Inc. (ED)
One would think a utility provider's revenue history would be one of slow-and-steady increases. One would be wrong, though. Due to ever-changing rates and production costs, New York power provider Consolidated Edison, Inc. (NYSE: ED ) sports a surprisingly volatile top line .
Take a look at the bottom line though, and things not only stabilize, they show that slow and steady growth you'd expect to see from a company that effectively no household can refuse to buy from.
The company's dividend growth has been just as consistent, up almost every year going back to the 90's.
The kicker: If the economy takes off in 2018 and President Trump is able to restore the United States' former manufacturing greatness, demand for electrify will ramp up, bolstering Consolidated Edison's bottom line even without rate increases.
Source: Mark Hunter via Flickr (Modified)
Dividend Aristocrats to Buy: Stanley Black & Decker, Inc. (SWK)
One would think a toolmaker like Stanley Black & Decker, Inc. (NYSE: SWK ) would suffer too many cyclical ups and downs to be one of the market's better dividend stocks. Indeed, one wouldn't expect a toolmaker to be pegged as a dividend stock to begin with. One would be wrong on both counts, however.
Yes, Stanley Black & Decker saw a slight - and only a slight - revenue lull between 2000 and 2002 when it was still just Stanley, while other companies were in dire straits. The company took a slightly harder hit in 2009 following the fallout from the subprime mortgage meltdown. By the next year though, thanks to the merger of Stanley Works and Black & Decker, the combined company was on pace to record revenue. It never really looked back either, with last year's $12.7 billion in sales being yet another record.
7 Future Stalwart Stocks to Arm Your Portfolio With
The end result is 50 straight years of rising dividends , with profits far in excess of its dividend in almost all of those quarters. Tools are a more resilient business than you might suspect.
Source: Shutterstock
Dividend Aristocrats to Buy: Walmart Inc (WMT)
The world's biggest retailer, Walmart Inc (NYSE: WMT ), has struggled with its sheer size in the past. Just a few years ago, lousy customer service and bare shelves were not only the norm , but a mere symptom of how out-of-touch management had become with what's happening at the proverbial front.
Since then the company has fixed the vast majority of its woes, with last quarter's same-store sales growth of 2.6% serving as the evidence. It would be naive, however, to think that Walmart won't eventually fall into the same trap again at some point in the future.
So how does the retailer deserve a spot on a list of dividend stocks that are better than any others?
Because being the biggest is about 80% of the retail battle. As long as the company continues to learn from its mistake, its dividend growth is more than adequately shielded.
That dividend has grown every year for the past 29 years, by the way .
Source: Shutterstock
Dividend Aristocrats to Buy: Microsoft Corporation (MSFT)
Last but not least, add Microsoft Corporation (NASDAQ: MSFT ) to any list of dividend stocks that's become stunningly reliable. Yes, Microsoft, the former software giant that's slowly but surely entrenching itself as a cloud play.
That's not what makes Microsoft a budding dividend aristocrat though. It's the nature of its new business model. Many of its new products like Office 365 and access to its Azure cloud-management platform are sold and billed as "software as a service," or SaaS. These billing cycles are either monthly or quarterly, and are recurring with a high level of customer loyalty. Recurring revenue is what makes a dividend stock a reliable payer.
The current yield of 1.7% isn't earth-shattering, but surprisingly enough, Microsoft boasts one of the most consistent dividend-growth trends not just among tech stocks, but among all industries.
10 Dividend-Payers to Own for Month-to-Month Income
That trend is only going to solidify as more recurring revenue products are launched.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter , at @jbrumley.
Compare Brokers
The post 10 Dividend Aristocrats You Never Have to Worry About appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: Flickr Dividend Aristocrats to Buy: Abbott Laboratories (ABT) It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. Income-oriented investors seeking safe, reliable exposure to the technology sector may want to consider Texas Instruments Incorporated (NASDAQ: TXN ), tapping into its current dividend yield of 2.3%. | Source: Flickr Dividend Aristocrats to Buy: Abbott Laboratories (ABT) It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. Source: Shutterstock Dividend Aristocrats to Buy: Kimberly Clark Corp (KMB) Most everyone knows Kimberly Clark Corp (NYSE: KMB ) is a paper company. | Source: Flickr Dividend Aristocrats to Buy: Abbott Laboratories (ABT) It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. Source: Dawn Via Flickr Dividend Aristocrats to Buy: Johnson & Johnson (JNJ) Like Texas Instruments, Johnson & Johnson (NYSE: JNJ ) may be one of the most boring health product companies an investor could think of. | Source: Flickr Dividend Aristocrats to Buy: Abbott Laboratories (ABT) It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. The company's dividend growth has been just as consistent, up almost every year going back to the 90's. |
33317.0 | 2018-03-09 00:00:00 UTC | Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs? | ABT | https://www.nasdaq.com/articles/is-big-pharma-using-corporate-tax-savings-to-lower-drug-costs-2018-03-09 | nan | nan | With the passing of the new tax bill, the corporate tax rate has come down from 35% to 21% which is likely to boosts profit margins. Moreover, the cash repatriation window allowed in the bill will help companies to bring in cash stashed in foreign locations at a one-time tax rate of 10%, leaving these companies with extra spending power.
Most big pharma companies discussed their plans to use the extra cash they save from the new tax bill at their fourth-quarter conference calls. The extra cash will mostly be invested in capital expenditures, products/pipeline, in-licensing or acquisition deals or rewarding shareholders through higher dividends and share buybacks. However, the majority of companies did not mention any effort regarding lowering of prescription drug costs.
Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017. She is concerned about the fact that the companies are favoring investors instead of using the savings to bring down prescription drug costs. Major life-saving drugs which are protected by patents are steeply priced. Thus, making these drugs affordable will help consumers, as it will lower their medical costs.
The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul.
The prices of major prescription drugs have skyrocketed over the past years, pinching hard U.S. citizens as their medical bills have soared. Moreover, the government also has to pay higher costs for the drugs that are covered under Medicare. The concern of the senator is thus justified. A move to restrict the use of tax savings for boosting shareholders will be a welcome move for consumers.
Moreover, large players from every other industry have similar plans, which have undercut President Donald Trump's plans to create jobs and boost wages.
Senator Smith is also working toward making cheaper generic drugs available in the market faster by introducing a new legislation, as reported by KDAL .
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Don't Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Most big pharma companies discussed their plans to use the extra cash they save from the new tax bill at their fourth-quarter conference calls. | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Large Cap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % Return Don't Even Think About Buying Bitcoin Until You Read This The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017. | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017. |
33318.0 | 2018-03-07 00:00:00 UTC | Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio | ABT | https://www.nasdaq.com/articles/abbott-gets-fda-nod-for-masters-hp-15mm-boosts-portfolio-2018-03-07 | nan | nan | AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm.
Notably, Abbott's breakthrough pediatric mechanical heart valve will help treat newborns and infants with congenital heart defects (CHD) and in need of a valve replacement procedure. Moreover, with approval, the company has expanded the Masters Series portfolio under the Structural Heart business. Interestingly, the Masters Series line now offers seven valves with diameter sizes varying from 15-27mm.
Furthermore, the approval can be majorly attributed to positive results from a clinical trial on patients with a damaged, diseased or malfunctioning heart valve aged five years or below.
Apart from widening the portfolio, the approval will allow Abbott to timely cater to unmet needs in the niche market.
A Glimpse of the Structural Heart Business
Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business.
Sales growth at this segment was driven by double-digit growth in Heart Failure, Electrophysiology, Structural Heart, Neuromodulation and Diabetes Care in the last reported quarter.
Notably, the Structural Heart business accounted for 9.3% of total revenues in the Medical devices segment. The upside was led by continued double-digit growth of MitraClip, the company's market-leading device for the repair of mitral regurgitation.
Last November, the company announced the receipt of Japan's Ministry of Health, Labour and Welfare (MHLW) approval for the same. We believe the latest development will help the company boost top-line contributions from this business.
Market Prospects
Per a report by Research and Markets and published by Cardiovascular Business, the global pediatric interventional cardiology market is expected to see a CAGR of 9% between 2016 and 2022. Per the company, about 40,000 children are born with CHD in the United States every year. Thus, the addition of Masters HP 15mm will help Abbott cash in on the abundant opportunities in the pediatric interventional cardiology market.
Share Price Movement
Over the past three months, Abbott has been outperforming its industry . The stock has gained 11.3% compared with the industry's 4.7%.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO , PetMed Express PETS and PerkinElmer PKI .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
PetMed has a long-term expected earnings growth rate of 10% and a Zacks Rank #1.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion - more than a 3,800% increase in the previous 12 months. They're now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
PerkinElmer, Inc. (PKI): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Furthermore, the approval can be majorly attributed to positive results from a clinical trial on patients with a damaged, diseased or malfunctioning heart valve aged five years or below. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. A Glimpse of the Structural Heart Business Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. A Glimpse of the Structural Heart Business Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, with approval, the company has expanded the Masters Series portfolio under the Structural Heart business. |
33319.0 | 2018-03-06 00:00:00 UTC | iShares Russell 1000 Value ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-russell-1000-value-etf-experiences-big-inflow-2018-03-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $123.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 298,800,000 to 299,800,000). Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $123.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 298,800,000 to 299,800,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57. | Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $123.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 298,800,000 to 299,800,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57. |
33320.0 | 2018-03-05 00:00:00 UTC | Here's My Top Stock to Buy in March | ABT | https://www.nasdaq.com/articles/heres-my-top-stock-buy-march-2018-03-05 | nan | nan | March is known for quite a few things. There's college basketball's "March madness." Julius Caesar was assassinated on the Ides of March. March flowers, of course, bring April showers. St. Patrick's Day brings out a lot of green clothes. And in much of the U.S., we have the beginning of daylight-saving time, when everyone has to remember to "spring forward" by setting clocks one hour ahead.
I think there's one other thing for which March should be known: a time to buy great stocks. Scientifically speaking, March is the best month of all to buy stocks. OK, I made that up. However, March is a great month to buy stocks, because for long-term investors, the sooner you buy a great stock, the more time you have to accumulate gains.
But what great stock to buy? Here's why AbbVie (NYSE: ABBV) is my top stock to buy in March.
Dividend
AbbVie stock is up more than 80% over the past 12 months and more than 15% so far this year. Some might ask, "Why not wait for AbbVie's share price to come down some and buy on the dip?" The answer is that you can't time the market. There's no way to know when AbbVie will have a dip -- or, perhaps more importantly, how far a dip might go.
There is one thing that you can time, though: when you can begin receiving AbbVie's dividend payments. If you buy the stock in March, you'll be eligible to get the pharmaceutical company's next dividend when it's paid on May 15. (Technically, anyone owning shares as of April 13 will receive the dividend, but why be a procrastinator?)
Believe me, you'll like AbbVie's dividend. The company recently increased its dividend payout by 35%, bringing the yield up to 3.25%. Dividend increases are a way of life at AbbVie. Since being spun off from parent Abbott Labs in 2013, the drugmaker has increased its dividend by a whopping 140%. Including the time that AbbVie was part of Abbott, the company has a track record of 46 consecutive years of dividend increases.
Growth
Dividends are good, but growth is great. AbbVie has definitely generated significant revenue and earnings growth in the past. Even better, that growth led to impressive total shareholder returns. In 2017, AbbVie ranked as the top big pharma stock in total shareholder return. It was the same story over the past three years and five years.
But what about future growth? There's more great news. Wall Street analysts project that AbbVie will increase earnings by an average annual rate of 17% over the next five years. They have solid reasons to be optimistic.
AbbVie's Humira claimed the title of top-selling drug in the world last year, with sales of $18.4 billion. The autoimmune-disease drug should bring in close to $21 billion in sales by 2020. Imbruvica, which AbbVie co-markets with Johnson & Johnson , made nearly $2.6 billion for AbbVie in 2017, an impressive 40% year-over-year jump. More strong growth should be in store for the cancer drug. New hepatitis C drug Mavyret appears likely to become the company's next blockbuster.
Rick Gonzalez, AbbVie's CEO, stated at a major healthcare conference in January that the company believes it will generate $35 billion in risk-adjusted non-Humira sales by 2025. Imbruvica and Mavyret will be key in making that happen, but so will AbbVie's pipeline. The company could have several new big winners on the way, including endometriosis and uterine fibroids drug elagolix, cancer drug Rova-T, and autoimmune disease drugs risankizumab and upadacitinib.
Value
You might glance at the AbbVie's trailing-12-month price-to-earnings ratio of 34.5 and think the stock is expensive. That's not the case. Actually, AbbVie looks like a pretty good bargain right now.
Remember that in investing, the future is more important than the past. Instead of looking at AbbVie's valuation based on past earnings, look at its stock price in proportion to the earnings that the company should generate. AbbVie's shares currently trade at only 13 times expected earnings. And if you factor in the solid growth prospects for the drugmaker over the next five years, AbbVie stock appears even more attractively valued.
Spring forward
Like any stock, buying AbbVie comes with risks. That's especially true for a pharmaceutical stock, with the prospects of clinical failures and regulatory rejections. It's possible that AbbVie could encounter pipeline setbacks. The company is also heavily dependent on sales of Humira. Any headwinds for the drug would definitely hurt AbbVie.
However, the company has a pipeline that is both deep and wide -- plenty of drugs in multiple therapeutic categories. AbbVie could weather a pipeline setback or two relatively well. The company also appears to be on the right track to reduce its dependence on Humira.
AbbVie has what I consider to be a fantastic combination of a high dividend yield, a strong track record of dividend increases, excellent growth prospects, and relatively low valuation. I'm not sure there's a stock on the market that checks off all of those boxes as well as AbbVie does. In my opinion, there's no better time than now to spring forward in buying this top pharma stock.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Including the time that AbbVie was part of Abbott, the company has a track record of 46 consecutive years of dividend increases. Wall Street analysts project that AbbVie will increase earnings by an average annual rate of 17% over the next five years. Rick Gonzalez, AbbVie's CEO, stated at a major healthcare conference in January that the company believes it will generate $35 billion in risk-adjusted non-Humira sales by 2025. | Including the time that AbbVie was part of Abbott, the company has a track record of 46 consecutive years of dividend increases. In 2017, AbbVie ranked as the top big pharma stock in total shareholder return. AbbVie has what I consider to be a fantastic combination of a high dividend yield, a strong track record of dividend increases, excellent growth prospects, and relatively low valuation. | However, March is a great month to buy stocks, because for long-term investors, the sooner you buy a great stock, the more time you have to accumulate gains. Here's why AbbVie (NYSE: ABBV) is my top stock to buy in March. Dividend AbbVie stock is up more than 80% over the past 12 months and more than 15% so far this year. | I think there's one other thing for which March should be known: a time to buy great stocks. Growth Dividends are good, but growth is great. And if you factor in the solid growth prospects for the drugmaker over the next five years, AbbVie stock appears even more attractively valued. |
33321.0 | 2018-03-04 00:00:00 UTC | 3 Stocks With Blazingly Fast-Growing Dividends | ABT | https://www.nasdaq.com/articles/3-stocks-blazingly-fast-growing-dividends-2018-03-04 | nan | nan | Some dividend stocks belong in a league of their own. For these stocks, the dividend yields look great. The companies are in strong financial shape to keep the dividend checks flowing. But even better, their dividend payments are growing incredibly fast.
Not many stocks fit those criteria. But AbbVie (NYSE: ABBV) , Boeing (NYSE: BA) , and Texas Instruments (NASDAQ: TXN) do. Here's why these three stocks have been able to grow their dividends impressively over the past three years.
AbbVie
AbbVie increased its dividend by 88% over the last three years. The big pharma company's yield now stands at a solid 3.25%. Since being spun off from parent Abbott Labs in 2013, AbbVie's dividend has soared 140%.
There's one primary reason AbbVie has been able to deliver such impressive dividend growth: the success of Humira. The autoimmune-disease drug again ranked as the top-selling drug in the world last year , with revenue of $18.4 billion.
While Humira still accounts for 65% of AbbVie's total revenue, the company has other products that will help generate higher cash flow over the next several years. Cancer drug Imbruvica is already a huge success, with sales of nearly $2.6 billion in 2017 and 40% year-over-year growth. AbbVie's new hepatitis C drug, Mavyret, is expected to become the company's next blockbuster. In addition, the drugmaker's pipeline includes several promising candidates with tremendous potential.
AbbVie currently uses less than 44% of free cash flow to fund its dividend program. Its strong cash flow, along with its great growth prospects, gives the company considerable flexibility to keep its streak of dividend hikes going.
Boeing
Boeing only narrowly trails AbbVie, with dividend growth over the past three years of just a little below 88%. Since 2013, Boeing's dividend skyrocketed nearly 253%. The aviation giant's dividend now yields 1.89%.
Selling jets to the commercial airline industry provides the primary source of Boeing's revenue. In 2017, the company's commercial airplanes segment generated almost 61% of total revenue. Boeing also sells military aircraft and weapons systems to governments, a business that contributed over 22% of total revenue. The company's global services segment, which offers aviation services support, spare parts, training, and other services to customers, kicks in most of the rest of Boeing's revenue.
After a strong performance last year, Boeing appears to be set for another good year in 2018 . The commercial airline industry is expected to enjoy continued profitability, which is great news for aircraft manufacturers as well. Boeing also has a large backlog of orders and has ramped up production of its 737 and 787 jets thanks to strong demand.
Investors shouldn't have to worry that Boeing won't be able to increase its dividend in the future. The company uses only 30% of free cash flow to pay out dividends.
Texas Instruments
Texas Instruments (TI) boosted its dividend by an impressive 82% over the past three years. The large semiconductor company increased dividend payments by 121% since 2013. After these dividend increases, TI's dividend yield now stands at 2.29%.
Purchases of semiconductors by industrial customers, including manufacturers of appliances, factory automation, and medical devices, account for roughly 35% of TI's total revenue. Sales related to personal electronics, such as mobile phones, PCs, and TVs, contributes another 25% of total revenue. TI makes around 19% of total revenue from the automotive industry. Most of the rest of the company's revenue stems from selling semiconductors for communications equipment, enterprise systems such as servers and multi-function printers, and a staple for TI for many years -- calculators.
TI turned in a great performance in 2017 , and its growth prospects continue to look good. The company is especially focused on the automotive and industrial markets. TI thinks demand for semiconductors in these areas will grow significantly in the future because of their increasing semiconductor content.
But can TI keep those attractive dividend increases coming over the next several years? It seems likely. The company uses only 45% of free cash flow to fund the dividend program, giving TI ample room to boost dividends down the road.
Best bet
If I could only pick one of these great dividend stocks to buy, it would be AbbVie. There are three main reasons I like it the most.
First, the drugmaker has the better growth prospects than Boeing or Texas Instruments. AbbVie is expected to grow earnings by 17% annually over the next five years, which is higher than growth projections for the other two companies.
Second, AbbVie presents the better value. Currently, the stock trades at only 13 times expected earnings. By comparison, the forward earnings multiples for Boeing and TI are 21 and 19, respectively.
Third, AbbVie claims the highest dividend yield of the three stocks. And it doesn't hurt that the company has increased its dividend at a faster rate over the past three years than either Boeing or TI.
All three of these stocks appear to be in solid shape to continue paying and increasing dividends in the future. But AbbVie stands out as perhaps the best combination of growth, value, and income on the market right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its strong cash flow, along with its great growth prospects, gives the company considerable flexibility to keep its streak of dividend hikes going. Purchases of semiconductors by industrial customers, including manufacturers of appliances, factory automation, and medical devices, account for roughly 35% of TI's total revenue. Most of the rest of the company's revenue stems from selling semiconductors for communications equipment, enterprise systems such as servers and multi-function printers, and a staple for TI for many years -- calculators. | While Humira still accounts for 65% of AbbVie's total revenue, the company has other products that will help generate higher cash flow over the next several years. Texas Instruments Texas Instruments (TI) boosted its dividend by an impressive 82% over the past three years. The large semiconductor company increased dividend payments by 121% since 2013. | AbbVie AbbVie increased its dividend by 88% over the last three years. Boeing Boeing only narrowly trails AbbVie, with dividend growth over the past three years of just a little below 88%. And it doesn't hurt that the company has increased its dividend at a faster rate over the past three years than either Boeing or TI. | For these stocks, the dividend yields look great. AbbVie AbbVie increased its dividend by 88% over the last three years. That's right -- they think these 10 stocks are even better buys. |
33322.0 | 2018-03-01 00:00:00 UTC | Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-abbott-becton-and-dickinson-stryker-varian-medical-and | nan | nan | For Immediate Release
Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX.
Industry: Medical Devices, Part 2
Link: https://www.zacks.com/commentary/151130/medtechs-long-term-prospects-outweigh-near-term-risks
In the past few years, the U.S. medical device market has undergone substantial transformation. While there are a number of regulatory and financial issues unlikely to be resolved soon, powerful long-term tailwinds, including mergers & acquisitions (M&As), emerging market expansion, positive demographic trends and product innovation, have been contributing to the continued growth of the sector.
In addition, the recent change in consumer demand and market dynamics led to a dramatic transformation in the healthcare system. This is evident from the growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model among others.
Let us go through some of the major long-term tailwinds for the MedTech sector.
M&A Boom Continues
Going by the last available EvaluateGroup data, the first half of 2017 saw a massive 178% surge in the total value of M&A deals within MedTech. Although the next report is yet to be released, the pace of M&A activity is said to have been the same in the rest of the year. The trend is likely to continue in 2018.
Following the company's colossal $25 billion consolidation with St. Jude Medical in January, Abbott recently closed the $5.3 billion acquisition of Alere. With the successful wrap-up of this transaction, the combined company is anticipated to emerge as a lead player in the $7 billion point-of-care diagnostic space.
Another mega consolidation was that of medical device major Becton, Dickinson and Co. and medical, surgical, diagnostic and patient care devices provider C. R. Bard, for $24 billion. After the completion of the deal in December 2017, Becton, Dickinson is on its way to expand to new areas like vascular access segments - PICCs (peripherally inserted central catheters), midlines and drug delivery ports.
Stryker is also on an M&A spree. The company is going to buy Entellus Medical for $662 million to strengthen its position in the ENT space. The company is also on track to close the €183 million acquisition of VEXIM, which specializes in the development and sale of vertebral compression fracture solutions.
Varian Medical also inked a major M&A deal of late. In January 2018, the company signed an agreement to acquire Australia-based global life sciences company, Sirtex Medical Limited for a total deal value of $1.28 billion. The investment will strengthen the company's position in the interventional oncology therapies.
This apart, Boston Scientific's major $90 million investment in Santa Rosa, CA-based Millipede is expected to boost its position in the growing field of mitral regurgitation (MR), which falls under the company's structural heart business. We note that the company's acquisition of Switzerland-based Symetis SA in mid-2017 has already started to strengthen its structural heart business in Europe.
Divestments
Medical device majors continue to offload their non-core business lines and assets that are similar to the ones acquired through mergers to focus on the main segments. These divestures have been mandated by the U.S. Federal Trade Commission (FTC) and other international anti-trust regulators. This restricts chances of monopoly in the market.
Earlier this month, BD divested its soft tissue core needle biopsy line and Aspira product line to Merit Medical for $100 million. The divestment is related to its acquisition of C.R. Bard.
Orthopedic implant device maker Exactech recently sold itself off to TPG Capital for $737 million. The alliance with TPG will enable the consolidated company to invest in growth so as to compete with larger competitors in the orthopedic industry.
Apprehending that China's drug distribution reform may slow down the company's growth in the region (according to a Reuters report), Cardinal Health completed the sale of its China business to Shanghai Pharmaceuticals Holding for $1.2 billion.
Following the announcement of its two major buyouts, Abbott divested its eyecare business Abbott Medical Optics (AMO) to Johnson & Johnson for about $4.33 billion to streamline its newly added business lines.
A marketer of aesthetic treatment systems, Cynosure, sold itself to Hologic. Notably, Hologic acquired all outstanding Cynosure shares for approximately $1.65 billion.
Emerging Market Openings
Though the performance of the U.S. medical device market has been dull (though it still holds the leading position, with almost one-third of the world market share) due to rising regulatory and legislative uncertainty, global growth has been strong. In 2016, the emerging market grew 5%, a pace last seen before the financial crisis.
Going by a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India, the fifth largest MedTech market in the world, currently records 17% annual growth. At this pace, India may soon pose stiff competition for Japan and Germany by 2022.
Among other emerging geographical regions, Latin America, even in the face of general economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, the Central and South American nations significantly increased per capita spending on healthcare between 2008 and 2014.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. While there are a number of regulatory and financial issues unlikely to be resolved soon, powerful long-term tailwinds, including mergers & acquisitions (M&As), emerging market expansion, positive demographic trends and product innovation, have been contributing to the continued growth of the sector. | For Immediate Release Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Another mega consolidation was that of medical device major Becton, Dickinson and Co. and medical, surgical, diagnostic and patient care devices provider C. R. Bard, for $24 billion. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/151130/medtechs-long-term-prospects-outweigh-near-term-risks In the past few years, the U.S. medical device market has undergone substantial transformation. | For Immediate Release Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/151130/medtechs-long-term-prospects-outweigh-near-term-risks In the past few years, the U.S. medical device market has undergone substantial transformation. |
33323.0 | 2018-02-28 00:00:00 UTC | Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-johnson-johnson-medtronic-covidien-and-smith-nephew | nan | nan | For Immediate Release
Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX.
Industry: Medical Devices, Part 1
Link: https://www.zacks.com/commentary/150968/medical-device-industry-outlook---february-2018
The Q4 earnings season is approaching its end with more than 80% of the S&P 500 companies having released their quarterly earnings. Most of the companies have incurred big one-time charges related to the change in tax law this time around. The gap between adjusted operating earnings and reported earnings is in fact the widest in recent years. The MedTech space is also not immune to the trend.
Last year, the MedTech space witnessed a good deal of uncertainty on account of a series of political events. While the Affordable Care Act (ACA) or Obamacare was not rolled back as was originally expected, the year ended with the tax overhaul. As part of the latest tax reform, corporate tax rates have been slashed to 21% from 35% earlier.
Industry Appears Vulnerable to Change
Many of the economists expect the new tax law to have a negative impact on the industry due to a possible cut in overall Medicare spending if certain criteria are not met by a specific date.
The Congressional Budget Office (CBO) apprehends that if it doesn't find any alternative to meet the fiscal deficit from the huge tax cut, automatic cuts worth $136 billion, including $25 billion in Medicare cuts, from mandatory spending in 2018 could be triggered.
Delayed Medical Device Tax: Boon to the Industry
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors. The original 2018 tax reform bill did not include any mention of this temporary repeal and investors were apprehensive that medical device tax will be reinforced in 2018.
This 2.3% tax took a toll on the entire medical device industry since its enactment in 2013. Per the Advanced Medical Technology Association lobbying group, this tax had a significant negative impact on medical innovation resulting in loss or deferred creation of jobs.
Johnson & Johnson made a payment of $180 million as medical device sales tax in 2014. Medtronic, the legacy Covidien and Smith & Nephew paid $112 million, $60 million and $25 million, respectively in 2014.
Medical device giant Stryker Corporation reported net earnings of $1.14 billion and paid approximately $229 million as medical device excise tax in 2015 -- nearly 16% of Stryker's bottom line income (data from a Med Device Online report). No wonder, this dreadful tax drew severe criticism from both Democrats and Republicans and was delayed by Congress in 2015 for two years.
Regarding the latest two-year suspension of the tax, Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA) has stated that, "Congress must permanently repeal this disastrous policy in order to fully realize the long-term investments in patient care and job creation that are critical to growth." It remains to be seen whether the tax is fully eliminated or resumed after the two-year period. For now, the deferral will encourage R&D activities in this space.
Zacks Industry Rank
Within the Zacks Industry classification, Medical Device is broadly grouped into the Medical sector (one of the 16 Zacks sectors) and further sub-divided into four industries at the expanded level: Medical - Instruments, Medical - Products, Medical - Dental Supplies and Medical Info Systems.
We rank all 250-plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each.
The Zacks Industry Rank is #168 (bottom 34% of the 250 plus Zacks classified industries) for Medical - Instruments, #179 (bottom 30%) for Medical - Products, #135 (bottom 47%) for Medical - Dental Supplies, #132 (bottom 48%) for Medical Info Systems. Our backtesting shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Upon analyzing the Zacks Industry Rank for different Medical Device segments, it can be said that the near-term outlook for these aforementioned MedTech subsectors is bearish.
Price Performance
The price performance of two major Zacks categorized subindustries, Medical Product and Medical Instruments, however, indicate a bullish market sentiment.
Medical Product stocks have increased 2.1% in this period. Some players from this space are Abbott Labs and Boston Scientific.
Year to date, while the S&P 500 has gained 1.6%, the med instruments space has risen 7.5%.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic plc (MDT): Free Stock Analysis Report
Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic plc (MDT): Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report To read this article on Zacks.com click here. Regarding the latest two-year suspension of the tax, Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA) has stated that, "Congress must permanently repeal this disastrous policy in order to fully realize the long-term investments in patient care and job creation that are critical to growth." | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic plc (MDT): Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX. Zacks Industry Rank Within the Zacks Industry classification, Medical Device is broadly grouped into the Medical sector (one of the 16 Zacks sectors) and further sub-divided into four industries at the expanded level: Medical - Instruments, Medical - Products, Medical - Dental Supplies and Medical Info Systems. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic plc (MDT): Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX. Zacks Industry Rank Within the Zacks Industry classification, Medical Device is broadly grouped into the Medical sector (one of the 16 Zacks sectors) and further sub-divided into four industries at the expanded level: Medical - Instruments, Medical - Products, Medical - Dental Supplies and Medical Info Systems. | For Immediate Release Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic plc (MDT): Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report To read this article on Zacks.com click here. Delayed Medical Device Tax: Boon to the Industry Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors. |
33324.0 | 2018-02-27 00:00:00 UTC | Mid-Day Update: Stocks Turn Negative as Powell Spooks Wall Street With Hint of Four Rate Hikes | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-turn-negative-powell-spooks-wall-street-hint-four-rate-hikes-2018-02 | nan | nan | The Dow Jones Industrial Average is poised to close in the red for the first time in four days as comments from Federal Reserve chairman Jerome Powell during his first Humphrey-Hawkins testimony to Congress spooked Wall Street.
Citing increasing price pressures and a strengthening economy, Powell indicated that the Fed might reconsider the number of rate hikes in 2018 at the March Federal Open Market Committee meeting. Led by losses in interest rate sensitive sectors and consumer discretionary shares, the blue chip index gave up early gains to trade lower at midday on Tuesday.
Leading into Powell's testimony, the major market averages perked up and were briefly positive on the back of a 17-year high in consumer confidence and significant increase in the Richmond Fed manufacturing index. The data offset early losses associated with a larger-than-expected decline in durable goods orders and widening in the US trade deficit in goods.
Powell's prepared remarks to the House Committee on Financial Services also gave an early boost to Wall Street amid assurances that the Fed will continue to gradually raise interest rates. However, his response to a question about the number of rate hikes in 2018 during the Q&A segment rattled investors as Powell suggested the Fed might hike rates more than three times. In the aftermath, the dollar rallied, bond yields lunged higher and stocks traded lower.
Most European bourses absorbed the reversal on Wall Street except for those impacted by a decision from a German court to allow cities to ban diesel cars. Accordingly, the selling pressure on automakers weighed on Germany's DAX and Euro Stoxx, causing both to underperform their EU peers.
Crude oil was down $0.99 to $62.92 per barrel. Natural gas was unchanged at $2.69 per 1 million BTU. Gold was down $16.80 to $1,316.00 an ounce, while silver was down $0.23 to $16.38 an ounce. Copper was down $0.04 to $3.18 per pound.
Among energy ETFs, the United States Oil Fund was down $1.63 to $12.65 with the United States Natural Gas Fund was up 0.27% to $22.45. Among precious-metal funds, the Market Vectors Gold Miners ETF was down 2.44% to 21.59 while SPDR Gold Shares were down 1.36% to $124.73. The iShares Silver Trust was down 1.53% to $15.44.
Here's where the markets stand at mid-day:
US MARKETS
NYSE Composite Index was down 66.70 points (-0.62%) to 12,919.13
Dow Jones Industrial Index was down 38.29 points (-0.15%) to 25,670.98
S&P 500 was down 12.57 points (-0.45%) to 2,767.02
Nasdaq Composite Index was down 66.25 points (-0.90%) to 7,354.75
GLOBAL SENTIMENT
FTSE 100 was up 12.76 points (+0.18%) to 7,302.34
DAX was down 17.78 points (-0.14%) to 12,509.26
CAC 40 was up 6.27 points (+0.12%) to 5,350.53
Nikkei 225 was up 236.23 points (+1.07%) to 22,389.86
Hang Seng Index was down 229.94 points (-0.73%) to 31,268.66
Shanghai China Composite Index was down 38.05 points (-1.14%) to 3,291.53
NYSE SECTOR INDICES
NYSE Energy Sector Index was down 64.28 points (-0.58%) to 10,971.33
NYSE Financial Sector Index was down 43.49 points (-0.52%) to 8,399.52
NYSE Healthcare Sector Index was down 86.26 points (-0.59%) to 14,652.41
UPSIDE MOVERS
(+) MNK (+21.87%) Fiscal Q4 results top expectations
(+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected
(+) DDS (+12.69%) Reported better-than-expected Q4 results
(+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon
DOWNSIDE MOVERS
(-) AKRX (-33.90%) Fresenius says looking into Akorn's alleged breaches of FDA data integrity requirements
(-) NSPR (-30.71%) Priced 1 million shares at $3 each
(-) AKCA (-25.60%) Reported wider-than-expected Q4 loss
(-) NTRI (-21.68%) Sets Q1 guidance below Street view
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) MNK (+21.87%) Fiscal Q4 results top expectations (+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected (+) DDS (+12.69%) Reported better-than-expected Q4 results (+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon The Dow Jones Industrial Average is poised to close in the red for the first time in four days as comments from Federal Reserve chairman Jerome Powell during his first Humphrey-Hawkins testimony to Congress spooked Wall Street. Leading into Powell's testimony, the major market averages perked up and were briefly positive on the back of a 17-year high in consumer confidence and significant increase in the Richmond Fed manufacturing index. | (+) MNK (+21.87%) Fiscal Q4 results top expectations (+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected (+) DDS (+12.69%) Reported better-than-expected Q4 results (+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon Led by losses in interest rate sensitive sectors and consumer discretionary shares, the blue chip index gave up early gains to trade lower at midday on Tuesday. NYSE Composite Index was down 66.70 points (-0.62%) to 12,919.13 Dow Jones Industrial Index was down 38.29 points (-0.15%) to 25,670.98 S&P 500 was down 12.57 points (-0.45%) to 2,767.02 Nasdaq Composite Index was down 66.25 points (-0.90%) to 7,354.75 | (+) MNK (+21.87%) Fiscal Q4 results top expectations (+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected (+) DDS (+12.69%) Reported better-than-expected Q4 results (+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon NYSE Composite Index was down 66.70 points (-0.62%) to 12,919.13 Dow Jones Industrial Index was down 38.29 points (-0.15%) to 25,670.98 S&P 500 was down 12.57 points (-0.45%) to 2,767.02 Nasdaq Composite Index was down 66.25 points (-0.90%) to 7,354.75 FTSE 100 was up 12.76 points (+0.18%) to 7,302.34 DAX was down 17.78 points (-0.14%) to 12,509.26 CAC 40 was up 6.27 points (+0.12%) to 5,350.53 Nikkei 225 was up 236.23 points (+1.07%) to 22,389.86 Hang Seng Index was down 229.94 points (-0.73%) to 31,268.66 Shanghai China Composite Index was down 38.05 points (-1.14%) to 3,291.53 | (+) MNK (+21.87%) Fiscal Q4 results top expectations (+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected (+) DDS (+12.69%) Reported better-than-expected Q4 results (+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon The Dow Jones Industrial Average is poised to close in the red for the first time in four days as comments from Federal Reserve chairman Jerome Powell during his first Humphrey-Hawkins testimony to Congress spooked Wall Street. Led by losses in interest rate sensitive sectors and consumer discretionary shares, the blue chip index gave up early gains to trade lower at midday on Tuesday. |
33325.0 | 2018-02-26 00:00:00 UTC | George Soros Just Bought These 2 Biotech Stocks. Should You? | ABT | https://www.nasdaq.com/articles/george-soros-just-bought-these-2-biotech-stocks-should-you-2018-02-26 | nan | nan | Billionaire George Soros' namesake fund, Soros Fund Management, has consistently beat the broader markets over the past 40-plus years. The fund's quarterly buys and sells are therefore must-read material for any serious investor.
What was the fund buying in the fourth quarter of 2017? In the high-growth biotech space, the fund initiated new, albeit modest, positions in both the diabetes device maker DexCom (NASDAQ: DXCM) and the clinical-stage drugmaker AnaptysBio, Inc. (NASDAQ: ANAB) , according to the latest 13F filings with the U.S. Securities and Exchange Commission.
Should investors take a cue from this elite money management firm and buy these two biotech stocks? Let's dig deeper to find out.
Time to buy this falling knife?
DexCom is a top player in the relatively new field of continuous blood glucose sensing devices. Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid.
As Abbott's continuous glucose monitoring device is both cheaper than the G5 Mobile and doesn't need to be calibrated, DexCom's G5 Mobile system is clearly at a competitive disadvantage at this point. So it's not entirely surprising that investors are growing more and more concerned about DexCom's future growth prospects.
Despite this new competitive threat, however, DexCom's sales are still expected to climb by an impressive 18.7% to $846 million this year. The company is also on track to reportedly launch its own "no-calibration" G6 continuous glucose monitoring device later this year, and its G5 system did reportedly outperform Abbott's FreeStyle Libre System in terms of the time required to detect hypoglycemia in people with type 1 diabetes in a head-to-head study earlier this year.
The downside is that DexCom's shares remain on the expensive side even after this latest pullback. The company's trailing price-to-sales ratio, for example, currently stands at a sky-high 7.32. So you have to be willing to pay a fairly sizable premium if you want to buy into DexCom's supercharged growth story.
Can this rocket-like trajectory continue?
AnaptysBio's shares have quadrupled in value in the just the past 12 months. The catalyst?
ANAB data by YCharts .
Investors are apparently excited about AnaptysBio's experimental atopic dermatitis (eczema) candidate ANB020. This clinical-stage drug works by inhibiting the cell signaling molecule interleukin-33, which is known to play a key role in numerous inflammatory disorders.
Recently, the company reported overwhelmingly positive results for ANBO20 in a small mid-stage study in adult patients with moderate-to-severe atopic dermatitis. And based on this encouraging outcome, AnaptysBio is planning to evaluate the drug's safety and efficacy in a much larger mid-stage study for atopic dermatitis later this year. The company is also currently assessing ANBO20 in adult patients with peanut allergies and eosinophilic asthma.
The big idea, if you will, is that ANBO20 may be able to grab the lion's share of the $4 billion skin disorder market if it proves to be as potent as advertised. That's a tall order for any experimental anti-inflammatory drug, but the initial results do appear to back this claim thus far.
Are either of these biotechs worth buying right now?
DexCom and AnaptysBio both have incredibly enticing long-term growth trajectories, but they also come with a hefty dose of risk. After all, there's no guarantee that DexCom can continue to grab market share in an increasingly competitive space, and the company will also have to constantly innovate to stay ahead of the field.
AnaptysBio, for its part, still has a lot to prove in terms of the efficacy and safety of ANBO20 -- its most valuable product candidate. No matter how profound, small mid-stage trial results should always be taken with a rather large grain of salt.
What's the verdict? These two mid-cap biotech stocks might be appealing to risk-tolerant investors on the hunt for unusual growth opportunities. But conservative investors should probably keep their distance because of their highly uncertain outlooks.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Feb. 5, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. And based on this encouraging outcome, AnaptysBio is planning to evaluate the drug's safety and efficacy in a much larger mid-stage study for atopic dermatitis later this year. After all, there's no guarantee that DexCom can continue to grab market share in an increasingly competitive space, and the company will also have to constantly innovate to stay ahead of the field. | Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. In the high-growth biotech space, the fund initiated new, albeit modest, positions in both the diabetes device maker DexCom (NASDAQ: DXCM) and the clinical-stage drugmaker AnaptysBio, Inc. (NASDAQ: ANAB) , according to the latest 13F filings with the U.S. Securities and Exchange Commission. The company is also on track to reportedly launch its own "no-calibration" G6 continuous glucose monitoring device later this year, and its G5 system did reportedly outperform Abbott's FreeStyle Libre System in terms of the time required to detect hypoglycemia in people with type 1 diabetes in a head-to-head study earlier this year. | Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. In the high-growth biotech space, the fund initiated new, albeit modest, positions in both the diabetes device maker DexCom (NASDAQ: DXCM) and the clinical-stage drugmaker AnaptysBio, Inc. (NASDAQ: ANAB) , according to the latest 13F filings with the U.S. Securities and Exchange Commission. The company is also on track to reportedly launch its own "no-calibration" G6 continuous glucose monitoring device later this year, and its G5 system did reportedly outperform Abbott's FreeStyle Libre System in terms of the time required to detect hypoglycemia in people with type 1 diabetes in a head-to-head study earlier this year. | Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. Investors are apparently excited about AnaptysBio's experimental atopic dermatitis (eczema) candidate ANB020. Recently, the company reported overwhelmingly positive results for ANBO20 in a small mid-stage study in adult patients with moderate-to-severe atopic dermatitis. |
33326.0 | 2018-02-23 00:00:00 UTC | IUSG, MCD, ABT, AMGN: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/iusg-mcd-abt-amgn-etf-inflow-alert-2018-02-23 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $72.6 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 61,900,000 to 63,200,000). Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $72.6 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 61,900,000 to 63,200,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. | Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $72.6 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 61,900,000 to 63,200,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. |
33327.0 | 2018-02-23 00:00:00 UTC | Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound? | ABT | https://www.nasdaq.com/articles/abbott-abt-down-6.7-since-earnings-report%3A-can-it-rebound-2018-02-23 | nan | nan | It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Shares have lost about 6.7% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
Abbott reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Earnings improved 13.8% year over year and met the high end of the company's guided range of 72 cents to 74 cents.
However, reported loss in the quarter came in at 50 cents per share, as against year-ago earnings of 51 cents. Notably, this includes anticipated net expense of $1.46 billion as an impact of U.S. tax reform.
Full-year 2017 adjusted earnings came in at $2.50 per share, in line with the Zacks Consensus Estimate. However, the figure beat the year-ago number by 13.6%.
Fourth-quarter worldwide sales came in at $7.59 billion, up 42.3% year over year on a reported basis. The figure also beat the Zacks Consensus Estimate of $7.37 billion by 2.9%.
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 7.7% year over year in the reported quarter.
Worldwide sales in the full year came in at $27.39 billion, up 31.3% year over year on a reported basis. The figure also surpassed the Zacks Consensus Estimate of $27.15 billion.
Quarter in Detail
Abbott operates through four segments - Established Pharmaceuticals Division ("EPD"), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 17% on a reported basis (up 14% on comparable operational basis) to $1.15 billion. This included a positive impact of 3% from currency fluctuations. Sales in key emerging markets increased 15% (up 12.5%), driven by double-digit growth in Latin America, India and China.
The Medical Devices business sales rose 102.2% on a reported basis to $2.74 billion. On a comparable operational basis, sales increased 9.6%.
Cardiovascular and Neuromodulation sales soared 222.5% on a reported basis (up 6.9% on comparable operational basis) on double-digit growth in Electrophysiology, Structural Heart, Heart Failure and Neuromodulation.
Vascular product sales, however, declined 1.9% on a comparable operational basis. Within Rhythm Management, the company saw a sales drop of 8% on a comparable operational basis. However, the company received FDA approval for magnetic resonance (MR)-conditional labeling for its Quadra Assura and Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) devices and its Fortify Assura implantable cardioverter defibrillator (ICD) in the quarter under review.
Diabetes Care sales improved 27.6% on a comparable operational basis, buoyed by double-digit international sales growth, led by continued consumer uptake of FreeStyle Libre - the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 3% year over year on a reported basis (2% on a comparable operational basis). Foreign exchange drove sales by 1%. Pediatric Nutrition sales increased 1.5% on a comparable operational basis. Adult Nutrition sales were up 2.8% on a comparable operational basis.
Diagnostics sales rose 51.7% year over year on a reported basis (up 6.7% on a comparable operational basis). Core Laboratory and Point of Care Diagnostics sales grew 7.2% and 6.8%, respectively, on a comparable operational basis. Molecular Diagnostics sales were up a nominal 2.4% as strong growth in the infectious disease testing business was partially offset by the planned scale down of the genetics business. Rapid Diagnostics recorded sales of $540 million, driven by solid contributions from infectious disease testing, including flu and strep testing.
Guidance
Abbott issued full-year 2018 guidance. Adjusting for certain net specified items for the full year, adjusted earnings per share from continuing operations are expected in the band of $2.80-$2.90. The current Zacks Consensus Estimate is pegged at $2.83, near the low end of the projected range.
The company also provided first-quarter 2018 adjusted earnings per share guidance. It expects to report adjusted earnings from continuing operations in the range of 57 cents to 59 cents in the quarter. The current Zacks Consensus Estimate of 56 cents is below the projected range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. There has been one revision higher for the current quarter.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
VGM Scores
At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B. The stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is primarily suitable for growth investors while also being suitable for those looking for momentum and to a lesser degree value.
Outlook
Estimates have been trending upward for the stock and the magnitude of this revisions also looks promising. Interestingly, ABT has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B. | Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B. It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? | It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B. | It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B. |
33328.0 | 2018-02-21 00:00:00 UTC | There Are Better Options Than Medtronic PLC Stock | ABT | https://www.nasdaq.com/articles/there-are-better-options-medtronic-plc-stock-2018-02-21 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
On Tuesday, Medtronic plc (NYSE: MDT ) reported its fiscal 2018 third-quarter results. Earnings were in-line with expectations while revenue grew 1.2% and topped analysts' expectations. However, the quarterly report wasn't enough to jolt Medtronic stock higher, with shares falling 2%. Should investors flock to MDT stock or should they look elsewhere?
Medtronic stock is far from a bad pick. In fact, Medtronic is a very good company. MDT stock has a 2.25% dividend yield, makes quality products and trades at a reasonable valuation. But, in my view, there are other, more attractive alternatives out there.
Let's look at Medtronic stock more specifically, though.
7 Ways to Play Rising Yields With Inverse Treasury ETFs
Analysts expect earnings of $4.77 per share this year, which is up about 3.7% from last year. Further, analysts expect sales to fall about 1% this year. It's worth pointing out that management expects sales to grow 4% to 5% in constant currency terms. They also expect non-GAAP earnings to grow 9% to 10% this year on a constant currency basis.
So, even though on paper it doesn't look like things are going well for this Dublin-based company, it's actually not going as bad as it may seem. For the record, analysts expect a better fiscal 2019. They're forecasting for earnings and sales growth of 8.6% and 3.4%, respectively.
While all of that may be true, the reality is that Medtronic stock trades at about 17 times this year's earnings and 16 times fiscal 2019 earnings. This valuation isn't horrendous by any means, but I'm not overwhelmingly attracted to it, given MDT's growth.
If Not MDT Stock, Then What?
If we're not buyers of MDT stock, then what do we like instead? We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). But instead, I'd suggest Johnson & Johnson (NYSE: JNJ ). While JNJ stock may not be a direct comparison to MDT stock in the form of an industry-to-industry peer, the two companies do have some overlap. Further, they're both in the same sector and that makes it a viable comparison in my eyes.
I recently did some research on JNJ stock and found that it was a definite buy . Shares fell 1.7% on Tuesday, giving investors a chance to do just that. I find JNJ attractive on a number of metrics.
J&J vs. Medtronic Stock
Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. Next year, those figures fall to 3.7% and 5.6%, respectively. However, given that JNJ has beat earnings expectations for at least 17 straight quarters, I'm willing to bet that estimates for 2019 may be too low.
JNJ pays a 2.5% dividend yield, which slightly edges the 2.25% yield from MDT stock. Further, J&J has a slightly better valuation based on both 2018 and 2019 earnings (trading at ~16 and 15 times those estimates). I'll admit, it's very close. But consider which company has the better margins? Which has the better cash flows?
While MDT tops JNJ on gross margins, as that money makes its way down the line, JNJ does a better job of retaining the most of each dollar. JNJ sports stronger operating and profit margins and its cash flows are better too. JNJ obviously generates larger cash flows because it's a much larger company. That being said, though, both operating cash flow and free-cash flow are trending higher for JNJ, while the opposite is true for MDT.
For all of these reasons - growth, valuation, dividends, margins and cash flow - I see little reason to buy Medtronic stock over J&J.
One last note to consider? The brand strength. It's hard to top J&J as one of the world's leading blue-chip brands.
Trading MDT Stock Price
Despite the favoring of JNJ stock over Medtronic, MDT stock price actually has a pretty decent chart. You'll notice the level of support in the $74 to $76 area, as well as trend-line support (blue line). Resistance rests at $88.
Click to Enlarge
Investors can try buying near these support levels, or on a breakout over resistance.
The 10 Safest Stocks to Buy If Markets Overheat Again
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . As of this writing, Bret Kenwell held a position in JNJ.
More From InvestorPlace
7 Great REITs to Own in Good Times and Bad
8 Companies That Could Disappear by 2019
10 Dividend Stocks to Buy With Low Yields, But Big Dividend Growth
Compare Brokers
The post There Are Better Options Than Medtronic PLC Stock appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). J&J vs. Medtronic Stock Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. The 10 Safest Stocks to Buy If Markets Overheat Again Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . | We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Tuesday, Medtronic plc (NYSE: MDT ) reported its fiscal 2018 third-quarter results. J&J vs. Medtronic Stock Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. | We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). J&J vs. Medtronic Stock Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. Trading MDT Stock Price Despite the favoring of JNJ stock over Medtronic, MDT stock price actually has a pretty decent chart. | We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Tuesday, Medtronic plc (NYSE: MDT ) reported its fiscal 2018 third-quarter results. J&J vs. Medtronic Stock Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. |
33329.0 | 2018-02-19 00:00:00 UTC | Is AbbVie or Gilead Sciences Stock a Better Buy? | ABT | https://www.nasdaq.com/articles/abbvie-or-gilead-sciences-stock-better-buy-2018-02-19 | nan | nan | AbbVie Inc. (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two of the world's biggest biotech stocks. However, their sales have been heading in different directions and each has offered up very different forecasts for 2018. Given that these titans are competing head to head for a share in the multibillion-dollar market for hepatitis C drugs, is one of these stocks a better buy than the other?
Grading their growth
It can pay to invest in companies that are growing sales and profit. By that measure, AbbVie is undeniably the better of the two stocks.
Because of increased competition from AbbVie and other hepatitis C drugmakers, Gilead Sciences' sales and earnings have been declining since 2016.
Gilead Sciences remains a dominant force in HIV treatment, and HIV drug sales have been increasing thanks to the launch of new combination therapies that include TAF, a safer reformulation of the popular HIV drug Viread. However, Gilead Sciences' HIV revenue growth hasn't been able to offset declining demand for the company's hepatitis C medicine, and since sales are falling faster than expenses, the company's earnings are suffering.
Gilead Sciences' hepatitis C sales fell 54% year over year to $1.5 billion in Q4 2017. Total revenue declined in 2017 to $26 billion from $30 billion in 2016, and EPS fell to $8.84 from $11.57.
It's been a very different story at AbbVie. Growing demand for its best-selling drugs, Humira and Imbruvica, and new drug launches, including Mavyret, the company's latest hepatitis C treatment, are increasing sales by double-digit percentages. Sales of its best-selling drug, Humira, grew 14.6% to $18.4 billion, and revenue from its second best-selling drug, Imbruvica, soared 40.5% to $2.6 billion in 2017. The launch of Mavyret last August boosted AbbVie's hepatitis C revenue by 63% year over year to $510 million in Q4 2017.
Those tailwinds translated into full-year sales of $28.2 billion, up 10% from one year ago, and EPS of $5.60, up from $4.82. With AbbVie's revenue and earnings rising and Gilead Sciences still descending, I have to give AbbVie the win in this category.
Pondering pipelines
Gilead Sciences invests heavily in mergers and acquisitions and in research and development. And that means it has exciting drugs advancing through its drug pipeline. However, I have to give the advantage to AbbVie in this category, too.
Gilead Sciences catapulted to the forefront of research into the use of gene therapies as cancer treatments when it acquired Kite Pharma for $11.9 billion last year, but it faces stiff competition in this field from many competitors, including Novartis (NYSE: NVS) and Celgene (NASDAQ: CELG) , that could limit that market opportunity.
Gilead Sciences' Yescarta is the only CAR-T gene therapy on the market for late-stage non-Hodgkin lymphoma currently, but it generated only $7 million in sales since its launch last October. With Novartis' gene therapy, Kymriah, already under priority review for use in Yescarta's indication and Celgene's gene therapy, JCAR017, possibly being filed for FDA approval this year, Gilead Sciences may have to fight tooth-and-nail for market share.
Gilead Sciences' filgotinib, an autoimmune-disease drug, and serotinib, a treatment for non-alcoholic fatty liver disease, appear promising, but we won't know just how promising until pivotal data emerges. Filgotinib's phase 3 rheumatoid arthritis data is expected this year, but we may have to wait until next year for more insight on serotinib.
Arguably, AbbVie's pipeline has fewer question marks. FDA decisions are pending for Elagolix, an endometrioisis drug, and Venclexta, a chronic lymphocytic leukemia drug, that could eventually lead to blockbuster revenue.
AbbVie also has three potential blockbuster drugs that it hopes to file for FDA approval soon: risankizumab, upadacitinib, and Rova-T.
Risankizumab has already successfully completed phase 3 psoriasis trials, and a filing is planned by the end of June. Upadacitinib has already put up impressive data in one phase 3 rheumatoid arthritis study, and two more phase 3 studies are expected to have data available shortly that could support a filing before the end of this year. Rova-T may also be filed for approval this year if it delivers strong phase 2 results in third-line or greater small-cell lung cancer. According to management, all three drugs could be multibillion-dollar-per-year top sellers.
Debating dividends
Both companies offer income investors market-beating dividend yields, and each company has wads of cash at its disposal to boost dividends in the future.
Gilead Sciences initiated its quarterly dividend in 2015, and since then, it's increased the payout from $0.43 to $0.57. Its fat operating margin means it generates more than enough free cash flow to support its dividend even though its sales are falling. In fact, its cash dividend payout ratio is only 23%, significantly lower than AbbVie's, which is north of 50%. Clearly, Gilead Sciences has wiggle room to return more money to investors through dividends.
AbbVie's dividend potential may be even more compelling, though. Since being spun out of Abbott Labs in 2013, its dividend has increased by 140%. Given AbbVie's double-digit top- and bottom-line growth, a recent 35% increase to its quarterly dividend payment, multiple potential blockbuster approvals, and a forward dividend yield of 3.3% that's better than Gilead Sciences' 2.8% rate, AbbVie looks better here, too.
One more thing
The one category where Gilead Sciences shines versus AbbVie is in valuation. AbbVie trades at a forward P/E of 13 and a price-to-sales of 6.4, while Gilead Sciences trades at 12.3 times forward EPS and 3.9 times sales. Clearly, Gilead Sciences is cheaper than AbbVie. That alone might not be enough of a reason to favor it over AbbVie, though.
Gilead Sciences is forecasting sales of between only $20 billion and $21 billion this year, down from $25.7 billion in 2016, and if its sales and profit fall faster than feared, then its valuation advantage could fade, especially if AbbVie over-delivers on its outlook for 13% sales growth this year.
For this reason, I think AbbVie is the better stock to buy until Gilead Sciences proves its sales and profit have stopped declining.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Todd Campbell owns shares of Celgene and Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead Sciences catapulted to the forefront of research into the use of gene therapies as cancer treatments when it acquired Kite Pharma for $11.9 billion last year, but it faces stiff competition in this field from many competitors, including Novartis (NYSE: NVS) and Celgene (NASDAQ: CELG) , that could limit that market opportunity. Gilead Sciences' Yescarta is the only CAR-T gene therapy on the market for late-stage non-Hodgkin lymphoma currently, but it generated only $7 million in sales since its launch last October. Rova-T may also be filed for approval this year if it delivers strong phase 2 results in third-line or greater small-cell lung cancer. | Growing demand for its best-selling drugs, Humira and Imbruvica, and new drug launches, including Mavyret, the company's latest hepatitis C treatment, are increasing sales by double-digit percentages. Given AbbVie's double-digit top- and bottom-line growth, a recent 35% increase to its quarterly dividend payment, multiple potential blockbuster approvals, and a forward dividend yield of 3.3% that's better than Gilead Sciences' 2.8% rate, AbbVie looks better here, too. AbbVie trades at a forward P/E of 13 and a price-to-sales of 6.4, while Gilead Sciences trades at 12.3 times forward EPS and 3.9 times sales. | Given AbbVie's double-digit top- and bottom-line growth, a recent 35% increase to its quarterly dividend payment, multiple potential blockbuster approvals, and a forward dividend yield of 3.3% that's better than Gilead Sciences' 2.8% rate, AbbVie looks better here, too. Gilead Sciences is forecasting sales of between only $20 billion and $21 billion this year, down from $25.7 billion in 2016, and if its sales and profit fall faster than feared, then its valuation advantage could fade, especially if AbbVie over-delivers on its outlook for 13% sales growth this year. For this reason, I think AbbVie is the better stock to buy until Gilead Sciences proves its sales and profit have stopped declining. | And that means it has exciting drugs advancing through its drug pipeline. Debating dividends Both companies offer income investors market-beating dividend yields, and each company has wads of cash at its disposal to boost dividends in the future. Gilead Sciences is forecasting sales of between only $20 billion and $21 billion this year, down from $25.7 billion in 2016, and if its sales and profit fall faster than feared, then its valuation advantage could fade, especially if AbbVie over-delivers on its outlook for 13% sales growth this year. |
33330.0 | 2018-02-16 00:00:00 UTC | Cardiovascular Systems Portfolio Solid, Competition Rife | ABT | https://www.nasdaq.com/articles/cardiovascular-systems-portfolio-solid-competition-rife-2018-02-16 | nan | nan | On Feb 12, we issued an updated research report on Cardiovascular Systems, Inc.CSII . The stock carries a Zacks Rank #3 (Hold).
This medical device manufacturer, developer and marketer of innovative solutions to treat patients with peripheral and coronary arterial diseases, including those with arterial calcium, saw a solid second quarter of fiscal 2018. The company witnessed year-over-year rise in revenues at both coronary arterial disease (CAD) and coronary arterial disease (PAD) businesses. Also, the expansion in gross margin was impressive.
Cardiovascular Systems has been expanding its product portfolio to enhance market reach. Currently, Cardiovascular Systems is pursuing product improvement and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools. Earlier, the company had received FDA approval for the Diamondback 360 Coronary OAS Micro Crown system to facilitate stent delivery in patients with CAD. The company also won approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the Diamondback 360 Coronary OAS Micro Crown and launched it commercially in February. Also, the company received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD.
We are upbeat about Cardiovascular Systems' two new partnerships, which have broadened its portfolio. The company is now the U.S. distributor of OrbusNeich balloon products. OrbusNeich PCI balloons include the Sapphire II Pro, which is scheduled to get FDA approval this year for the 1.0 mm coronary balloon. Moreover, the company has signed an original equipment manufacturer (OEM) agreement with Integer Holdings Corporation for CSI-branded ZILIENT guidewires.
We are also optimistic about the favorable trends in the PAD as well as CAD spaces. Per the American Heart Association, as many as 8-12 million Americans suffer from PAD. Moreover, an aging population coupled with rising incidence of diabetes and obesity is likely to increase the occurrence of PAD. This offers a huge scope for the unique PAD Orbital Atherectomy System (OAS) of Cardiovascular Systems.
Over the past three months, Cardiovascular Systems has been underperforming the industry . The stock has declined 7.8% against the industry's 1.9% rise.
Furthermore, the company faces cutthroat competition in the niche space. Its OAS products compete with a variety of other products or devices for the treatment of vascular disease, including stents, balloon angioplasty catheters and atherectomy catheters, as well as products used in vascular surgery. Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Moreover, on the profitability front, Cardiovascular Systems has a long history of net losses since its inception in 1989, with no immediate recovery in sight.
Key Picks
Some better-ranked stocks in the broader medical sector are PerkinElmer PKI and Bio-Rad Laboratories BIO .
Bio-Rad Laboratories has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The company has a long-term expected earnings growth rate of 25%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
PerkinElmer, Inc. (PKI): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier, the company had received FDA approval for the Diamondback 360 Coronary OAS Micro Crown system to facilitate stent delivery in patients with CAD. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Earlier, the company had received FDA approval for the Diamondback 360 Coronary OAS Micro Crown system to facilitate stent delivery in patients with CAD. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . The company witnessed year-over-year rise in revenues at both coronary arterial disease (CAD) and coronary arterial disease (PAD) businesses. | Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Cardiovascular Systems has been expanding its product portfolio to enhance market reach. |
33331.0 | 2018-02-16 00:00:00 UTC | Abbott Laboratories Jumps After Boosting Quarterly Dividend | ABT | https://www.nasdaq.com/articles/abbott-laboratories-jumps-after-boosting-quarterly-dividend-2018-02-16 | nan | nan | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924.
[ibd-display-video id=3151980 width=50 float=left autostart=true] The cash dividend is payable May 15 to shareholders of record at the close of business on April 13, Abbott said in a news release.
Abbott has increased its dividend payout for 46 consecutive years. Its 12-month dividend yield is 1.87% and the firm has a three-year dividend growth of 6.1%, a spokesperson told Investor's Business Daily.
In comparison, the average 12-month yield for health care companies in the S&P 500 is 1.79%.
Midday on the stock market today , Abbott rose 1.5%, near 60.40.
RELATED:
Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries
AbbVie Stock Rises After Increasing Dividend By 35%
This Biotech Stock May Need Anesthesia After Collapsing Nearly 20%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924. [ibd-display-video id=3151980 width=50 float=left autostart=true] The cash dividend is payable May 15 to shareholders of record at the close of business on April 13, Abbott said in a news release. Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries AbbVie Stock Rises After Increasing Dividend By 35% This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924. Abbott has increased its dividend payout for 46 consecutive years. Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries AbbVie Stock Rises After Increasing Dividend By 35% This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924. Its 12-month dividend yield is 1.87% and the firm has a three-year dividend growth of 6.1%, a spokesperson told Investor's Business Daily. Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries AbbVie Stock Rises After Increasing Dividend By 35% This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924. [ibd-display-video id=3151980 width=50 float=left autostart=true] The cash dividend is payable May 15 to shareholders of record at the close of business on April 13, Abbott said in a news release. Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries AbbVie Stock Rises After Increasing Dividend By 35% This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33332.0 | 2018-02-15 00:00:00 UTC | Noteworthy ETF Outflows: IWB, MDT, UNP, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwb-mdt-unp-abt-2018-02-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.0 million dollar outflow -- that's a 1.0% decrease week over week (from 133,450,000 to 132,050,000). Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.0 million dollar outflow -- that's a 1.0% decrease week over week (from 133,450,000 to 132,050,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. | Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.0 million dollar outflow -- that's a 1.0% decrease week over week (from 133,450,000 to 132,050,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. |
33333.0 | 2018-02-15 00:00:00 UTC | Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America? | ABT | https://www.nasdaq.com/articles/did-abbvie-inc-just-become-most-shareholder-friendly-stock-america-2018-02-15 | nan | nan | AbbVie, Inc. 's (NYSE: ABBV) on a roll and it wants its investors to profit. The company's dividend payments and stock buybacks since becoming public in 2013 have steadily increased, and on Thursday management outlined a new plan to return even more money to its shareholders.
Cashing in on clarity
AbbVie generates 65% of its sales from Humira, a best-selling autoimmune disease drug. Until recently, worry over Humira's patent protection has created uncertainty among investors that has weighed down the company's share price.
Concern over Humira's future began easing last fall, and that has management and investors cheering. A patent ruling on Humira in September thwarted a challenge by Coherus Biosciences ', and shortly thereafter Amgen (NASDAQ: AMGN) signed a non-exclusive license prohibiting it from marketing a Humira biosimilar in the U.S. until 2023.
The two events add conviction to management's claims that it can protect its biggest cash cow for a few more years. In January, management forecast that Humira's sales could grow from $18.4 billion in 2017 to $21 billion in 2020. Furthermore, it said it believes that Humira will contribute significantly to its sales until at least 2025.
The bullish outlook is encouraging because it suggests that management has plenty of time to expand its existing drugs into new indications and establish drugs that are currently in its pipeline as blockbusters .
In the past, AbbVie's said that peak sales of Imbruvica, a cancer drug, could be $7 billion. With a recent label expansion for use in graft-versus-host disease and full-year global sales of $2.573 billion in 2017, up 40.5% from 2016, it appears to be well on its way. Venxclexta label expansions, including one that's pending for its use alongside Rituxan in relapsing or refractory chronic lymphocytic leukemia, could significantly grow its sales, and if Elagolix wins FDA approval this year in endometriosis, then it could be an important revenue-producing drug, too. Management also has high hopes for its hepatitis C drug Mavyret, predicting last month its sales could drive hepatitis C revenue up to $2.5 billion this year from $1.3 billion in 2017.
Rova-T, a solid-tumor cancer drug, upadicitinib, a rheumatoid arthritis drug, and risankizumab, a psoriasis drug are the three most exciting potential blockbuster drugs in AbbVie's pipeline. Management's targeting FDA approvals for each in the coming year. If approved, all three have multibillion-dollar per year sales potential, according to forecasts.
Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks.
AbbVie boasts one of the best operating margins in the industry, and that's allowing it to return a substantial amount of money to investors. Since being spun-off from Abbott Labs in 2013, AbbVie's dividend has increased 77% through Wednesday. Following Thursday's announcement that it's increasing its quarterly dividend payment to $0.96 from $0.71, that figure jumps to an eye-popping 140% growth.
In addition to increasing its dividend by 35% Thursday, AbbVie announced a new $10 billion share buyback program. The program replaces its existing buyback plans, and over time it should provide additional support to future earnings-per-share growth.
The takeaway
If clinical trials go AbbVie's way, then it thinks its non-Humira revenue can grow from $9.6 billion in 2017 to over $16 billion in 2020 to over $35 billion in 2025. A lot could go wrong between now and then, but if sales end up anywhere near those projections, AbbVie should be able to offset any sales decline for Humira when it does eventually face-off against biosimilar copy-cats.
Overall, AbbVie's decision to increase its dividend by so much has me thinking management's comfortable that its cash flow isn't going to shrink anytime soon. With a runway toward ongoing double-digit top- and bottom-line growth and a forward dividend yield that's now 3.3%, an argument can be made that AbbVie's become the most shareholder-friendly stock investors can buy.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Venxclexta label expansions, including one that's pending for its use alongside Rituxan in relapsing or refractory chronic lymphocytic leukemia, could significantly grow its sales, and if Elagolix wins FDA approval this year in endometriosis, then it could be an important revenue-producing drug, too. Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. With a runway toward ongoing double-digit top- and bottom-line growth and a forward dividend yield that's now 3.3%, an argument can be made that AbbVie's become the most shareholder-friendly stock investors can buy. | Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. In addition to increasing its dividend by 35% Thursday, AbbVie announced a new $10 billion share buyback program. The program replaces its existing buyback plans, and over time it should provide additional support to future earnings-per-share growth. | Management also has high hopes for its hepatitis C drug Mavyret, predicting last month its sales could drive hepatitis C revenue up to $2.5 billion this year from $1.3 billion in 2017. Rova-T, a solid-tumor cancer drug, upadicitinib, a rheumatoid arthritis drug, and risankizumab, a psoriasis drug are the three most exciting potential blockbuster drugs in AbbVie's pipeline. Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. | The company's dividend payments and stock buybacks since becoming public in 2013 have steadily increased, and on Thursday management outlined a new plan to return even more money to its shareholders. Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. In addition to increasing its dividend by 35% Thursday, AbbVie announced a new $10 billion share buyback program. |
33334.0 | 2018-02-15 00:00:00 UTC | A Snapshot Of Abbott Labs' Business | ABT | https://www.nasdaq.com/articles/snapshot-abbott-labs-business-2018-02-15 | nan | nan | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. While there was some skepticism in the market initially as the acquisitions impacted the company's leverage and interest coverage, the stock's momentum in 2017 suggests that investors are valuing the longer term impact of Abbott's strategy in a positive light. To give investors a quick overview of Abbott's business, we have created an interactive dashboard using Trefis' technology that shows how Abbott has performed in recent years, and how is it likely to grow in the next 2 years.
Abbott's Revenue & EBITDA Composition
The Medical Devices business is Abbott's largest segment, and accounts for nearly 39% of its revenue and gross profit. This business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and the recently acquired St Jude Medical. The next largest segment, Nutritionals, accounts for 26% of revenue, followed by Diagnostics (19%) and Pharmaceuticals (16%). Abbott has a broad presence in the healthcare market, especially in medical devices and diagnostics businesses, and in addition to the St. Jude deal, it also acquired Alere to strengthen its market position.
Abbott's Past Revenue & Gross Profit Growth
Between 2012 and 2016, Abbott's revenue increased from $19 billion to $20.8 billion, growing at a CAGR of just 2.3%. This prompted the company to expand inorganically, with the aforementioned acquisitions of Alere and St Jude Medical which led to a sharp jump in revenue and gross profit in 2017. With these acquisitions, the company gained access to the fast growing rapid and point-of-care diagnostics market, as well as significantly improving its presence in the cardiovascular market. You can see segment-wise details of its revenue and EBITDA growth on our dashboard.
Abbott's Future Revenue & Gross Profit Growth
We expect Abbott's annual revenue to increase from $27.4 billion in 2017 to over $31 billion by 2019, implying a CAGR of 6.7%. This is significantly higher than the growth that Abbott saw between 2012 and 2016, before the acquisitions. This can partially be attributed to the fact that the year 2018 will reflect the full impact of these acquisitions. In addition, we expect Abbott's organic growth to improve as the company adjusts to new regulations in China, and leverages its stronger market position that it gained with the addition of St Jude Medical and Alere. To see details of segment revenue and EBITDA growth, see our dashboard.
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. While there was some skepticism in the market initially as the acquisitions impacted the company's leverage and interest coverage, the stock's momentum in 2017 suggests that investors are valuing the longer term impact of Abbott's strategy in a positive light. This prompted the company to expand inorganically, with the aforementioned acquisitions of Alere and St Jude Medical which led to a sharp jump in revenue and gross profit in 2017. | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. Abbott's Revenue & EBITDA Composition The Medical Devices business is Abbott's largest segment, and accounts for nearly 39% of its revenue and gross profit. Abbott's Past Revenue & Gross Profit Growth Between 2012 and 2016, Abbott's revenue increased from $19 billion to $20.8 billion, growing at a CAGR of just 2.3%. | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. Abbott's Revenue & EBITDA Composition The Medical Devices business is Abbott's largest segment, and accounts for nearly 39% of its revenue and gross profit. Abbott's Past Revenue & Gross Profit Growth Between 2012 and 2016, Abbott's revenue increased from $19 billion to $20.8 billion, growing at a CAGR of just 2.3%. | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. Abbott's Revenue & EBITDA Composition The Medical Devices business is Abbott's largest segment, and accounts for nearly 39% of its revenue and gross profit. This prompted the company to expand inorganically, with the aforementioned acquisitions of Alere and St Jude Medical which led to a sharp jump in revenue and gross profit in 2017. |
33335.0 | 2018-02-14 00:00:00 UTC | Analysts Anticipate XRLV To Hit $37 | ABT | https://www.nasdaq.com/articles/analysts-anticipate-xrlv-hit-37-2018-02-14 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares S&P 500 ex-Rate Sensitive Low Volatility Portfolio ETF (Symbol: XRLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $37.11 per unit.
With XRLV trading at a recent price near $33.62 per unit, that means that analysts see 10.37% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. Similarly, BLK has 12.47% upside from the recent share price of $521.27 if the average analyst target price of $586.25/share is reached, and analysts on average are expecting GD to reach a target price of $237.83/share, which is 12.29% above the recent price of $211.81. Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). | Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. | Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. |
33336.0 | 2018-02-14 00:00:00 UTC | 7 ‘Strong Buy’ Stocks That Look Cheap Right Now | ABT | https://www.nasdaq.com/articles/7-strong-buy-stocks-look-cheap-right-now-2018-02-14 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Hold onto your seats! The Dow Jones Industrial Average has just suffered its worst week in the last two years. And while the market may be edging back into the green, we can expect more volatility further down the road. However, it's important to distinguish between a crash and normal market fluctuations. Right now, fundamentals remain strong.
"When the nervousness hit, a lot of people who were thinking of quitting hit the exits," Key Private Bank's Bruce McCain told CNBC . "A lot of people want to let it settle out a bit and really make sure the worst has past … [but] for our standpoint on where we'll be over the next year: We see no signs of recession."
Indeed, for some market commentators, pullbacks can produce interesting buying opportunities. "Although a massive market drop can be attention-grabbing, it can also present a buying opportunity," wrote Kathryn Vasel, personal finance reporter for CNNMoney .
7 Stocks to Own Should the Latest Correction Get REALLY Ugly
And if we look at top analyst stock recommendations and price targets , these seven stocks look especially undervalued right now. I highly recommend tracking these seven stocks through this volatile market - especially as all seven stocks boast an analyst rating of "Strong Buy." This is based on only the last three months of ratings. Let's delve in to these seven stock picks now:
Strong Buy Stock: Facebook (FB)
Source: Shutterstock
- 28 analyst buy ratings, two hold ratings and one sell rating in last three months
- 28% upside potential from current share price to average analyst price target
Social media giant Facebook Inc (NASDAQ: FB ) hasn't escaped the recent pullback. Shares are down by 6% over the last week. However, on a one-year basis, note shares are firmly in the green with growth of over 31%. And according to top RBC Capital analyst Mark Mahaney , if there is one key tech stock that has strong growth potential right now, it's Facebook.
He ramped up his FB price target from $230 to $250 (40% upside potential) on February 1 following "very impressive" Q4 fundamentals. Revenue hit a whopping $12.97 billion , soaring past Thomas Reuters consensus of $12.55 billion. Mahaney also highlighted the stock's "very consistent and premium growth with record-high Operating Margins."
At the same time, he didn't miss the opportunity to remind investors that: "FB is the Best Growth Story in Tech. And we believe that's FB's current low market shares - less than 20% of Global Online Advertising & mid-single-digit % of Global Total Advertising - will help it maintain premium growth for a long time." Plus FB still has many big growth drivers up its sleeve from Instagram to video.
Strong Buy Stock: Abbott Labs (ABT)
- 12 analyst buy ratings vs two hold ratings in last three months
- 21% upside potential from current share price to average analyst price target
Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. But shares are still marginally up over the last three months (and 33% over the last year). Following the latest price move, David Toung's new $80 price target suggests impressive upside potential of 40%. He bumped up his price target from just $66 on Jan. 30.
3 Sector ETFs to Buy Now at Discounted Prices
He is a fan of the stock's strong Q4 top-line growth and sees the company's future expansion driven by 1) the acquisitions of St. Jude Medical and Alere and 2) the recent launch of new products. As a result, Toung is confident that the stock now merits a premium valuation. And as the stock's 'Strong Buy' consensus shows, analysts clearly agree with him.
Strong Buy Stock: Lam Research (LRCX)
- 54% upside potential from current share price to average analyst price target
Semiconductor hot stock Lam Research Corporation (NASDAQ: LRCX ) is trading at around $182 right now. Given that LRCX has only buy ratings and upside potential of over 40%, the signs from the Street appear promising for a significant rebound. Bear in mind that even with the recent fall, prices are still up on a one-year basis by over 40%.
Five-star Credit Suisse analyst Farhan Ahmad has a strong record from the Street. On Lam Research specifically he scores an 80% success rate and 38% average return. He recently ramped up his 12-month price target from $245 to $275. This is the Street's highest price target yet in LRCX and indicates big upside potential of 66%.
Ahmad explains why the market is still undervaluing LRCX: "We believe that investors continue to underestimate secular growth driven by rising capital intensity (LRCX revs per 1% bit growth has more than tripled over the last four years), and underestimate its increasing installed base which has supported +20% CAGR for Services (25% of revs)." He believes that the company has 'a solid case for target EPS of >$20' at analyst day on March 6.
Strong Buy Stock: Amazon (AMZN)
- 35 analyst buy ratings vs two hold ratings in last three months
- 14% upside potential from current share price to average analyst price target
Even shares in one of the world's most exciting companies suffered last week, with shares off by 6.32% at $1,339. However, this is just a small blip on Amazon.com, Inc.'s (NASDAQ: AMZN ) massive growth trajectory. On a one-year basis shares are up by no less than 73% - and even on a three-month basis shares are up over 26%.
Looking forward, Amazon has plenty of meaningful revenue streams to keep growth rates rising. Most notably, the company is now reportedly planning a new service to pick up packages from businesses and deliver them to consumers. According to the Wall Street Journal , the service, called "Shipping With Amazon," is expected to start in LA and roll out more broadly within the year.
10 High-Risk, High-Reward Stocks to Buy as the Market Shudders
Baird's Colin Sebastian estimates that with "just 1% of the market, Amazon could create a new $5B revenue stream." Shares in rival delivery companies UPS and FedEx slipped on the news.
Strong Buy Stock: CVS Health (CVS)
- Nine analyst buy ratings vs two hold ratings in last three months
- 27% upside potential from current share price to average analyst price target
US pharmacy and retail health care giant CVS Health Corporation (NYSE: CVS ) took a battering over the last week with shares down by 9%. Indeed- shares have under-performed over the last year. But top Oppenheimer analyst Mohan Naidu is not giving up hope. On the contrary, he has just reiterated his buy rating with a price target of $92 (32% upside potential).
Naidu is bullish on CVS's plan to acquire Aetna Inc. (NYSE: AET ) for a whopping $69 billion. He says: "Despite the numbers move near term, we think the focus should be on the CVS-AET combination, which should strengthen CVS's position and have significant positive long-term impact."
The deal - which would create a massive integrated health care company with both pharmacy and health benefits as well as preventative care services - is due to close in the second half of the year. A shareholder vote is planned for March 20 and according to a recent comment by CVS CEO Larry Merlo, "things are moving along as planned."
Strong Buy Stock: Prudential Financial (PRU)
- Five analyst buy ratings vs one hold rating in last three months
- 23% upside potential from current share price to average analyst price target
The largest U.S. life insurer by assets, I believe that Prudential Financial Inc (NYSE: PRU ) is a key stock to track right now. The company has just reported solid earnings results for the fourth quarter, beating consensus EPS estimates of $2.65 at $2.69. However, shares are still down by almost 10% over the last week - and the stock is now trading at just $106.
Top B.Riley FBR analyst Randy Binner likes what he sees. He noted the "unusually good" results from the retirement and asset management unit, and above-forecast results for Japan and Gibraltar in particular. He tells investors: "While U.S. protection margins were weaker, the larger segments did well, showing the benefits of the company's broad diversification. We maintain our Buy rating considering favorable valuation at 9.1x 2018E EPS."
Indeed Binner's $140 price target comes in way above consensus and indicates 32% upside potential ahead.
7 Stocks to Buy That Could Skyrocket with a Weakened CFPB
Note that Binner is one of the top 250 analysts on TipRanks with a 70% success rate and 15% average return.
Strong Buy Stock : Activision Blizzard (ATVI)
- 11 analyst buy ratings vs 3 hold ratings in last 3 months
- 14% upside potential from current share price to average analyst price target
Video game publisher Activision Blizzard, Inc. (NASDAQ: ATVI ) is the name behind masterpieces like Candy Crush, Call of Duty and World of Warcraft. And Jefferies' Timothy O'Shea doesn't hold back when he says that: "We believe Activision is building a Disney-style entertainment business for the 21st century, but with higher operating margins." Plus, while ATVI may be down by 6% over the last week, over the last year the stock is up by an incredible 69%.
Now ATVI has just released Q4 results that beat Street expectations, boosted by the successful launch of Activision's "Call of Duty: WWII." The game made $1 billion in just six weeks, and even became the top grossing console game of the year globally. "With a direct connection to 385MM deeply engaged users (50 mins/day), we continue to see a vast opportunity for ATVI to more deeply monetize its audience" says O'Shea.
He took the opportunity to bump up his price target from $82 to $86. Now this top analyst is anticipating a 28% price spike in the coming months.
TipRanks offers investors the latest insight into eight different sectors by tracking the activity of 4,500 analysts, 5,000 financial bloggers and even 37,000 corporate insiders. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 7 'Strong Buy' Stocks That Look Cheap Right Now appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Strong Buy Stock: Abbott Labs (ABT) - 12 analyst buy ratings vs two hold ratings in last three months - 21% upside potential from current share price to average analyst price target Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. 3 Sector ETFs to Buy Now at Discounted Prices He is a fan of the stock's strong Q4 top-line growth and sees the company's future expansion driven by 1) the acquisitions of St. Jude Medical and Alere and 2) the recent launch of new products. Strong Buy Stock : Activision Blizzard (ATVI) - 11 analyst buy ratings vs 3 hold ratings in last 3 months - 14% upside potential from current share price to average analyst price target Video game publisher Activision Blizzard, Inc. (NASDAQ: ATVI ) is the name behind masterpieces like Candy Crush, Call of Duty and World of Warcraft. | Strong Buy Stock: Abbott Labs (ABT) - 12 analyst buy ratings vs two hold ratings in last three months - 21% upside potential from current share price to average analyst price target Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. Let's delve in to these seven stock picks now: Strong Buy Stock: Facebook (FB) Source: Shutterstock - 28 analyst buy ratings, two hold ratings and one sell rating in last three months - 28% upside potential from current share price to average analyst price target Social media giant Facebook Inc (NASDAQ: FB ) hasn't escaped the recent pullback. Strong Buy Stock: CVS Health (CVS) - Nine analyst buy ratings vs two hold ratings in last three months - 27% upside potential from current share price to average analyst price target US pharmacy and retail health care giant CVS Health Corporation (NYSE: CVS ) took a battering over the last week with shares down by 9%. | Strong Buy Stock: Abbott Labs (ABT) - 12 analyst buy ratings vs two hold ratings in last three months - 21% upside potential from current share price to average analyst price target Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. Let's delve in to these seven stock picks now: Strong Buy Stock: Facebook (FB) Source: Shutterstock - 28 analyst buy ratings, two hold ratings and one sell rating in last three months - 28% upside potential from current share price to average analyst price target Social media giant Facebook Inc (NASDAQ: FB ) hasn't escaped the recent pullback. Strong Buy Stock: Amazon (AMZN) - 35 analyst buy ratings vs two hold ratings in last three months - 14% upside potential from current share price to average analyst price target Even shares in one of the world's most exciting companies suffered last week, with shares off by 6.32% at $1,339. | Strong Buy Stock: Abbott Labs (ABT) - 12 analyst buy ratings vs two hold ratings in last three months - 21% upside potential from current share price to average analyst price target Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. But shares are still marginally up over the last three months (and 33% over the last year). Strong Buy Stock: Amazon (AMZN) - 35 analyst buy ratings vs two hold ratings in last three months - 14% upside potential from current share price to average analyst price target Even shares in one of the world's most exciting companies suffered last week, with shares off by 6.32% at $1,339. |
33337.0 | 2018-02-11 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in February | ABT | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-february-2018-02-11 | nan | nan | The recent market downturn has created some great buying opportunity for opportunistic healthcare investors. But which stocks can be safely purchased today? We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) .
Everybody can love this stock
Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. In fact, it's unusual to find a stock that does have such an appeal. However, I think AbbVie does. It's a stock everybody can love.
Let's start with growth. Over the past three years, AbbVie has generated the highest total shareholder return and the highest adjusted earnings-per-share growth of any big pharma stock. The drugmaker should be able to keep its impressive momentum going.
Humira is on track to continue its reign as the world's top-selling drug for years to come. Sales for cancer drug Imbruvica are soaring. Hepatitis C drug Mavyret should become AbbVie's next blockbuster. And the company has a pipeline chock-full of potential big winners. Wall Street expects AbbVie to grow earnings by 17% annually over the next five years.
What about valuation? Even after gaining more than 80% over the last 12 months, AbbVie stock still trades at only 13 times expected earnings. Factoring growth potential in makes the stock's valuation look even more attractive for value investors.
Of course, income investors are more interested in juicy dividends. AbbVie's got that base covered, too. The company's dividend currently yields 2.44%. AbbVie has increased its dividend payout by nearly 78% since being spun off from Abbott Labs (NYSE: ABT) in 2013.
Whatever your style of investing, AbbVie has something to offer. And with several new product launches and pipeline updates on the way , February is a great time to buy this pharma stock.
A key player in the fight to keep healthcare costs down
Chuck Saletta (Mylan Laboratories): Generic-drug maker Mylan Laboratories is a recognized leader when it comes to keeping a lid on escalating healthcare costs. A generic pharmaceutical manufacturer tracing its history back to the 1960s, Mylan Laboratories has long played a role in driving down the costs of medicines that have lost their patent protections.
What makes Mylan Laboratories look like a strong potential investment right now, though, is the fact that its shares are priced at a bargain compared to its potential. Its shares currently fetch less than eight times its forward earnings, and those earnings are anticipated to grow by better than 4% annualized over the next five years. While that's not exactly a rapid growth trajectory, it is positive expectations, making that forward price-to-earnings ratio a bargain price for a solid business.
Backing up that earnings potential is a solid balance sheet. Mylan Laboratories currently sports a bit more than $760 million in cash, a debt-to-equity ratio just slightly above 1, and a current ratio above 1.4. That balance-sheet strength gives Mylan the ability to ride out ups and downs in the economy without major worry regarding being able to roll its debts as they mature.
It's not often that you can buy shares of a well-capitalized, leading and growing business for less than 10 times its expected earnings, but right now, with Mylan Laboratories, you can.
Pharma's go-to partner
Brian Feroldi (IQVIA Holdings): Developing a new drug from scratch is a long and grueling process fraught with risk. What's more, even if you cross the finish line, there's no guarantee that healthcare providers, insurers, or patients will even use your product.
With millions (or billions) on the line, most drug developers are willing to do anything they can to give their compound the best shot at success. That's why many of them choose to partner up with IQVIA Holdings.
IQVIA -- formerly known as Quintiles IMS -- is the world's largest clinical research organization. Drug developers can hire IQVIA to run their clinical trials, gather the lab work, and analyze the data. This is a process that IQVIA understands inside and out, which is why so many companies are willing to partner with it. For evidence of its popularity, consider that the company's backlog of projects stood at $10.3 billion as of the end of September.
Better yet, if a drug does makes it to market, IQVIA can also help with the commercialization process. IQVIA boasts a huge database of patient records and prescriptions that can be accessed for a fee. Most pharmaceutical companies are happy to pay up for access because it enables their sales team to reach maximum efficiency.
When combined, these two businesses enable IQVIA to make money from all facets of the drug development process. With its shares currently trading hands for around 18 times 2018 earnings estimates, right now is a great time to get in.
10 stocks we like better than IQVIA Holdings, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and IQVIA Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Brian Feroldi has no position in any of the stocks mentioned. Chuck Saletta has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie. The Motley Fool recommends IQVIA Holdings, Inc. and Mylan. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has increased its dividend payout by nearly 78% since being spun off from Abbott Labs (NYSE: ABT) in 2013. A generic pharmaceutical manufacturer tracing its history back to the 1960s, Mylan Laboratories has long played a role in driving down the costs of medicines that have lost their patent protections. That balance-sheet strength gives Mylan the ability to ride out ups and downs in the economy without major worry regarding being able to roll its debts as they mature. | AbbVie has increased its dividend payout by nearly 78% since being spun off from Abbott Labs (NYSE: ABT) in 2013. We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. | AbbVie has increased its dividend payout by nearly 78% since being spun off from Abbott Labs (NYSE: ABT) in 2013. We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. | AbbVie has increased its dividend payout by nearly 78% since being spun off from Abbott Labs (NYSE: ABT) in 2013. However, I think AbbVie does. Factoring growth potential in makes the stock's valuation look even more attractive for value investors. |
33338.0 | 2018-02-07 00:00:00 UTC | Vanguard Value ETF Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/vanguard-value-etf-experiences-big-outflow-2018-02-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $148.0 million dollar outflow -- that's a 0.4% decrease week over week (from 345,465,467 to 344,067,457). Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $148.0 million dollar outflow -- that's a 0.4% decrease week over week (from 345,465,467 to 344,067,457). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. | Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33339.0 | 2018-02-07 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABT | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2018-02-07 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on CAH - FREE
Get the latest Zacks research report on ABT - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on CAH - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | Get the latest Zacks research report on CAH - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on CAH - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Get the latest Zacks research report on CAH - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. |
33340.0 | 2018-02-06 00:00:00 UTC | 3 Top-Rated Dividend Aristocrats For 2018 | ABT | https://www.nasdaq.com/articles/3-top-rated-dividend-aristocrats-for-2018-2018-02-06 | nan | nan | Given the current market volatility it makes sense to look for stocks with stability. And if you are looking for dividend stocks with consistent growth and a favorable outlook then you are in luck. The Dividend Aristocrats are a group of 50 companies in the S&P 500 Index, with 25-plus straight years of dividend increases. These companies span all eleven sectors within the index and encompass both large-cap growth and large-cap value stocks.
But out of all 50 stocks, how can investors pick the best Dividend Aristocrats to invest in right now? The answer is simple -- see what financial experts are saying about each of the stocks. With this in mind, we used TipRanks to search for Dividend Aristocrats that score a 'Strong Buy' analyst consensus rating. We also checked the upside potential from the average analyst price target. In each case, the bullish outlook underscores the fact that these dividend stocks make compelling investing opportunities right now.
Let’s take a closer look at these three top dividend picks:
McDonald's Corp (MCD)
Fast food emporium McDonalds’ may be best known for its Big Mac, but it also deserves recognition for its impressive dividend payout. Back in September, the board of directors approved a significant payout increase of 7%. This is now McDonald's 41st straight dividend increase. Following the move, McDonald's paid shareholders a $1.01 quarterly dividend in December with a 2.3% yield.
And the picture from the Street also looks encouraging. A post-earnings sell off share shares pull back from $178 to the current share price of $169. But according to the Street this dip represents a new buying opportunity. For example, BTIG analyst Peter Saleh has just reiterated his buy rating with a $200 price target.
On the back of the stock’s growing momentum he says: “We expect McDonald’s to continue to take market share, particularly in the U.S, driven by the introduction of its new value platform, Experience of the Future (EOTF), mobile ordering and upgrades to its food quality. We believe this comp momentum can continue for several years.”
Overall, we can see from TipRanks that MCD boasts a ‘Strong Buy’ analyst consensus rating. This breaks down into 17 buy ratings vs just 4 hold ratings over the last three months. Plus on Feb 2, five star Credit Suisse upgraded MCD from hold to buy- a key signal of the shifting sentment for this burger giant. In terms of price target, on average analysts see the stock spiking over 13% to hit $191 in the coming months.
Abbott Labs (ABT)
Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. The company has declared an incredible 376 consecutive quarterly dividends since 1924. We can also see how the dividend payout has increased for 46 consecutive years. With a 1.9% yield, shareholders can expected the next quarterly payment of $0.28 on Feb 15.
Following a fantastic Q4 earnings beat and topline growth, Abbott has received a slew of bullish analyst calls. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. This indicates big upside potential of 30%. Toung says the stock deserves a premium valuation due to 1) the recent launch of new products, and 2) the acquisitions of St. Jude Medical and Alere.
Abbott picked up medical device company St Jude for a hefty $25 billion back in 2017. As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. Its takeover of Alere has proved more complex however, and the $5 billion deal only completed in September.
This ‘Strong Buy’ stock has received 11 buy ratings in the last three months. During this time, only two analysts have published more cautious hold ratings on the stock. Given that ABT is currently trading at $61.69, analysts are projecting (on average) 13% upside from the current share price.
Chevron Corp (CVX)
Oil and gas giant Chevron Corporation is a top-rated Dividend Aristocrat. The company scores a double whammy of steady dividend increases over the last 30 years and a lucrative annual dividend yield of 3.6%. This is versus the basic materials sector average of just 2.13%. Just last week, healthy cash flow enabled Chevron to bump up its quarterly dividend payout by 4 cents to $1.12. According to the company, the increase "puts Chevron on track to make 2018 the 31st consecutive year with an increase in annual dividend payout.”
Indeed, Chevron has just reported a massive earnings beat, with $1.65 EPS on $36.4 billion in revenues for Q4. However, top Jefferies analyst Jason Gammel quickly pointed out that the beat resulted from a very significant $2 billion tax reform boost. Without this crucial addition, earnings of $0.72 would have missed the Street estimate of $1.22. Nonetheless, this news did not deter him from his bullish take on the stock. In fact Gammel reiterated his buy rating with a $149 price target (26% upside).
Furthermore, as the screenshot below reveals, top analysts have 100% buy ratings on CVX stock right now. In the last three months the Street’s best-performing analysts- i.e. the analysts who consistently get it right- have published 4 buy ratings on CVX. This comes with a bullish average price target of $148.75 suggesting big upside potential of almost 25% from the current share price.
Our database covers over 5,000 stocks. Find your own “Strong Buy” stocks in the sector that interests you the most. Go to the Nasdaq Smart Portfolio stock screener now.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. Abbott Labs (ABT) Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. | Abbott Labs (ABT) Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. | Abbott Labs (ABT) Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. | Abbott Labs (ABT) Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. |
33341.0 | 2018-02-06 00:00:00 UTC | Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View | ABT | https://www.nasdaq.com/articles/centene-cnc-beats-q4-earnings-revenues-ups-18-view-2018-02-06 | nan | nan | Centene Inc.CNC reported fourth-quarter 2017 adjusted net income per share of 97 cents, which beat the Zacks Consensus Estimate by 3.2%. Earnings, however, declined 18% year over year on higher expenses.
For the fourth quarter, total revenues grew 8% to $12.8 billion from the year-ago quarter, primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017. Revenues surpassed the Zacks Consensus Estimate of $12.3 billion by 4%.
Full-Year Update
For 2017, the company reported adjusted earnings of $5.03, up 13.5% year over year. The figure also surpassed the Zacks Consensus Estimate by 0.8%.
Centene reported total revenues of $48.4 billion, up 19% year over year. The rise was primarily driven by Health Net's results throughout the year, impact of growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017.
At the end of the year, managed care membership totaled 12.2 million, up 7% from 2016.
Quarterly Operational Update
Health Benefit Ratio (HBR) for the fourth quarter was 87.3% compared with 84.8% in the prior-year quarter. This reflects a year-over-year improvement of 250 basis points (bps).
In the quarter, adjusted selling, general & administrative (SG&A) ratio was 10.5%, up 110 bps year over year. The deteriorationis a result of increased business expansion costs over the prior-year quarter. Notably, revenues recognized in the fourth quarter of 2016, relating to the minimum MLR amendment in California, had reduced the quarter's adjusted SG&A expense ratio. Hence, the expense ratio for the fourth-quarter 2017 appears higher compared to the year-ago quarter.
Total operating expenses of $12.6 billion at the end of fourth quarter increased nearly 11% from the prior-year quarter.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote
Financial Update
As of Dec 31, 2017, Centene had cash and cash equivalents of $4 billion, up 3.6% from 2016 end.
Total assets of $21.8 billion grew 8.2%.
As of Dec 31, 2017, Centene's long-term debt totaled $4.7 billion, up 0.9%.
For 2017, cash inflow from operations was $1,489 million compared with $1,851 million at the end of 2016.
2018 Guidance
Centene expects adjusted earnings per share to be in the range of $6.95-$7.35, up from the previously guided range of $5.47-$5.87.
Total revenues are expected to be in the range of $60.6-$61.4 billion, up from the earlier guidance of $60.0 billion to $60.8 billion.
HBR is expected in the range of 86.2-86.7% compared with the previous guidance of 86.3% to 86.8%.
Adjusted SG&A expense ratio is expected in the range of 9.2-9.7%, up from the previous guidance of 9.0% to 9.5%.
Shares outstanding is expected be between 199.1 million and 200.1 million, down from the previous guidance of 201.1 million to 202.1 million.
Zacks Rank and Performance of Other Peers
Centene sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene Inc.CNC reported fourth-quarter 2017 adjusted net income per share of 97 cents, which beat the Zacks Consensus Estimate by 3.2%. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene Corporation Price, Consensus and EPS Surprise Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote Financial Update As of Dec 31, 2017, Centene had cash and cash equivalents of $4 billion, up 3.6% from 2016 end. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Centene reported total revenues of $48.4 billion, up 19% year over year. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene reported total revenues of $48.4 billion, up 19% year over year. |
33342.0 | 2018-02-02 00:00:00 UTC | How Much Can Abbott's Stock Move In 2018? | ABT | https://www.nasdaq.com/articles/how-much-can-abbotts-stock-move-2018-2018-02-02 | nan | nan | 2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. The momentum continued in the first month of 2018 as well, as better than expected Q4'17 results triggered the stock movement. It appears that Abbott's acquisitions of St Jude Medical and Alere, which were earlier seen as risky bets, are paying off. Does this mean that the stock can move further this year? Our base case analysis suggests that the potential certainly exists. We have created an interactive valuation calculator dashboard using Trefis' interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott's 2018 earnings (non-GAAP net income). If you have a different view, you can create your own scenario and come up with your own price estimate for Abbott.
Our base case gives a $70 price estimate for Abbott. We estimate that the company's trailing 12 month P/E multiple will be around 22 at the end of 2018, which is the average of the figures for the last 5 years. We believe this is a reasonable assumption because Abbott's P/E multiple has oscillated in a narrow range. We further estimate that Abbott's earnings (non-GAAP net income) for 2018 will hit nearly $5.46 billion. While we continue to believe that growth in the Nutritionals segment will be quite low (although better than before), we see moderate growth in the Pharmaceuticals business as the company will continue to benefit from the demand in emerging markets such as India, China and Latin America. In addition, we expect a strong jump in Diagnostics revenue and consequently, earnings, due to the Alere acquisition. If you have a different view, go to our interactive valuation calculator dashboard and modify the assumptions (blue dots) to come up with your own price estimate for Abbott.
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. It appears that Abbott's acquisitions of St Jude Medical and Alere, which were earlier seen as risky bets, are paying off. In addition, we expect a strong jump in Diagnostics revenue and consequently, earnings, due to the Alere acquisition. | 2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. We have created an interactive valuation calculator dashboard using Trefis' interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott's 2018 earnings (non-GAAP net income). We further estimate that Abbott's earnings (non-GAAP net income) for 2018 will hit nearly $5.46 billion. | 2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. We have created an interactive valuation calculator dashboard using Trefis' interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott's 2018 earnings (non-GAAP net income). If you have a different view, go to our interactive valuation calculator dashboard and modify the assumptions (blue dots) to come up with your own price estimate for Abbott. | 2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. The momentum continued in the first month of 2018 as well, as better than expected Q4'17 results triggered the stock movement. We have created an interactive valuation calculator dashboard using Trefis' interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott's 2018 earnings (non-GAAP net income). |
33343.0 | 2018-02-01 00:00:00 UTC | Boston Scientific Tops Fourth-Quarter Sales Views, Earnings In Line | ABT | https://www.nasdaq.com/articles/boston-scientific-tops-fourth-quarter-sales-views-earnings-line-2018-02-01 | nan | nan | Boston Scientific ( BSX ) issued a better-than-expected 2018 outlook on Thursday helped, in part, by stronger sales in its MedSurg unit, which topped the consensus by nearly 3% in the fourth quarter.
[ibd-display-video id=3119741 width=50 float=left autostart=true] For 2018, Boston Scientific now sees $9.65 billion to $9.8 billion in revenue, above the Street's model of $9.59 billion. But guidance for adjusted profit of $1.35-$1.39 per share was just in line with analysts' view for $1.37.
March-quarter guidance for $2.32 billion to $2.35 billion in sales beat the consensus for $2.295 billion. Boston Scientific said it expects adjusted earnings of 30-32 cents per share, in line with consensus at 31 cents.
By the closing bell on the stock market today , Boston Scientific lost 1.2% to close at 27.63. At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18.
During the fourth quarter, Boston Scientific brought in $2.41 billion in sales, growing 9.9%. That topped analysts' estimate for $2.37 billion in sales. Adjusted profit of 34 cents per share grew 13.3% and met expectations.
IBD'S TAKE:Boston Scientific has an IBD Composite Rating of 85, meaning it outperforms more than eight in 10 stocks in terms of key growth metrics. Head to IBD Stock Checkup for a look at stronger medtech stocks.
The lion's share of the sales growth was driven by Boston Scientific's MedSurg unit , which increased 14.2% to $931 million. Analysts had expected the MedSurg unit to bring in $905 million in sales, Evercore analyst Vijay Kumar said in a note to clients.
Organically, the unit grew 11%, RBC analyst Glenn Novarro said in a report. MedSurg sales include endoscopy, pelvic health and neuromodulation revenues. Sales of all three grew by double digit percentages during the quarter.
Cardiovascular unit sales were also a bright spot in the quarter, Evercore analyst Kumar said. Sales of $913 million grew 8.7% and beat views for $896 million.
In rhythm management, sales of defibrillators grew 8.5%, while pacemaker sales declined 7.1%. Defibrillator sales were helped by the introduction of devices that can be used in an MRI machine, Novarro said. Pacemakers are facing competition from Abbott.
RELATED:
Lilly Issues Beat-And-Raise But Dives Alongside Other Drug Stocks
Sage Therapeutics Just Popped To A Record High - Here's Why
Will 2018 Biopharma Merger Activity Become An AbbVie Story?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18. Boston Scientific ( BSX ) issued a better-than-expected 2018 outlook on Thursday helped, in part, by stronger sales in its MedSurg unit, which topped the consensus by nearly 3% in the fourth quarter. The lion's share of the sales growth was driven by Boston Scientific's MedSurg unit , which increased 14.2% to $931 million. | At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18. March-quarter guidance for $2.32 billion to $2.35 billion in sales beat the consensus for $2.295 billion. Boston Scientific said it expects adjusted earnings of 30-32 cents per share, in line with consensus at 31 cents. | At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18. Boston Scientific ( BSX ) issued a better-than-expected 2018 outlook on Thursday helped, in part, by stronger sales in its MedSurg unit, which topped the consensus by nearly 3% in the fourth quarter. March-quarter guidance for $2.32 billion to $2.35 billion in sales beat the consensus for $2.295 billion. | At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18. But guidance for adjusted profit of $1.35-$1.39 per share was just in line with analysts' view for $1.37. That topped analysts' estimate for $2.37 billion in sales. |
33344.0 | 2018-01-30 00:00:00 UTC | VTV, GE, AMGN, ABT: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/vtv-ge-amgn-abt-etf-inflow-alert-2018-01-30 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $129.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 344,312,330 to 345,465,467). Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $129.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 344,312,330 to 345,465,467). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. | Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $129.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 344,312,330 to 345,465,467). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. |
33345.0 | 2018-01-30 00:00:00 UTC | HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised) | ABT | https://www.nasdaq.com/articles/hca-healthcares-hca-q4-earnings-revenues-beat-estimates-revised-2018-01-30 | nan | nan | HCA Healthcare, Inc.HCA reported fourth-quarter 2017 adjusted earnings of $2.12 per share, which surpassed the Zacks Consensus Estimate of $1.86 by 14%. The bottom line also rose nearly 12.2% year over year.
The company reported net income per share of $1.30 in the fourth quarter that includes a non-cash increase in the company's provision for income taxes of 83 cents per share, stemming from the impact of the Tax Cuts and Jobs Act. This reflects 45% year-over-year decline.
For 2017, the company reported net income per share of $5.95, down 18% year over year.
HCA Healthcare generated revenues of $11.6 billion in the fourth quarter that surpassed the Zacks Consensus Estimate by 3.5%. The reported figure was up 8.6% from the year-ago quarter. The upside was primarily driven by an increase of 2.3% in same facility equivalent admissions and an increase of 3.5% in same facility revenue per equivalent admission compared to the year-ago quarter.
For 2017, the company reported revenues of $43.6 billion, up 5% year over year.
Quarterly Details
Adjusted EBITDA totaled $2.4 billion, up 7.1% year over year.
Same facility equivalent admissions inched up 2.3% year over year, while same facility admissions jumped 1.4%. Same facility revenue per equivalent admission increased 3.5%.
Total operating expenses increased 12% year over year to $10.2 billion.
As of Dec 31, 2017, HCA Healthcare ran 179 hospitals and 120 free-standing surgery centers.
HCA Holdings, Inc. Price, Consensus and EPS Surprise
HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote
Financial Update
As of Dec 31, 2017, the company had cash and cash equivalents of $732 million, total long-term debt of $32.8 billion and total assets of $36.6 billion.
During the reported quarter, capital expenditures totaled $982 million, excluding acquisitions. Cash flow provided by operating activities totaled $1.7 billion, up 2.1% year over year.
Share Repurchase Update
The company repurchased 7.2 million shares of its common stock for $576 million in the fourth quarter.
For 2017, the company repurchased 25.1 million shares of its common stock for $2.051 billion.
The company plans to increase its three-year capital expenditures program to pursue growth opportunities in its existing markets. The new capital investment program is expected to be of roughly $10.5 billion, up from the previous three-year spend of nearly $8.2 billion.
Dividend Update
HCA Healthcare has declared a quarterly cash dividend of 35 cents per share on the company's common stock. The dividend will be paid on Mar 30, 2018 to stockholders of record at the close of business on Mar 1.
The initiation of quarterly dividends reflects the company's financial strength.
2018 Guidance
The company expects 2018 revenues in the range of $45-$46 billion, adjusted EBIDTA of $8.45-$8.75 billion, EPS of $8.50-$9.00 and capital expenditures of about $3.5 billion.
Zacks Rank and Performance of Other Stocks
HCA Healthcare carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate.
Don't Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>
(We are reissuing this article to correct a mistake. The original article, issued on Jan 30, 2018, should no longer be relied upon.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
HCA Holdings, Inc. (HCA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. Don't Even Think About Buying Bitcoin Until You Read This The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Financial Update As of Dec 31, 2017, the company had cash and cash equivalents of $732 million, total long-term debt of $32.8 billion and total assets of $36.6 billion. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. For 2017, the company reported revenues of $43.6 billion, up 5% year over year. | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. For 2017, the company reported revenues of $43.6 billion, up 5% year over year. |
33346.0 | 2018-01-29 00:00:00 UTC | MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN | ABT | https://www.nasdaq.com/articles/medtech-stock-q4-earnings-slated-for-jan-30%3A-syk-zbh-algn-2018-01-29 | nan | nan | The fourth-quarter earnings season has commenced on a positive note for most sectors, with a decent picture from the 133 S&P 500 participants that have reported till Jan 26. Total earnings for these companies are up 12.3% year over year on 8.8% higher revenues, with 81.2% beating earnings estimates and 78.9% surpassing top-line expectations.
Notably, about 121 S&P 500 companies are reporting their earnings this week.
Per the latest Earnings Preview , overall earnings for the fourth quarter are expected to increase 11.6% on 7.5% growth in revenues. This indicates an improved growth projection from the previous quarter driven by a corporate-tax overhaul and relatively healthy job data. These factors have boosted corporate earnings and stoked investments.
Based on this pattern, the fourth quarter is expected to register modest double-digit percentage earnings growth on a year-over-year basis.
MedTech Earnings So Far
Medical, one among the 16 Zacks sectors, is expected to stand out this quarter. The sector benefits from favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value-based model.
This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . The companies exited the fourth quarter on a solid note, beating the Zacks Consensus Estimate on both counts. An upbeat FY18 guidance also instills confidence.
For the fourth quarter, the earnings growth rate for the medical sector is pegged at 4.2% on 4.9% revenue growth.
Upcoming Releases
Let's take a look at three major other MedTech stocks slated to release their quarterly reports on Jan 30, 2018:
Stryker Corporation's SYK results are scheduled for release after the market closes . Notably, the Zacks Consensus Estimate for fourth-quarter revenues is pegged at $3.46 billion, up 9.5% year over year. The Zacks Consensus Estimate for fourth-quarter earnings is $1.95, up 9.6% on a year-over-year basis.
Stryker recently announced better-than-expected preliminary net sales results for fourth-quarter 2017. For full-year 2017, net sales are estimated at $12.4 billion, up 9.8% from the year-ago quarter on a constant-currency basis. The figure beat the Zacks Consensus Estimate of $12.38 billion.
Buoyed by these prospects, our quantitative model indicates an earnings beat for Stryker this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. Stryker's Earnings ESP is +0.01%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . Stryker carries a Zacks Rank #3 (read more: Will Core Segmental Growth Aid Stryker in Q4 Earnings? ).
Stryker Corporation Price and Consensus
Stryker Corporation Price and Consensus | Stryker Corporation Quote
Zimmer Biomet Holdings, Inc ZBH ) is set to report results, before the market opens. Notably, the Zacks Consensus Estimate for fourth-quarter revenues is pegged at $2.03 billion, up 0.9% year over year. The Zacks Consensus Estimate for fourth-quarter earnings is projected at $2.10, down 1.9% on a year-over-year basis.
Despite solid prospects in the company's S.E.T. (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) arm, macroeconomic uncertainties and unfavorable currency fluctuations have been denting sales over the past few quarters.
The company has been dealing with pricing pressure. In this regard, Zimmer Biomet witnessed negative pricing pressure of approximately 2.1% last quarter. In the absence of any favorable changes on these lines, these headwinds might reflect in the company's fourth-quarter results (read more: Will S.E.T. Arm Drive Zimmer Biomet's Q4 Earnings? ).
As a result, our proven model does not conclusively show earnings beat for Zimmer Biomet this quarter. Zimmer Biomet has an Earnings ESP of +0.38%. The stock carries a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) Stocks Here .
Zimmer Biomet Holdings, Inc. Price and Consensus
Zimmer Biomet Holdings, Inc. Price and Consensus | Zimmer Biomet Holdings, Inc. Quote
Align Technology, Inc ALGN ) is set to report results after the market closes. Notably, the Zacks Consensus Estimate for fourth-quarter revenues is pegged at $395.5 million, up 34.9% year over year. The Zacks Consensus Estimate for fourth-quarter earnings is at 96 cents, up 43.3% on a year-over-year basis.
Align Technology achieved a milestone of five million patients undergoing treatment with its flagship clear aligner system - InvisAlign - in November 2017. The company has been adopting several strategies to drive adoption of its core InvisAlign product line.
In 2017, the company received two U.S. patents for Align Technology's SmartTrack aligner material that is exclusively used for InvisAlign aligner treatment. Moreover, in a bid to gain traction in the InvisAlign platform, Align Technology collaborated with Digital Smile Design in the recent past (read more: Can Invisalign Drive Align Technology's Q4 Earnings? ).
Despite the positive developments, our proven model does not conclusively show that Align Technology is likely to beat earnings this quarter. Align Technology has an Earnings ESP of -2.08%. The stock carries a Zacks Rank #2.
Align Technology, Inc. Price and Consensus
Align Technology, Inc. Price and Consensus | Align Technology, Inc. Quote
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The sector benefits from favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value-based model. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . Stryker Corporation Price and Consensus Stryker Corporation Price and Consensus | Stryker Corporation Quote Zimmer Biomet Holdings, Inc ZBH ) is set to report results, before the market opens. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . Zimmer Biomet Holdings, Inc. Price and Consensus Zimmer Biomet Holdings, Inc. Price and Consensus | Zimmer Biomet Holdings, Inc. Quote Align Technology, Inc ALGN ) is set to report results after the market closes. | This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The companies exited the fourth quarter on a solid note, beating the Zacks Consensus Estimate on both counts. |
33347.0 | 2018-01-26 00:00:00 UTC | This Explains Why Senseonics Holdings Inc. Is Falling Today | ABT | https://www.nasdaq.com/articles/explains-why-senseonics-holdings-inc-falling-today-2018-01-26 | nan | nan | What happened
In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday.
So what
Senseonics announced on late Thursday afternoon that it wanted to raise capital from a convertible notes offering. The company succeeded and announced the terms of the deal on Friday morning:
$50 million of convertible notes were sold with an interest rate of 5.25%.
The underwriters of the deal were granted a 30-day option to purchase an additional $7.5 million worth of notes.
The notes mature on Feb. 1, 2023, and can be converted into common stock at a price of $3.40 per share.
The deal is expected to net Senseonic $48 million, or $55.3 million if the underwriter exercises their option in full.
That $3.40 conversion price is above Thursday's closing price of $3.20, so why are shares falling on this pricing news? The most likely answer is that they are not reacting to the pricing details at all. Instead, the markets are probably focusing on the preliminary quarterly results that were provided on late Thursday afternoon as part of the proposal letter.
Management stated on Thursday that its fourth-quarter revenue is expected to be approximately $2.9 million. While that's sharply higher than the $0.3 million that was recorded in the year-ago period, it trails the $2.96 million that Wall Street had expected.
Traders appear to be slamming shares today based on the disappointing revenue result.
Now what
Senseonics' continuous glucose monitoring system is called Eversense and it stands apart from other devices because it is implantable and can last for up to 90 days. While the device has not yet received FDA approval, Senseonics is already selling the device in Europe.
Will the Eversense be a hit in the U.S. if it wins approval? That's tough to say. The company will face a healthy amount of competition from the market leaderDexcom (NASDAQ: DXCM) , not to mention medical device giant Medtronic and newcomerAbbott Laboratories . While the 90-day wear time is appealing, the device does have to be implanted underneath the skin to work. That might be an unappealing prospect for many patients. On the other hand, the market for diabetes is so huge that all four of these companies might post growth as adoption of continuous glucose monitoring systems continues to grow.
Personally, I think that Senseonics' device does look compelling, but this company is losing money hand-over-fist right now, so I have no interest in buying this stock. Still, the technology looks promising, so I plan on remaining attentive to this company's progress.
10 stocks we like better than Senseonics Holdings, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company succeeded and announced the terms of the deal on Friday morning: $50 million of convertible notes were sold with an interest rate of 5.25%. Instead, the markets are probably focusing on the preliminary quarterly results that were provided on late Thursday afternoon as part of the proposal letter. The company will face a healthy amount of competition from the market leaderDexcom (NASDAQ: DXCM) , not to mention medical device giant Medtronic and newcomerAbbott Laboratories . | What happened In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday. Instead, the markets are probably focusing on the preliminary quarterly results that were provided on late Thursday afternoon as part of the proposal letter. On the other hand, the market for diabetes is so huge that all four of these companies might post growth as adoption of continuous glucose monitoring systems continues to grow. | What happened In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday. The notes mature on Feb. 1, 2023, and can be converted into common stock at a price of $3.40 per share. Personally, I think that Senseonics' device does look compelling, but this company is losing money hand-over-fist right now, so I have no interest in buying this stock. | What happened In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday. The notes mature on Feb. 1, 2023, and can be converted into common stock at a price of $3.40 per share. Now what Senseonics' continuous glucose monitoring system is called Eversense and it stands apart from other devices because it is implantable and can last for up to 90 days. |
33348.0 | 2018-01-26 00:00:00 UTC | ABT Crosses Above Average Analyst Target | ABT | https://www.nasdaq.com/articles/abt-crosses-above-average-analyst-target-2018-01-26 | nan | nan | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 17 different analyst targets contributing to that average for Abbott Laboratories, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $48.00. And then on the other side of the spectrum one analyst has a target as high as $68.00. The standard deviation is $4.867.
But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Abbott Laboratories:
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on ABT - FREE .
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? | And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? |
33349.0 | 2018-01-26 00:00:00 UTC | Boston Scientific's (BSX) Millipede Deal Aids MR Business | ABT | https://www.nasdaq.com/articles/boston-scientifics-bsx-millipede-deal-aids-mr-business-2018-01-26 | nan | nan | Boston Scientific CorporationBSX has recently announced a major investment in Santa Rosa, CA-based Millipede, Inc., to augment its position in the field of mitral regurgitation (MR). Millipede is the developer of IRIS Transcatheter Annuloplasty Ring System for the treatment of severe MR.
Per the terms of the agreement, Boston Scientific has purchased a portion of Millipede for $90 million. The company has also kept an option to acquire the remaining shares of Millipede at any point of time prior to the completion of a first-in-human clinical study that meets certain parameters.
Also, Millipede has the option to compel Boston Scientific to purchase its remaining shares upon the closure of the clinical study. The full buyout of Millipede needs additional $325 million payment by Boston Scientific and a further $125 million will be paid upon achievement of a commercial milestone.
In this regard, management noted that MR occurs by a leaking mitral valve causing blood to regurgitate from the left ventricle to the left atrium of the heart. This condition can gradually lead to heart failure and heart rhythm problems. Patients with severe MR often complain of compromised heart functions and cannot tolerate open-heart surgery for the repair or replacement of the leaking valve.
Management is optimistic about the large patient population in this space, which is unfortunately underserved at the moment. Hence, this area represents a lucrative market to be tapped into. This patient population could benefit from a fully-percutaneous transcatheter procedure that can fix the dilated mitral annulus and reduce regurgitation without undergoing surgery.
Encouragingly, the Millipede IRIS annuloplasty ring claims to be highly customizable to a specific patient's anatomy and disease state. This device is supplied via a transcatheter-transseptal delivery system and follows the standard surgical approach to mend and decrease the size of a dilated mitral annulus.
On a positive note, the global transcatheter mitral valve replacement market is growing stupendously at a CAGR of approximately 22% over 2016-2020, as per the data provided by Technavio.
Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific CorporationBSX has recently announced a major investment in Santa Rosa, CA-based Millipede, Inc., to augment its position in the field of mitral regurgitation (MR). | Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT . Boston Scientific CorporationBSX has recently announced a major investment in Santa Rosa, CA-based Millipede, Inc., to augment its position in the field of mitral regurgitation (MR). | Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Patients with severe MR often complain of compromised heart functions and cannot tolerate open-heart surgery for the repair or replacement of the leaking valve. |
33350.0 | 2018-01-26 00:00:00 UTC | Don’t Chase AbbVie Inc Stock After Its Huge Earnings Win | ABT | https://www.nasdaq.com/articles/dont-chase-abbvie-inc-stock-after-its-huge-earnings-win-2018-01-26 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). Friday morning's fourth-quarter results beat consensus on the top and bottom lines for the fourth straight quarter. The midpoint of updated 2018 guidance implies 32% per-share earnings growth in 2018. And yet, AbbVie stock trades at less than 16 times that guidance, even after gaining 9% in early trading Friday.
AbbVie's multiple of 16 and its growth of 32% suggest a so-called PEG (price/earnings-growth) ratio of 0.5x - a figure not found often, or ever, in this bull market. To top it off, ABBV stock still yields 2.6%. The combination makes AbbVie stock look like an incredible deal, even with the stock up 65% just since August. And with momentum strong coming out of the report, and 2018 results likely to be solid, that may be the case in the near term.
But as strong as recent results have been, and as good as 2018 looks, there's a case to take profits at this point. There are a number of risks here, and looking backward in the pharmaceutical industry is a dangerous way to invest.
ABBV does look cheap, but most pharmaceutical stocks do from time to time, and as recent performance has shown, they can get a lot cheaper.
ABBV Crushes Earnings
To be sure, Q4 earnings themselves show little reason for caution. Revenue rose 13.8%, more than three points faster than analysts suggested. Adjusted EPS of $1.48 was 4 cents ahead of the Street. And 2018 guidance is impressive, with AbbVie projecting EPS of $7.33 to $7.43, raised from a prior $6.37-$6.57.
10 Boring Stocks with Thrilling Growth
Corporate tax reform is helping on that front, but more than half of the EPS growth is expected to come from the operating business. That operating business contributed 8 cents of the guidance increase as well.
The news looks good on a more granular business. Abbvie's 7 largest drugs all grew sales year-over-year. The largest drug, arthritis treatment Humira, saw revenue rise 12.6% in constant currency. Sales of second-place Imbruvica rose nearly 39%. Operating margins expanded nearly 90 basis points, but AbbVie also increased its R&D spending 19% on an adjusted basis.
The fourth quarter looks like nothing but good news, but questions remain for ABBV stock holders.
Will the Gains Hold?
The Q4 gains don't necessarily come as a surprise.
AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. But, again, in the pharma space, it's dangerous to look backward - because patent protection and regulatory impacts can have a huge effect on earnings.
And ABBV does have a few reasons for caution. The most obvious is that it remains heavily reliant on Humira. The drug drove a whopping 65% of total 2017 sales. And as seen at Gilead Sciences, Inc. (NASDAQ: GILD ), whose sales have been heavily weighted toward its hepatitis C treatment Solvadi, that kind of revenue concentration can be dangerous.
AbbVie no doubt is better-positioned that Gilead was at Sovaldi's peak. The rest of its pipeline looks stronger. Humira, unlike Solvadi, doesn't cure the disease - and lead to an end of treatment. But Humira will come under some pressure.
A patent dispute settled with Amgen, Inc. (NASDAQ: AMGN ) allows Amgen a non-exclusive license to Humira in Europe starting Oct. 16. (Roughly one-third of 2017 sales of Humira came from outside the U.S.) U.S. competition will follow in 2023. AbbVie still will make a royalty from Amgen products - but it likely will have to cut prices for Humira as a response, hurting sales and margins.
And before that, after 2018, corporate tax reform actually will move AbbVie's tax rate up, per the Q4 release, presenting a modest headwind until U.S. competition arrives.
ABBV Stock Is Cheap, But Not Cheap Enough
AbbVie has a pair of drugs in the pipeline that hopefully will cushion any declines in Humira. Upadacitinib, an immunology drug, should be launched for multiple indications by 2022. Psoriasis treatment risankizumab showed strong phase 3 results last year.
But the lesson of the drug space is that it's difficult to truly replace a blockbuster drug. GILD is down over 30% from its 2015 highs - though it looked cheap as Sovaldi came to market. Stocks across the space have been crushed when sales weaken: Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ), and Mallinckrodt PLC (NYSE: MNK ) all have been seen huge declines in the last few years.
ABBV is not VRX or TEVA, to be sure. It doesn't have the same debt, and it has a much more stronger and more diversified portfolio. But the broader point is that drug stocks usually look cheap on the way up - and quite often struggle once revenue peaks.
That peak isn't necessarily here for AbbVie. If Humira holds up and the pipeline assets drive revenue, overall sales and profits can grow well into the next decade. But as good as Q4 earnings look, investors need to be careful. Everything looks positive for ABBV at the moment - but at some point, the path will get rockier.
As of this writing, Vince Martin has no positions in any securities mentioned.
More From InvestorPlace
5 Biotech and Pharmaceutical Stocks Going Bonkers
Netflix, Inc. Stock Will Grow Into Its Valuation… in the Year 2029
3 Earnings Reports to Watch Next Week
Compare Brokers
The post Don't Chase AbbVie Inc Stock After Its Huge Earnings Win appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. Friday morning's fourth-quarter results beat consensus on the top and bottom lines for the fourth straight quarter. But, again, in the pharma space, it's dangerous to look backward - because patent protection and regulatory impacts can have a huge effect on earnings. | AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). And yet, AbbVie stock trades at less than 16 times that guidance, even after gaining 9% in early trading Friday. | AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). ABBV Stock Is Cheap, But Not Cheap Enough AbbVie has a pair of drugs in the pipeline that hopefully will cushion any declines in Humira. | AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. To top it off, ABBV stock still yields 2.6%. But as strong as recent results have been, and as good as 2018 looks, there's a case to take profits at this point. |
33351.0 | 2018-01-24 00:00:00 UTC | Markets Keep Gaining Amid Strong Corporate Earnings | ABT | https://www.nasdaq.com/articles/markets-keep-gaining-amid-strong-corporate-earnings-2018-01-24 | nan | nan | This morning's pre-market indexes look for fresh all-time highs today, as another robust earnings season hits high gear. Commodities like oil and gold are also starting in positive territory this morning, and the 10-year t-bill is now residing around 2.65%. All good things, relatively.
Let's start Q4 reports with the worst performer on the Dow Jones Industrial Average through 2017: General Electric GE . The Zacks Rank #5 (Strong Sell) company with a Zacks Style Score of F (Value, Growth, Momentum) missed bottom line estimates of 28 cents per share by a penny, on quarterly revenues of $31.4 billion which fell far short of the $32.9 billion expected in the Zacks consensus.
For fiscal 2018, GE guidance is currently between $1.00-1.07 per share. Recently installed CEO John Flannery has called 2018 a "reset year," seeking to reduce corporate costs by $2 billion and laying off 12K GE workers. Also, don't rule out the possibility of GE being hived off into separate entities at some point in the future. For more on GE's earnings, click here.
From former owner of NBCUniversal to the present one, Comcast CMCSA has also put out earnings results prior to today's opening bell, reporting 49 cents per share on $21.9 billion in revenues - both better than the 47 cents and $21.8 billion expected. Revenues grew 4.2% year over year on growth in high-speed Internet and security and automation customers, somewhat offset by losses in voice and video subscribers. For more on CMCSA's earnings, click here.
Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. Positive results were attributed to higher sales in Pharma, Devices, Diagnostics and Nutrition. Pre-market shares were up close to 2%. For more on ABT's earnings, click here.
Fellow Illinois-based company Illinois Tool Works ITW also outperformed bottom-line expectations with quarterly earnings of $1.70 per share ahead of the $1.62 expected. Revenues, however, came in light at $6.59 billion, below the $6.7 billion we had been looking for. For more on ITW's earnings, click here.
Finally, both United Technologies UTX and General Dynamics GD - two Defense industry Zacks Rank #2 (Buy) stocks -- topped bottom-line expectations: $1.60 and $2.50, which beat the $1.56 and $2.37 estimates, respectively. Revenues for UTX also beat, while GD quarterly sales came up short in its Q4. For more on UTX's earnings, click here . For more on GD's earnings, click here .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
General Dynamics Corporation (GD): Free Stock Analysis Report
Comcast Corporation (CMCSA): Free Stock Analysis Report
United Technologies Corporation (UTX): Free Stock Analysis Report
General Electric Company (GE): Free Stock Analysis Report
Illinois Tool Works Inc. (ITW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT's earnings, click here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. |
33352.0 | 2018-01-24 00:00:00 UTC | Plethora of Q4 Earnings Amid New Market Highs | ABT | https://www.nasdaq.com/articles/plethora-q4-earnings-amid-new-market-highs-2018-01-24 | nan | nan | Wednesday, January 24, 2018
This morning's pre-market indexes look for fresh all-time highs today, as another robust earnings season hits high gear. Commodities like oil and gold are also starting in positive territory this morning, and the 10-year t-bill is now residing around 2.65%. All good things, relatively.
Let's start Q4 reports with the worst performer on the Dow Jones Industrial Average through 2017: General Electric GE . The Zacks Rank #5 (Strong Sell) company with a Zacks Style Score of F (Value, Growth, Momentum) missed bottom line estimates of 28 cents per share by a penny, on quarterly revenues of $31.4 billion which fell far short of the $32.9 billion expected in the Zacks consensus.
For fiscal 2018, GE guidance is currently between $1.00-1.07 per share. Recently installed CEO John Flannery has called 2018 a "reset year," seeking to reduce corporate costs by $2 billion and laying off 12K GE workers. Also, don't rule out the possibility of GE being hived off into separate entities at some point in the future. For more on GE's earnings, click here.
From former owner of NBCUniversal to the present one, Comcast CMCSA has also put out earnings results prior to today's opening bell, reporting 49 cents per share on $21.9 billion in revenues - both better than the 47 cents and $21.8 billion expected. Revenues grew 4.2% year over year on growth in high-speed Internet and security and automation customers, somewhat offset by losses in voice and video subscribers. For more on CMCSA's earnings, click here.
Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. Positive results were attributed to higher sales in Pharma, Devices, Diagnostics and Nutrition. Pre-market shares were up close to 2%. For more on ABT's earnings, click here.
Fellow Illinois-based company Illinois Tool Works ITW also outperformed bottom-line expectations with quarterly earnings of $1.70 per share ahead of the $1.62 expected. Revenues, however, came in light at $6.59 billion, below the $6.7 billion we had been looking for. For more on ITW's earnings, click here.
Finally, both United Technologies UTX and General Dynamics GD - two Defense industry Zacks Rank #2 (Buy) stocks -- topped bottom-line expectations: $1.60 and $2.50, which beat the $1.56 and $2.37 estimates, respectively. Revenues for UTX also beat, while GD quarterly sales came up short in its Q4. For more on UTX's earnings, click here . For more on GD's earnings, click here .
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
General Dynamics Corporation (GD): Free Stock Analysis Report
Comcast Corporation (CMCSA): Free Stock Analysis Report
United Technologies Corporation (UTX): Free Stock Analysis Report
General Electric Company (GE): Free Stock Analysis Report
Illinois Tool Works Inc. (ITW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT's earnings, click here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. | Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. |
33353.0 | 2018-01-24 00:00:00 UTC | Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance | ABT | https://www.nasdaq.com/articles/abbott-abt-tops-q4-earnings-and-revenues-issues-guidance-2018-01-24 | nan | nan | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Earnings improved 13.8% year over year and met the high end of the company's guided range of 72 cents to 74 cents.
However, reported loss in the quarter came in at 50 cents per share, as against year-ago earnings of 51 cents. Notably, this includes anticipated net expense of $1.46 billion as an impact of U.S. tax reform.
Full-year 2017 adjusted earnings came in at $2.50 per share, in line with the Zacks Consensus Estimate. However, the figure beat the year-ago number by 13.6%.
Fourth-quarter worldwide sales came in at $7.59 billion, up 42.3% year over year on a reported basis. The figure also beat the Zacks Consensus Estimate of $7.37 billion by 2.9%.
On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 7.7% year over year in the reported quarter.
Worldwide sales in the full year came in at $27.39 billion, up 31.3% year over year on a reported basis. The figure also surpassed the Zacks Consensus Estimate of $27.15 billion.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
Quarter in Detail
Abbott operates through four segments - Established Pharmaceuticals Division ("EPD"), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 17% on a reported basis (up 14% on comparable operational basis) to $1.15 billion. This included a positive impact of 3% from currency fluctuations. Sales in key emerging markets increased 15% (up 12.5%), driven by double-digit growth in Latin America, India and China.
The Medical Devices business sales rose 102.2% on a reported basis to $2.74 billion. On a comparable operational basis, sales increased 9.6%.
Cardiovascular and Neuromodulation sales soared 222.5% on a reported basis (up 6.9% on comparable operational basis) on double-digit growth in Electrophysiology, Structural Heart, Heart Failure and Neuromodulation.
Vascular product sales, however, declined 1.9% on a comparable operational basis. Within Rhythm Management, the company saw a sales drop of 8% on a comparable operational basis. However, the company received FDA approval for magnetic resonance (MR)-conditional labeling for its Quadra Assura and Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) devices and its Fortify Assura implantable cardioverter defibrillator (ICD) in the quarter under review.
Diabetes Care sales improved 27.6% on a comparable operational basis, buoyed by double-digit international sales growth, led by continued consumer uptake of FreeStyle Libre - the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 3% year over year on a reported basis (2% on a comparable operational basis). Foreign exchange drove sales by 1%. Pediatric Nutrition sales increased 1.5% on a comparable operational basis. Adult Nutrition sales were up 2.8% on a comparable operational basis.
Diagnostics sales rose 51.7% year over year on a reported basis (up 6.7% on a comparable operational basis). Core Laboratory and Point of Care Diagnostics sales grew 7.2% and 6.8%, respectively, on a comparable operational basis. Molecular Diagnostics sales were up a nominal 2.4% as strong growth in the infectious disease testing business was partially offset by the planned scale down of the genetics business. Rapid Diagnostics recorded sales of $540 million, driven by solid contributions from infectious disease testing, including flu and strep testing.
Guidance
Abbott issued full-year 2018 guidance. Adjusting for certain net specified items for the full year, adjusted earnings per share from continuing operations are expected in the band of $2.80-$2.90. The current Zacks Consensus Estimate is pegged at $2.83, near the low end of the projected range.
The company also provided first-quarter 2018 adjusted earnings per share guidance. It expects to report adjusted earnings from continuing operations in the range of 57 cents to 59 cents in the quarter. The current Zacks Consensus Estimate of 56 cents is below the projected range.
Our Take
Abbott has steered past the Zacks Consensus Estimate for earnings and sales. We are optimistic about the company's strong and consistent EPD and Medical Devices performance. We are upbeat about contributions from the company's other two businesses as well.
The company continues to benefit from the recently completed acquisition of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. We are also upbeat about Abbott's successful closure of the Alere acquisition. Synergies from the buyout, in the form of revenues from Rapid Diagnostics, have been benefiting the company.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories, Inc. BIO , Intuitive Surgical, Inc. ISRG and Amedisys AMED . Notably, Bio-Rad sports a Zacks Rank #1 (Strong Buy), while Amedisys and Intuitive Surgical carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Bio-Rad is expected to release fourth-quarter 2017 results on Feb 22. The Zacks Consensus Estimate for fourth-quarter adjusted EPS is $1.27 and for revenues is $617.2 million.
Amedisys is expected to release fourth-quarter 2017 results on Feb 27. The Zacks Consensus Estimate for fourth-quarter adjusted EPS is 59 cents and for revenues is $394.9 million.
Intuitive Surgical is expected to release fourth-quarter 2017 results on Jan 25. The Zacks Consensus Estimate for fourth-quarter adjusted EPS is pegged at $2.27 and for revenues is $877.2 million.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Amedisys Inc (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Amedisys Inc (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The company continues to benefit from the recently completed acquisition of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Amedisys Inc (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Quarter in Detail Abbott operates through four segments - Established Pharmaceuticals Division ("EPD"), Medical Devices, Nutrition and Diagnostics. | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Amedisys Inc (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Diagnostics sales rose 51.7% year over year on a reported basis (up 6.7% on a comparable operational basis). | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Amedisys Inc (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 7.7% year over year in the reported quarter. |
33354.0 | 2018-01-24 00:00:00 UTC | Abbott (ABT) Beats Earnings and Revenue Estimates in Q4 | ABT | https://www.nasdaq.com/articles/abbott-abt-beats-earnings-and-revenue-estimates-in-q4-2018-01-24 | nan | nan | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.67%.
Currently, Abbott has a Zacks Rank #3 (Hold), but that could definitely change following the company's second quarter 2017 earnings report which was just released. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : The Zacks Consensus Estimate remained steady at 73 cents per share over the last 60 days. Abbott' fourth quarter 2017 earnings per share from continuing operations of 74 cents outpaced this estimate by a penny.
Revenues : Abbott posted fourth quarter revenues of $7.59 billion beating the Zacks Consensus Estimate for revenues of $7.36 billion.
Key Stats: Worldwide Nutrition sales increased 2% on a reported basis in the fourth quarter to $1.78 billion while worldwide Diagnostics sales increased 6.7% on a reported basis to $1.9 billion while total Established Pharmaceuticals sales increased 14% on a reported basis to $1.14 billion. Revenues of Worldwide Medical Devices increased 9.6% on a reported basis to $2.73 billion.
Major Factors: Abbott issued earnings outlook for 2018, reflecting strong double-digit growth. The company banks on new product approvals and launches. Notably, Abbott received FDA clearance for its Confirm Rx Insertable Cardiac Monitor in October. Also, the company won FDA approval for magnetic resonance (MR)-conditional labeling for its Quadra Assura and Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) devices and its Fortify Assura implantable cardioverter defibrillator (ICD).
Stock Price: Following the earnings release, share prices rose 1.77% during the pre-market trading session.
Check back later for our full write up on this Abbott earnings report!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.67%. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.67%. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott has a Zacks Rank #3 (Hold), but that could definitely change following the company's second quarter 2017 earnings report which was just released. |
33355.0 | 2018-01-24 00:00:00 UTC | Health Care Sector Update for 01/24/2018: JNJ, PFE, ABT, MRK, AMGN, STML, AERI, BSX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01242018-jnj-pfe-abt-mrk-amgn-stml-aeri-bsx-2018-01-24 | nan | nan | Top Health care stocks:
JNJ: +0.2%
PFE: -0.1%
ABT: +2.3%
MRK: flat
AMGN: +1%
Health care shares were higher ahead of the bell on Wednesday.
Expected movers:
- Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates
- Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium
- Aerie Pharmaceuticals ( AERI ): prices $75 million share offering
Other news:
- Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates - Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium - Aerie Pharmaceuticals ( AERI ): prices $75 million share offering Other news: - Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health care stocks: Health care shares were higher ahead of the bell on Wednesday. | Expected movers: - Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates - Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium - Aerie Pharmaceuticals ( AERI ): prices $75 million share offering Other news: - Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health care stocks: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates - Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium - Aerie Pharmaceuticals ( AERI ): prices $75 million share offering Other news: - Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. MRK: flat All rights reserved. | Expected movers: - Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates - Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium - Aerie Pharmaceuticals ( AERI ): prices $75 million share offering Other news: - Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health care stocks: MRK: flat |
33356.0 | 2018-01-24 00:00:00 UTC | Abbott Spikes To Record After Topping Quarterly Expectations | ABT | https://www.nasdaq.com/articles/abbott-spikes-record-after-topping-quarterly-expectations-2018-01-24 | nan | nan | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017.
[ibd-display-video id=3102574 width=50 float=left autostart=true] By the closing bell on the stock market today , Abbott had jumped 4.2% to finish at 61.72. Shares broke out of a flat base with a buy point at 56.79 in mid-December and have since traded in a buy zone.
Cowen analyst Joshua Jennings expects Abbott's operational momentum to drive the stock higher over the next 12 months. He reiterated his outperform rating and 68 price target.
"We believe the company's impressive sales results are sufficient to quell investor doubts about Abbott's stock plateauing following a big run in 2017," he said in a note to clients. "The shares remain a top pick for us."
For its fourth quarter, Abbott reported adjusted profit of 74 cents a share, rising 13.8%. Sales of $7.6 billion grew from $5.3 billion in the year-earlier period. Both metrics beat the consensus for adjusted income of 73 cents per share on $7.37 billion in sales.
The fourth quarter represented a return to growth, RBC analyst Glenn Novarro wrote in a note to clients. U.S. revenue of $2.68 billion increased 7.2% operationally, which was a significant improvement over 2% growth in the third quarter.
IBD'S TAKE:Biotechs Biogen and Celgene are slated to report their fourth-quarter earnings early Thursday. Keep tabs on which stocks look likely to surprise to the upside by visiting IBD Industry Themes .
Diagnostics and medical device sales benefited from Abbott's acquisitions of Alere and St. Jude Medical, respectively. Total diagnostic revenue rose 6.7% operationally to $1.91 billion. Medical device sales of $2.74 billion grew 9.6% on an operational basis.
Alere sales were $65 million higher than Novarro's estimate. The acquisition closed in early October.
Within medical devices, sales in the cardiovascular/neuromodulation and diabetes care units topped Novarro's expectations. Electrophysiology grew 16.1%, structural heart product sales rose 11.9% and neuromodulation revenue was up 29.5%. Sales in diabetes care jumped 27.6%.
For 2018, Abbott guided to adjusted profit of $2.80-$2.90 per share, which would be up 14% at the midpoint. Analysts polled by Zacks Investment Research had called for $2.83 a share on $30.18 billion in sales.
RELATED:
Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ?
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
How Electricity Could Replace Opioids In Treating Chronic Pain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017. Cowen analyst Joshua Jennings expects Abbott's operational momentum to drive the stock higher over the next 12 months. "We believe the company's impressive sales results are sufficient to quell investor doubts about Abbott's stock plateauing following a big run in 2017," he said in a note to clients. | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017. For its fourth quarter, Abbott reported adjusted profit of 74 cents a share, rising 13.8%. Diagnostics and medical device sales benefited from Abbott's acquisitions of Alere and St. Jude Medical, respectively. | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017. Diagnostics and medical device sales benefited from Abbott's acquisitions of Alere and St. Jude Medical, respectively. Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 How Electricity Could Replace Opioids In Treating Chronic Pain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017. Sales of $7.6 billion grew from $5.3 billion in the year-earlier period. Both metrics beat the consensus for adjusted income of 73 cents per share on $7.37 billion in sales. |
33357.0 | 2018-01-24 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-636-follow-through-indicator-24-sensitive-0 | nan | nan | Expected Earnings Release: 01/24/2018, Premarket
Avg. Extended-Hours Dollar Volume: $1,821,035
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 62.5%
Average next regular session additional gain: 2.1%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 2.1% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $1,821,035 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 2.1% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $1,821,035 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 2.1% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $1,821,035 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $1,821,035 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 2.1% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. |
33358.0 | 2018-01-24 00:00:00 UTC | Wednesday Sector Leaders: Healthcare, Materials | ABT | https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-materials-2018-01-24 | nan | nan | In afternoon trading on Wednesday, Healthcare stocks are the best performing sector, up 0.5%. Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 7.54% year-to-date. Abbott Laboratories, meanwhile, is up 8.45% year-to-date, and McKesson Corp is up 12.23% year-to-date. Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV.
The next best performing sector is the Materials sector, higher by 0.3%. Among large Materials stocks, Newmont Mining Corp (Symbol: NEM) and PPG Industries Inc (Symbol: PPG) are the most notable, showing a gain of 3.3% and 1.2%, respectively. One ETF closely tracking Materials stocks is the Materials Select Sector SPDR ETF ( XLB ), which is up 0.3% in midday trading, and up 4.59% on a year-to-date basis. Newmont Mining Corp , meanwhile, is up 11.00% year-to-date, and PPG Industries Inc is up 1.62% year-to-date. Combined, NEM and PPG make up approximately 7.6% of the underlying holdings of XLB.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, five sectors are up on the day, while four sectors are down.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV. Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Combined, NEM and PPG make up approximately 7.6% of the underlying holdings of XLB. | Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV. Among large Materials stocks, Newmont Mining Corp (Symbol: NEM) and PPG Industries Inc (Symbol: PPG) are the most notable, showing a gain of 3.3% and 1.2%, respectively. | Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 7.54% year-to-date. | Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 7.54% year-to-date. |
33359.0 | 2018-01-23 00:00:00 UTC | This Week's Amazing Earnings Charts | ABT | https://www.nasdaq.com/articles/weeks-amazing-earnings-charts-2018-01-23 | nan | nan | Earnings season kicks it up a notch this week with over 300 companies reporting, including a bunch of Dow Industrial and S&P 500 large caps.
It's not easy beating the earnings estimate every quarter, or nearly every quarter, for several years. Many investors underestimate the management skills it takes to consistently beat.
Yet these companies have beaten, or missed only once, every quarter for 5 years. That's impressive.
With the pressure mounting on them to keep their great earnings surprise records, will they be able to comply again this quarter?
This Week's Amazing Earnings Charts
1. Illinois Tool Works ITW hasn't missed since 2014 yet it still doesn't get any respect from investors. Shares have nearly doubled over the last 2 years though. Will it beat again?
2. Abbott Labs ABT hasn't missed since early 2007. Now THAT'S impressive. It continued to beat on earnings even during the chaos of the Great Recession. Shares have broken out to new 5-year highs. Can it keep the momentum?
3. United Rentals URI has missed only once in 5 years and that was in 2016 when crude prices were plunging. The largest equipment rental company in North America has some oil and gas business but that market has improved. Shares are soaring on hopes that the US economy continues to generate momentum.
4. Honeywell HON is getting the last laugh as it was kicked out of the Dow Industrials years ago but look at it now. It's only missed once in 5 years and shares are at new 5-year highs.
5. Starbucks SBUX has only missed once in the last 5 years but shares have been stuck in a narrow trading range for more than 2 years. Will 2018 finally be the year that it joins in the rally?
[In full disclosure, the author of this article owns shares of URI and SBUX in her personal portfolio.]
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want to Learn How to Trade Options?
Have you always wanted to trade stock options but are unsure where to begin or what to look for?
Each week, Zacks' Dave Bartosiak will bring you a detailed explanation of the trades "live" on YouTube.
Watch him go through the trade as he answers your questions in real time.
Become one of Dave's minions. Join the Zacks Live Trader community today. It's free!
Click here to join Dave >>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
United Rentals, Inc. (URI): Free Stock Analysis Report
Honeywell International Inc. (HON): Free Stock Analysis Report
Illinois Tool Works Inc. (ITW): Free Stock Analysis Report
Starbucks Corporation (SBUX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT hasn't missed since early 2007. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings season kicks it up a notch this week with over 300 companies reporting, including a bunch of Dow Industrial and S&P 500 large caps. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed since early 2007. Illinois Tool Works ITW hasn't missed since 2014 yet it still doesn't get any respect from investors. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed since early 2007. It's not easy beating the earnings estimate every quarter, or nearly every quarter, for several years. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed since early 2007. Yet these companies have beaten, or missed only once, every quarter for 5 years. |
33360.0 | 2018-01-23 00:00:00 UTC | Pre-Market Earnings Report for January 24, 2018 : CMCSA, GE, UTX, ABT, GD, ITW, NSC, TEL, PGR, NVS, APH, RCL | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-january-24-2018-cmcsa-ge-utx-abt-gd-itw-nsc-tel-pgr-nvs-aph-rcl | nan | nan | The following companies are expected to report earnings prior to market open on 01/24/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Comcast Corporation ( CMCSA ) is reporting for the quarter ending December 31, 2017. The cable tv company's consensus earnings per share forecast from the 17 analysts that follow the stock is $0.47. This value represents a 6.82% increase compared to the same quarter last year. In the past year CMCSA has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CMCSA is 20.92 vs. an industry ratio of 117.70.
General Electric Company ( GE ) is reporting for the quarter ending December 31, 2017. The diversified operations company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.28. This value represents a 39.13% decrease compared to the same quarter last year. GE missed the consensus earnings per share in the 3rd calendar quarter of 2017 by -40.82%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GE is 15.40 vs. an industry ratio of 29.00.
United Technologies Corporation ( UTX ) is reporting for the quarter ending December 31, 2017. The diversified operations company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.56. This value represents a no change for the same quarter last year. In the past year UTX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for UTX is 20.46 vs. an industry ratio of 29.00.
Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. The medical products company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.73. This value represents a 12.31% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.54%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry.
General Dynamics Corporation ( GD ) is reporting for the quarter ending December 31, 2017. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.36. This value represents a 9.92% decrease compared to the same quarter last year. In the past year GD has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for GD is 21.22 vs. an industry ratio of 18.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. ( ITW ) is reporting for the quarter ending December 31, 2017. The machinery company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.62. This value represents a 16.55% increase compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 3.64%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ITW is 25.88 vs. an industry ratio of 27.50.
Norfolk Souther Corporation ( NSC ) is reporting for the quarter ending December 31, 2017. The transportation (rail) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.56. This value represents a 9.86% increase compared to the same quarter last year. In the past year NSC has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 6.71%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for NSC is 23.38 vs. an industry ratio of 19.70, implying that they will have a higher earnings growth than their competitors in the same industry.
TE Connectivity Ltd. ( TEL ) is reporting for the quarter ending December 31, 2017. The electrical instrument company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.25. This value represents a 8.70% increase compared to the same quarter last year. In the past year TEL has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.76%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for TEL is 19.18 vs. an industry ratio of 11.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Progressive Corporation ( PGR ) is reporting for the quarter ending December 31, 2017. The insurance (property & casualty) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.77. This value represents a 24.19% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for PGR is 23.57 vs. an industry ratio of -30.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Novartis AG ( NVS ) is reporting for the quarter ending December 31, 2017. The large cap pharmaceutical company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.16. This value represents a 3.57% increase compared to the same quarter last year. In the past year NVS has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 3.2%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for NVS is 18.16 vs. an industry ratio of 17.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Amphenol Corporation ( APH ) is reporting for the quarter ending December 31, 2017. The electrical connectors company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.81. This value represents a 8.00% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 11.39%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for APH is 28.65 vs. an industry ratio of 14.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Royal Caribbean Cruises Ltd. ( RCL ) is reporting for the quarter ending December 31, 2017. The leisure (recreational) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.20. This value represents a 2.44% decrease compared to the same quarter last year. In the past year RCL has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.75%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for RCL is 17.42 vs. an industry ratio of 32.80.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry. |
33361.0 | 2018-01-22 00:00:00 UTC | Noteworthy ETF Outflows: IWB, AMGN, GILD, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwb-amgn-gild-abt-2018-01-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $109.2 million dollar outflow -- that's a 0.5% decrease week over week (from 135,550,000 to 134,850,000). Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $109.2 million dollar outflow -- that's a 0.5% decrease week over week (from 135,550,000 to 134,850,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50. | Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33362.0 | 2018-01-21 00:00:00 UTC | 3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street | ABT | https://www.nasdaq.com/articles/3-fastest-growing-diabetes-stocks-2018-according-wall-street-2018-01-21 | nan | nan | Diabetes ranks as one of the top healthcare issues in the United States. Between 1990 and 2010, the number of Americans with diabetes tripled. By 2030, it's projected that nearly 55 million Americans will have diabetes -- a 54% increase from 2015.
With such a dire need, you'd think lots of companies would be developing products to help manage and treat diabetes. And you'd be right. The diabetes market has grown significantly and should continue to grow well into the future.
With that in mind, I checked out which stocks of companies focused on diabetes products Wall Street analysts think will perform the best in 2018. What I found was somewhat surprising. Senseonics Holdings (NYSEMKT: SENS) , Lexicon Pharmaceuticals (NASDAQ: LXRX) , and MannKind (NASDAQ: MNKD) ranked as the three diabetes stocks that Wall Street projects will grow the fastest over the next 12 months. But is this optimism justified?
Senseonics
The consensus Wall Street one-year price target for Senseonics represents a 55% increase over the current stock price. That would be a huge improvement over the medical device stock's performance in 2017, with Senseonics' share price dropping slightly last year.
Senseonics makes the Eversense continuous glucose monitoring (CGM) system. Eversense is an implantable sensor that lasts up to 90 days. It comes with a transmitter that sticks to the skin on a patient's arm and a mobile application that runs on iOS and Android platforms. Eversense notifies patients when blood sugar levels are low or high through the mobile app and by the transmitter vibrating on their skin.
The company is still awaiting FDA clearance of its device but has already received European approval for Eversense. Senseonics teamed up with Rubin Medical to market the system in seven Scandinavian countries and with healthcare giant Roche to market Eversense in the rest of Europe, Middle East, and Africa.
There's no question that the potential for CGM is huge. In the U.S. alone, nearly 7 million patients are on insulin, but only 250,000 or so use CGM systems. Senseonics claims that Eversense has the highest accuracy, longest sensor life, and best convenience of any CGM on the market. If the company wins its anticipated FDA clearance, Wall Street's target for the stock just might be attainable.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals stock could more than double if Wall Street analysts' price targets aren't too far off. If that happens, it would be a night-and-day difference between 2018 and 2017, when Lexicon stock plunged nearly 29%.
The company won FDA approval in February 2017 for its first commercial product, Xermelo, in treating carcinoid syndrome diarrhea. However, Lexicon's lead pipeline candidate, sotagliflozin, is an oral SGLT1/SGLT2 inhibitor for treating treatment of type 1 and type 2 diabetes.
Lexicon and its partner, Sanofi (NYSE: SNY) , expect to submit for approval of sotagliflozin in the U.S. and Europe for treating type 1 diabetes in the first half of 2018. The two companies have already announced positive results from a couple of late-stage studies. Late-stage studies for type 2 diabetes are also now under way. The earliest of these studies should wrap up in 2019.
If sotagliflozin wins approval, market research firm EvaluatePharma projects the drug could reach sales of nearly $1.2 billion by 2022. However, potential approval probably won't come until 2019. Wall Street could be right on the price target for Lexicon, but the timing might be a little off.
MannKind
MannKind could be the biggest diabetes stock of 2018 if Wall Street projections are accurate. The consensus one-year price target for the biotech reflects a massive increase of over 170% from MannKind's current share price. For a short period last year, MannKind was one of the hottest biotech stocks on the market . However, its run fizzled out, and the stock ended the year down 27%.
The company gained FDA approval of its inhaled insulin product, Afrezza, back in 2014. MannKind lined up Sanofi as its commercialization partner for the drug. After a disappointing launch, though, Sanofi handed Afrezza back over to MannKind in early 2016.
In November, I interviewed MannKind CEO Michael Castagna , who wasn't with the biotech during the period when it partnered with Sanofi. He stated that his view is that Afrezza wasn't a top priority for the French drugmaker. Castagna has also predicted that a label update the FDA approved in October should boost Afrezza sales in 2018. MannKind's direct-to-consumer marketing for the drug could also make a difference.
If Castagna's predictions are right, Wall Street's price target could also be right. However, MannKind will almost certainly conduct one or more stock offerings this year to raise additional cash. Dilution to the value of existing shares could prevent Wall Street's optimism from being realized.
A second opinion
Wall Street thinks Senseonics, Lexicon, and MannKind to be the biggest diabetes stock winners of the year. However, I think Abbott Labs (NYSE: ABT) could be the safest diabetes stock to buy for 2018.
Abbott stock soared nearly 50% last year. The company won FDA clearance for its FreeStyle Libre GCM system in September. It's the first FDA-approved CGM system that doesn't require a finger-stick blood sample. And unlike Senseonics' Eversense system, FreeStyle Libre doesn't have to be implanted beneath the skin.
Investors should also like Abbott's dividend, which currently yields 1.9%. The company has increased its dividend for 45 consecutive years. I expect that streak to continue -- and for Abbott stock to generate solid gains in 2018.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, I think Abbott Labs (NYSE: ABT) could be the safest diabetes stock to buy for 2018. That would be a huge improvement over the medical device stock's performance in 2017, with Senseonics' share price dropping slightly last year. Eversense notifies patients when blood sugar levels are low or high through the mobile app and by the transmitter vibrating on their skin. | However, I think Abbott Labs (NYSE: ABT) could be the safest diabetes stock to buy for 2018. Senseonics Holdings (NYSEMKT: SENS) , Lexicon Pharmaceuticals (NASDAQ: LXRX) , and MannKind (NASDAQ: MNKD) ranked as the three diabetes stocks that Wall Street projects will grow the fastest over the next 12 months. Senseonics The consensus Wall Street one-year price target for Senseonics represents a 55% increase over the current stock price. | However, I think Abbott Labs (NYSE: ABT) could be the safest diabetes stock to buy for 2018. Senseonics Holdings (NYSEMKT: SENS) , Lexicon Pharmaceuticals (NASDAQ: LXRX) , and MannKind (NASDAQ: MNKD) ranked as the three diabetes stocks that Wall Street projects will grow the fastest over the next 12 months. MannKind MannKind could be the biggest diabetes stock of 2018 if Wall Street projections are accurate. | However, I think Abbott Labs (NYSE: ABT) could be the safest diabetes stock to buy for 2018. Senseonics makes the Eversense continuous glucose monitoring (CGM) system. A second opinion Wall Street thinks Senseonics, Lexicon, and MannKind to be the biggest diabetes stock winners of the year. |
33363.0 | 2018-01-19 00:00:00 UTC | Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings? | ABT | https://www.nasdaq.com/articles/can-diagnostics-business-drive-abbotts-abt-q4-earnings-2018-01-19 | nan | nan | Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. We expect this strength to get reflected in fourth-quarter 2017 results, which are scheduled for release on Jan 24.
Core Laboratories Diagnostics
In June 2017, Abbott announced the CE Mark for Alinity hq, which has become the fifth diagnostic system to be launched in Europe along with the ongoing rollout of four instruments in the areas of immunoassay, clinical chemistry, blood screening and point of care. This has strengthened the company's Core Laboratory Diagnostics business considerably.
Of late, the company has been in the headlines following the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Notably, the Alinity portfolio covers clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics along with Abbott's AlinIQ. Interestingly, the company also continued the initial launch of certain new Alinity systems for the core laboratory, including "Alinity c" for clinical chemistry, "Alinity i" for immunoassay diagnostics and "Alinity s" for blood and plasma screening globally during the last reported third quarter.
Continuing with the slew of developments, this Illinois-based global medical device company signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust in August 2017. Per the terms of the collaboration, Abbott will be the authorized supplier of all analytical equipment and consumables, covering its Alinity ci and Alinity h series diagnostics instruments and AlinIQ. Per NWLP, the alliance, which presently covers 6% of the pathology market in the U.K., is expected to carry out 26 million tests per year. Thus, investors must be eagerly looking forward to the outcome of this deal on the company's financials. The Zacks Consensus Estimate for Core Laboratory Diagnostics revenues of $1.05 billion indicates a rise of 4.9% from the year-ago quarter reported number.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Point of Care
Abbott's successful closure of the Alere acquisition after a prolonged legal battle has instilled confidence in investors. The buyout closed in October 2017 under amended financial terms in favor of Abbott. Taking the attractive prospects of Point of Care testing within the in vitro diagnostics market into consideration, Abbott is highly optimistic about the Alere integration. According to the company, the Alere buyout will significantly expand its diagnostics presence and create the broadest Point of Care testing portfolio with strong positions in cardio, metabolic, infectious disease and toxicology testing. Moreover, Abbott expects Alere to contribute around $475 million to its top line in 2017. Thus, the Zacks Consensus Estimate for Point of Care revenues of $661 million indicates a massive rise of 389.6% from the year-ago quarter and a surge of 404.6% from the sequential quarter.
Molecular Diagnostics
Through 2017, Abbott has effectively focused on core areas and thus, the company has been strongly performing in the infectious disease testing business under Molecular Diagnostics. This has been partially offsetting declines due to planned scale down in other testing areas by the company. The Zacks Consensus Estimate for Molecular Diagnostics revenues of $122 million indicates a rise of 4.3% from the year-ago quarter.
With these positives in place, Abbott anticipates mid-single digit increase in Diagnostics sales in fourth-quarter 2017.
Here is what our quantitative model predicts:
Abbott does not have the right combination of two main ingredients - a positive Earnings ESP and Zacks Rank #3 (Hold) or higher - for increasing the odds of an earnings beat.
Zacks ESP : The Earnings ESP for Abbott is -0.62%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Abbott carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need to have a positive ESP to be confident of a positive earnings surprise.
The Zacks Consensus Estimate for earnings of 73 cents reflects a 12.3% rise on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories, Inc. BIO has an Earnings ESP of +4.45% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Myriad Genetics, Inc. MYGN has an Earnings ESP of +0.42% and a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.35% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the Alinity portfolio covers clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics along with Abbott's AlinIQ. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Notably, the Alinity portfolio covers clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics along with Abbott's AlinIQ. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Interestingly, the company also continued the initial launch of certain new Alinity systems for the core laboratory, including "Alinity c" for clinical chemistry, "Alinity i" for immunoassay diagnostics and "Alinity s" for blood and plasma screening globally during the last reported third quarter. | Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Molecular Diagnostics Through 2017, Abbott has effectively focused on core areas and thus, the company has been strongly performing in the infectious disease testing business under Molecular Diagnostics. |
33364.0 | 2018-01-18 00:00:00 UTC | Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings? | ABT | https://www.nasdaq.com/articles/can-epd-medical-devices-drive-abbotts-abt-q4-earnings-2018-01-18 | nan | nan | AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Last quarter, the company delivered a positive earnings surprise of 1.5%. Moreover, Abbott has delivered positive earnings surprises in the trailing four quarters, with an average beat of 4.5%. Let's see how things are shaping up for this announcement.
Key Catalysts
Similar to the prior quarter, Abbott is expected to gain from strong performance by the Established Pharmaceuticals Division ("EPD") business, which has been recording operational sales growth in the last few quarters. Major part of this growth was stimulated by a series of strategic actions, including Abbott's sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia. Accordingly, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 11.2% from the year-ago quarter.
Apart from Russia and Latin America, the company also continues to expect strong growth in EPD in the upcoming quarters, particularly in China, on the back of a strong market position and competitive advantage. Also, as expected, third-quarter sales in India were driven by purchasing patterns following the implementation of a new Goods and Services Tax system that dented second-quarter sales in the country. Thus, the Zacks Consensus Estimate for EPD revenues from key emerging markets of $867 million indicates a rise of 11.6% from the year-ago quarter.
We are also upbeat about the Medical Devices business, which has been on a healthy growth trajectory over the past few quarters. Abbott has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Historically, the company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of contributions from FreeStyle Libre. Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system, Abbott achieved another major milestone after the U.S. Centers for Medicare & Medicaid Services (CMS) granted FreeStyle Libre approval for Medicare coverage.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Moreover, last September, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. With these positives, Abbott's FreeStyle Libre system stands partially or fully covered in 21 countries, including France, Germany and Japan. Moreover, the Zacks Consensus Estimate for Diabetes Care revenues of $391 million indicates a rise of 26.1% from the year-ago quarter.
This apart, the market is bullish on Abbott's developments in other businesses which form part of the Medical Devices segment. In August 2017, the company announced FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device (LVAD) which is expected to boost top-line contributions from the Cardiovascular and Neuromodulation sub-segment. This segment has been the highest contributor to total Medical Devices revenues historically. The Zacks Consensus Estimate for Cardiovascular and Neuromodulation revenues of $2.24 billion indicates a rise of 0.9% from the sequential quarter.
Overall, fourth-quarter total revenues are projected at $7.37 billion, up 38.3% from the prior-year quarter.
Here is what our quantitative model predicts:
Abbott does not have the right combination of two main ingredients - a positive Earnings ESP and Zacks Rank #3 (Hold) or higher - for increasing the odds of an earnings beat.
Zacks ESP : The Earnings ESP for ResMed is -0.62%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Abbott carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need to have a positive ESP to be confident of a positive earnings surprise.
The Zacks Consensus Estimate for earnings of 73 cents reflects a 12.3% rise on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories, Inc. BIO has an Earnings ESP of +4.45% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Myriad Genetics, Inc. MYGN has an Earnings ESP of +0.42% and a Zacks Rank #3.
Henry Schein, Inc. HSIC has an Earnings ESP of +0.35% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Major part of this growth was stimulated by a series of strategic actions, including Abbott's sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system, Abbott achieved another major milestone after the U.S. Centers for Medicare & Medicaid Services (CMS) granted FreeStyle Libre approval for Medicare coverage. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Moreover, last September, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. | AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter . |
33365.0 | 2018-01-17 00:00:00 UTC | General Electric (GE): Does Breaking Up Make Sense? | ABT | https://www.nasdaq.com/articles/general-electric-ge-does-breaking-make-sense-2018-01-17 | nan | nan | Getty images
Breaking up is often hard to do, but when survival depends on business agility, nimbleness and a long-term competitive strategy, there’s sometimes no alternative.
And that’s where General Electric (GE) finds itself. While announcing on Tuesday that its insurance business, which is part of the slimmed-down GE Capital, would take a $6.2 billion charge for the fourth quarter, CEO John Flannery also shared his vision for a segmented vision. "We are looking aggressively at the best structure or structures for our portfolio to maximize the potential of our businesses," he said.
In other words, the 126-year old industrial conglomerate, which is set to report fourth quarter results next week, believes breaking up into smaller businesses is in its best interest. This strategic breakup may result in "separately traded assets really in any one of our units, if that's what made sense," Flannery said. But Wall Street hates the idea, punishing GE shares on Tuesday by as much as 4.26% to a session low of $17.96 on more than twice its average volume.
Gautam Khanna, Bill Ledley and Jeff Molinari, analysts at Cowen believes the company is worth far more together than as separate entities. “GE’s sum-of-the-parts valuation is below the current stock price, and that was true before [the] announcement today,” the analysts said in a research note Tuesday. “Thus, we see no quick fix for the stock.”
GE shares, which lost some 45% of its value in 2017, were the worst-performing component on the Dow Jones Industrial Average last year. GE’s stock grossly underperformed that of its closest peers such as Honeywell (HON), United Technologies (UTX), Boeing Co. (BA) and 3M (MMM) by significant margins. And this was partly because the Boston-based company has had a difficult time managing its many business, which includes lighting, health care, transportation, renewable energy, oil and gas, aviation and power.
This strategic breakup may result in "separately traded assets really in any one of our units, if that's what made sense," Flannery said. It would seem, by breaking up into smaller parts, the company is looking to reverse its fortunes with some financial creativity and flexibility. After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ).
But in GE’s case, it’s a double-edged sword. The breakup would also cause GE to lose synergies it has benefited from in terms of legal, tax and other costs, according to the Cowen analysts. What’s more, GE’s industrial operations would also be on the hook for the lion's share of the $32 billion in net debt held by the company’s financial services unit, GE Capital. And this could be just the one of the reasons investors were angry today.
GE stock closed Tuesday at $18.21, losing 3%. The shares have risen 4.36% year to date, compared with a 3.85% rise in the S&P 500 (SPX) index. It may be a while before this news of a possible breakup settles in. But the topic is poised to dominate GE’s conference call when its Q4 results are released next week. Stay tuned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ). In other words, the 126-year old industrial conglomerate, which is set to report fourth quarter results next week, believes breaking up into smaller businesses is in its best interest. GE’s stock grossly underperformed that of its closest peers such as Honeywell (HON), United Technologies (UTX), Boeing Co. (BA) and 3M (MMM) by significant margins. | After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ). While announcing on Tuesday that its insurance business, which is part of the slimmed-down GE Capital, would take a $6.2 billion charge for the fourth quarter, CEO John Flannery also shared his vision for a segmented vision. In other words, the 126-year old industrial conglomerate, which is set to report fourth quarter results next week, believes breaking up into smaller businesses is in its best interest. | After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ). While announcing on Tuesday that its insurance business, which is part of the slimmed-down GE Capital, would take a $6.2 billion charge for the fourth quarter, CEO John Flannery also shared his vision for a segmented vision. “GE’s sum-of-the-parts valuation is below the current stock price, and that was true before [the] announcement today,” the analysts said in a research note Tuesday. | After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ). In other words, the 126-year old industrial conglomerate, which is set to report fourth quarter results next week, believes breaking up into smaller businesses is in its best interest. “Thus, we see no quick fix for the stock.” GE shares, which lost some 45% of its value in 2017, were the worst-performing component on the Dow Jones Industrial Average last year. |
33366.0 | 2018-01-16 00:00:00 UTC | 5 Soaring ‘Strong Buy’ Stocks Ahead of Earnings Season | ABT | https://www.nasdaq.com/articles/5-soaring-strong-buy-stocks-ahead-earnings-season-2018-01-16 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Earnings season has now kicked off, and word on the Street is that it's going to be a very good one. Overall S&P 500 profits are expected to soar by 11.2% in Q417 according to UBS strategist Keith Parker . He told CNBC that this would be the second-strongest earnings growth period since 2011.
The economy has momentum and all sectors are expected to post increases.
With this bullish outlook in mind, I decided to look for five 'Strong Buy' stocks to keep a close eye on ahead of earnings. I found these stocks using TipRanks' nifty Earnings Calendar . The Calendar enables you to scan for stocks with upcoming earnings report and a 'Strong Buy' analyst consensus rating.
In this case, I specifically looked for stocks with a 'Strong Buy' consensus from the best-performing analysts on Wall Street. This means cutting out recent unhelpful stock ratings from under-performing analysts. The result: a list of five stellar stocks. All these stocks are also Top Picks. You can see below how analysts have named these stocks as their best ideas for 2018.
8 Stocks That Will Hit All-Time Highs in 2018
So now let's delve in and see which top stocks are hot right now:
'Strong Buy' Stock: Alphabet (GOOGL)
Source: Shutterstock
Alphabet Inc (NASDAQ: GOOGL ) will report Q4 results on February 1st after the close. The Street is looking for gross revenue of $31.57B and net revenue of $25.54B. GAAP EPS is estimated at $9.99 up from $9.36 last year. While GOOGL had a stellar year in general, investors are expecting that the tech giant ended the year on a high note. A very strong holiday retail season likely gave a solid boost to Google's ad revenue for the quarter. And looking forward, a weakening US dollar and upcoming tax reform should help push 2018 estimates higher.
Analysts are singing the praises of GOOGL - with top Robert W Baird analyst Colin Sebastian calling it his number 1 stock. He makes the unique (but apt) comparison to California's giant redwood trees:
"Despite significant outperformance vs. broader markets, Internet platforms still represent compelling investments… We believe they share characteristics with the 'giant redwoods' of the West Coast - dominance within their ecosystems, enduring growth, and ability to withstand a variety of threats."
In order of preference, he calls his top large-cap picks GOOGL, Amazon.com, Inc. (NASDAQ: AMZN ) and Facebook Inc (NASDAQ: FB ).
TipRanks reveals that this 'Strong Buy' stock stacks up well from a Street perspective. In the last three months, top analysts have published 19 buy ratings on GOOGL. This is versus just three hold ratings.
Meanwhile the average analyst price target stands at $1,194, with the highest price target from Jefferies' Brent Thill . His $1,350 PT suggests upside of close to 20%. "We see Google as having the clearest path of any company to $1 trillion, with multiple meaningful opportunities (both near and longer-term) in play," says Thill.
'Strong Buy' Stock: Starbucks (SBUX)
Source: Shutterstock
The inventor of coffees you never knew you wanted (see Unicorn Frappuccino), Starbucks Corporation (NASDAQ: SBUX ) is set to report its earning results on January 25 after the close. Analysts are expecting EPS of 57 cents vs 52 cents the previous year. While shares have experienced some volatility over the year, in the last three months prices have steadily increased. The stock is now trading at over $60. And it looks set to soar much higher.
Source: Starbucks
Unicorn Frappuccino
Source: Starbucks Four-star David Tarantino of Robert W Baird is confident that SBUX can reach $72 (19% upside) in the coming months. He calls SBUX his Best Idea for 2018 and says the company has a very appealing setup going into 2018. Tarantino explains:
"We are confident SBUX can deliver F2018 comps at or above our +3% forecast based on sales-driving initiatives (unlocking throughput constraints, expanding mobile order/pay, innovating on food and beverages) and prospects for a better consumer spending backdrop (amid individual income tax cuts)"
Notably, Tarantino isn't alone. Piper Jaffray's Nicole Miller Reagan has also just released a report titled "'The (2018) Year of the Restaurant': SBUX Top Pick." She believes that "highly attractive core business fundamentals support substantial future growth opportunities across its portfolio." Plus, strong cash flow generation supports continued reinvestment into the business and capital allocation.
10 Strong Buy Stocks From 2017's Best Analysts
Given these bullish forecasts, it's not surprising that Starbucks has a 'Strong Buy' analyst consensus rating on TipRanks. Indeed, in the last three months, it has received no less than 12 buy ratings and just 1 hold rating.
'Strong Buy' Stock: Abbott Laboratories (ABT)
Source: Phalinn Ooi via Flickr
Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. The Street consensus for sales of $7.4 billion and EPS of 73 cents is up from the EPS this time last year of $65 cents. Over this time frame, shares are up almost $20 from $41 to the current share price of $59.
And according to Morgan Stanley analyst David Lewis this price still seriously undervalues Abbott's potential. This is because ABT still trades in line with peers despite a premium growth profile.
"As risks fade, we see an emerging picture of top-tier growth that is not captured in Street expectations for 2018," explains Lewis. "We see multiple expansion on Abbott's premium profile and improving leverage driving outperformance."
Specifically, he believes Libre and Confirm can generate 5%-plus organic growth in 2018. Both Libre and Confirm use smartphone apps to help patients monitor their glucose and heartbeats more easily than ever before.
As a result, Lewis upgraded the stock from Hold to Buy at the beginning of January. His $67 price target translates into 14% upside from the current share price. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT. In the last three months this top stock has received 10 buy ratings with only 1 analyst choosing to remain sidelined. One of these analysts - Raymond James' Jayson Bedford - highlights ABT as a top pick with 'solid double-digit earnings growth.'
'Strong Buy' Stock: Priceline (PCLN)
Source: Shutterstock
Discount travel website Priceline Group Inc (NASDAQ: PCLN ) is out with its results for Q4 in early February. Crucially, the Street is expecting Total Bookings of $17.2 billion, up an impressive 14% year over year. The revenue consensus estimate is $2.7 billion with EPS of $14.08. The stock dropped back in November, but has since traded upwards, gaining $140 in just the last month.
"We believe this will be the first Beat & Bracket Quarter PCLN has printed since Q4:16 - a positive catalyst" says top RBC Capital analyst Mark Mahaney . He notes the site's very positive unique visitor trends, with Priceline traffic apparently growing by a whopping 51% in October and 52% in November. Add in positive hotel industry trends in the US and a bigger presence on Booking.com, and this is one key stock to keep a close eye on!
In fact, on January 12, Mahaney pushed Amazon off his top three long cap longs for 2018 to make room for Priceline. He explains: "A somewhat sold-off stock, still solid secular growth drivers (Online, Millennials, Emerging Markets' Emerging Middle Classes), and easing comps throughout '18 provide a potent combo."
10 High-Growth Stocks to Kick Your Portfolio into Hyper Drive
From top analysts, Priceline scores a Strong Buy consensus rating. This breaks down into 14 buy ratings and 4 hold ratings over the last three months. The average price target from these analysts stands at $2,011.
'Strong Buy' Stock: Amazon (AMZN)
Source: Mike Seyfang via Flickr
E-commerce giant Amazon.com, Inc. (NASDAQ: AMZN ) is out with its fourth-quarter numbers on February 2 after the close. GAAP EPS is estimated to come in at $1.89 on $59.6B Revenue, $1.5B in GAAP operating income. Following the Q3 print, Amazon has now recorded 60 Straight Quarters of 20%+ revenue growth.
And as for Q4, Amazon has already disclosed that tens of millions of Alexa-enabled devices were sold worldwide over the holidays. This is backed up by strong holiday retail sales data. According to Mastercard SpendingPulse, US holiday sales increased 4.9%, the largest year-over-year increase since 2011.
Mahaney may no longer list Amazon as one of his top three large-caps, but AMZN still ranks very highly on the Street's scales. Five-star Oppenheimer analyst Jason Helfstein has just assigned a buy rating and bullish $1,450 price target to AMZN. He says "We are naming AMZN our top 2018 large-cap pick after strong 2017 performance (+56% vs. +19% for S&P 500) and increasing our target to $1,450 from $1,330." The new price target indicates 11% upside potential. Helfstein further explains:
"Amazon is best positioned among our large-cap universe to benefit from secular trends - shift to ecommerce, Public Cloud, Automation and Digital Advertising - further supported by an improving global macroeconomic backdrop and domestic tax reform."
Indeed, we can see that Amazon has big backing from the Street. In the last three months, the stock has received 30 buy ratings and only 1 sell rating. The average analyst price target stands at $1,353.
TipRanks offers investors the latest insight into eight different sectors by tracking the activity of 4,500 analysts, 5,000 financial bloggers and even 37,000 corporate insiders. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 5 Soaring 'Strong Buy' Stocks Ahead of Earnings Season appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 'Strong Buy' Stock: Abbott Laboratories (ABT) Source: Phalinn Ooi via Flickr Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. This is because ABT still trades in line with peers despite a premium growth profile. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT. | 'Strong Buy' Stock: Abbott Laboratories (ABT) Source: Phalinn Ooi via Flickr Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. This is because ABT still trades in line with peers despite a premium growth profile. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT. | 'Strong Buy' Stock: Abbott Laboratories (ABT) Source: Phalinn Ooi via Flickr Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. This is because ABT still trades in line with peers despite a premium growth profile. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT. | 'Strong Buy' Stock: Abbott Laboratories (ABT) Source: Phalinn Ooi via Flickr Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. This is because ABT still trades in line with peers despite a premium growth profile. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT. |
33367.0 | 2018-01-12 00:00:00 UTC | iShares Edge MSCI USA Momentum Factor ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-edge-msci-usa-momentum-factor-etf-experiences-big-inflow-2018-01-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $507.6 million dollar inflow -- that's a 8.7% increase week over week in outstanding units (from 54,000,000 to 58,700,000). Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $76.67 per share, with $108.71 as the 52 week high point - that compares with a last trade of $108.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $507.6 million dollar inflow -- that's a 8.7% increase week over week in outstanding units (from 54,000,000 to 58,700,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $76.67 per share, with $108.71 as the 52 week high point - that compares with a last trade of $108.61. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $507.6 million dollar inflow -- that's a 8.7% increase week over week in outstanding units (from 54,000,000 to 58,700,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $76.67 per share, with $108.71 as the 52 week high point - that compares with a last trade of $108.61. | Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $507.6 million dollar inflow -- that's a 8.7% increase week over week in outstanding units (from 54,000,000 to 58,700,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $76.67 per share, with $108.71 as the 52 week high point - that compares with a last trade of $108.61. |
33368.0 | 2018-01-12 00:00:00 UTC | Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre | ABT | https://www.nasdaq.com/articles/abbotts-abt-diabetes-care-unit-strong-on-freestyle-libre-2018-01-12 | nan | nan | AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System.
The company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of solid contributions from FreeStyle Libre. Accordingly, it is leaving no stone unturned to cash in on the growing popularity of this CGM system that eliminates the need for daily finger sticks.
Developments in FreeStyle Libre
Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system, Abbott recently achieved another major milestone after U.S. Centers for Medicare & Medicaid Services (CMS) granted FreeStyle Libre approval for Medicare coverage. Post approval, FreeStyle Libre has become the only no- user calibration CGM device, under the Medicare coverage, available for around 30 million people with diabetes in the United States.
Meanwhile, Abbott has been steadily progressing with the development of its Diabetes Care segment. Last September, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. Notably, the FreeStyle Libre system is partially or fully covered in 21 countries, including France, Germany and Japan.
Moreover, the company announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System in June 2017. This drove the Diabetes Care segment, which saw revenue growth of 37.6% in third-quarter 2017 on continued acceptance of FreeStyle Libre internationally.
We believe the latest CMS reimbursement grant will boost the company's performance in the domestic arena as well.
We expect Freestyle Libre to contribute to Abbott's top line as along with the U.K., Japanese and Canadian developments, the French Health Ministry approved national reimbursement for the device last May.
Market Potential
An ageing population, unhealthy lifestyle and rising awareness and expenditure in healthcare are likely to drive growth further in the diabetes market. Moreover, per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%. Given the bullish market sentiments, we believe the recent regulatory approvals for FreeStyle Libre have come at an opportune moment.
However, this market is dominated by well-established players, Johnson & Johnson JNJ being the most prominent one. In this space, Johnson & Johnson has a tie-up with U.S.-based Animas Corporation to successfully develop and innovate insulin delivery systems.
Share Price Movement
Moreover, Abbott has been gaining investor confidence on consistently positive results. Over the last three months, the company's share price has outperformed the broader industry . The stock has gained 7.8%, in comparison with the broader industry's 5.2% gain.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories, Inc. BIO and Intuitive Surgical, Inc. ISRG .
Bio-Rad Laboratories flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25% and has gained 33.5% in a year.
Intuitive Surgical has a long-term expected earnings growth rate of 9.2%. The stock carries a Zacks Rank #2 and has surged 90.1% in a year.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Post approval, FreeStyle Libre has become the only no- user calibration CGM device, under the Medicare coverage, available for around 30 million people with diabetes in the United States. | AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Developments in FreeStyle Libre Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system, Abbott recently achieved another major milestone after U.S. Centers for Medicare & Medicaid Services (CMS) granted FreeStyle Libre approval for Medicare coverage. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. The company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of solid contributions from FreeStyle Libre. | AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Developments in FreeStyle Libre Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system, Abbott recently achieved another major milestone after U.S. Centers for Medicare & Medicaid Services (CMS) granted FreeStyle Libre approval for Medicare coverage. |
33369.0 | 2018-01-12 00:00:00 UTC | 3 of the Best Dividend Aristocrats for Retirement | ABT | https://www.nasdaq.com/articles/3-best-dividend-aristocrats-retirement-2018-01-12 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Retirement investing is a bit different from regular investing, and not because it depends more on dividend investing. See, we've been led to believe inflation is 3%, when it's really closer to 10%. That means that retired investors don't think they need stocks that offer capital gains alongside dividends, but they most certainly do.
Dividend Aristocrats were an important part of the retired investor's portfolio then, because their cash flow is not only so fantastic that they can continue raising dividends year after year, but because they also have enough growth in some cases to boost annual returns to that important 10% level.
7 Stocks With 'Tax Cut' Dividend Increases on Tap
I've got three Dividend Aristocrats that not only pay that yummy dividend, but that I think have a pretty decent shot at growing earnings enough that their stock prices should also rise to breach the 10% annual level.
Dividend Aristocrats for Retirement: Old Republic International Corporation (ORI)
Source: Pictures of Money via Flickr
Dividend Yield: 3.8%
The first stop for any retired investor, or a Dividend Aristocrats choice, should be an insurance stock like Old Republic International Corporation (NYSE: ORI ).
ORI is not just an insurance company, but one that has such a long history, that it now offers just about every kind of insurance any individual or business could ever want. Businesses of all stripes insure with ORI: forest products, education, transportation, healthcare, commercial construction, financial services, real estate, energy and manufacturing,
Businesses can also grab the necessary insurance for officers and directors, employee fidelity, asset protection, surety and E&O. It also handles the consumer side, including the highest margin products like home and extended auto warranty, and travel accident insurance.
It pays a 3.8% yield, and earnings growth has run between 6% and 10% the past few years.
Dividend Aristocrats for Retirement: VF Corp (VFC)
Source: Shutterstock
Dividend Yield: 2.4%
VF Corp (NYSE: VFC ) sounds about as boring of the Dividend Aristocrats as one can possibly find, and yet, you actually know its products. Ready? It's just the name of the holding company for some of the most popular outdoor and shoe consumer brands in the country.
They own The North Face, Eagle Creek, Timberland and Vans. If you know these products, you also know them to be of really high quality - the kind of go-to stuff that serious outdoors people will buy.
These products have a big advantage, and it's one of the reasons VF has been able to consistently generate cash flow and raise dividends. These are niche products, not subject to the usual whimsical tastes of other clothing retailers. They are name-brands associated with specific activities.
7 ETFs That Let You Invest in the Hottest New Technology
The dividend is 2.4%, and analysts see a five-year annualized earnings growth rate of 7.2%, which pushes the total return to just about 10%. Free cash flow is a bit erratic, but the payout ratio is never higher than 60%.
Dividend Aristocrats for Retirement: AbbVie Inc (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Dividend Yield: 2.8%
AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). The great thing about a legacy bio-pharmaceutical company as one of the Dividend Aristocrats is that once it has enough drugs in the world, and continues to research more, it produces tons of cash flow.
ABBV in particular is in areas that show no signs of slowing down: immunology, oncology and virology therapies. Moreover, it's trying to establish a foothold in neuroscience.
ABBV is a true growth stock on its own, with five-year annualized earnings growth pegged at 15%. ABBV has an active pipeline and it is truly amazing for a Dividend Aristocrat to also have this kind of growth. Add in the 2.8% dividend, and retired investors don't have to shy away from a terrific stock with dividend and growth all wrapped into one package.
Lawrence Meyers is the CEO of PDL Capital, a specialty lender focusing on consumer finance and is the Manager of The Liberty Portfolio at www.thelibertyportfolio.com. He does not own any stock mentioned. He has 23 years' experience in the stock market, and has written more than 1,800 articles on investing. Lawrence Meyers can be reached at TheLibertyPortfolio@gmail.com.
Compare Brokers
The post 3 of the Best Dividend Aristocrats for Retirement appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). It also handles the consumer side, including the highest margin products like home and extended auto warranty, and travel accident insurance. 7 ETFs That Let You Invest in the Hottest New Technology The dividend is 2.4%, and analysts see a five-year annualized earnings growth rate of 7.2%, which pushes the total return to just about 10%. | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). Dividend Aristocrats for Retirement: Old Republic International Corporation (ORI) Source: Pictures of Money via Flickr Dividend Yield: 3.8% The first stop for any retired investor, or a Dividend Aristocrats choice, should be an insurance stock like Old Republic International Corporation (NYSE: ORI ). Dividend Aristocrats for Retirement: VF Corp (VFC) Source: Shutterstock Dividend Yield: 2.4% VF Corp (NYSE: VFC ) sounds about as boring of the Dividend Aristocrats as one can possibly find, and yet, you actually know its products. | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). 7 Stocks With 'Tax Cut' Dividend Increases on Tap I've got three Dividend Aristocrats that not only pay that yummy dividend, but that I think have a pretty decent shot at growing earnings enough that their stock prices should also rise to breach the 10% annual level. Dividend Aristocrats for Retirement: Old Republic International Corporation (ORI) Source: Pictures of Money via Flickr Dividend Yield: 3.8% The first stop for any retired investor, or a Dividend Aristocrats choice, should be an insurance stock like Old Republic International Corporation (NYSE: ORI ). | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Retirement investing is a bit different from regular investing, and not because it depends more on dividend investing. Dividend Aristocrats were an important part of the retired investor's portfolio then, because their cash flow is not only so fantastic that they can continue raising dividends year after year, but because they also have enough growth in some cases to boost annual returns to that important 10% level. |
33370.0 | 2018-01-11 00:00:00 UTC | Miles White's Bold Moves Made Abbott Laboratories A Global Force | ABT | https://www.nasdaq.com/articles/miles-whites-bold-moves-made-abbott-laboratories-global-force-2018-01-11 | nan | nan | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company.
Today, he's one of the longest-serving chiefs in health care and has made a reputation as a master strategist, known for making bold moves at Abbott. And none was more dramatic than when he spun off the research-based pharmaceutical half of the firm as AbbVie ( ABBV ) in 2013. Before this, Abbott had a market capitalization at about half that of industry leaders Pfizer ( PFE ) and Merck ( MRK ).
It seemed crazy to many, but White perceived that developing new drugs had a completely different business rhythm than what the new Abbott would now focus on: devices, diagnostics, nutritional products and branded generic drugs. The result: Abbott's stock has since risen from 24 a share to around 59 a share, giving it a market cap of about $102 billion, while AbbVie's shares increased from 33 a share to near 100 a share, giving it a value approaching $159 billion. His creations combined are now worth around $260 billion, far more than Pfizer ($217 billion) or Merck ($156 billion). And White has been ranked by Barron's as one of the world's 30 best CEOs for nine straight years.
"It's about keeping the company current and relevant," White told IBD. "We continually shape our business to ensure we're where the needs and opportunities are for the future. For instance, our recent acquisition of St. Jude Medical makes us a leader across a range of growing medical device categories where new technology can make a huge difference - for the patient and for investors."
White grew up in Las Vegas and earned a Bachelor of Science in mechanical engineering at Stanford in 1978, and an MBA two years later. He joined McKinsey & Co. in Chicago as a consultant, but while he felt the work was fascinating, projects and clients came and went. White said he wanted something he "could feel connected to for a longer term, which would be more fulfilling."
White was hired by Abbott, based in the north Chicago suburb of Abbott Park, Ill., in 1984 as a director of sales in diagnostics, and four years later he was offered a chance to head the division's growing Asia-Pacific region - a prestigious position for a 33-year-old. But he turned it down because it meant moving to Japan; his wife wanted to open a children's bookstore in the U.S. White said he is a big believer in work-life balance and was confident that other opportunities for advancement would come his way. Indeed, 10 years later he was chosen to be the new CEO and the following year added the title of chairman of the board. (And his wife ran her bookstore for 19 years before selling it in 2008.)
Driving Transformation
Abbott had rarely done acquisitions or divestitures since its founding in 1888. A whirlwind of change followed after White took the helm, including:
Abbott purchasing Knoll in 2001, the pharmaceutical division of Germany's BASF.
Selling off its Selsun Blue, Clear Eyes and Murine brands in 2002.
Spinning off its hospital products division as Hospira in 2004 (bought by Pfizer for $17 billion in 2015), as well as acquiring TheraSense and merging with earlier acquisition MediSense to create its diabetes-care division.
Purchasing the vascular device business of Guidant Corp. in 2006.
But 2007 was dramatic and traumatic. Abbott acquired Kos Pharmaceuticals, a maker of cardiovascular drugs, for $3.7 billion in cash, but a deal to sell its core laboratory and point-of-care diagnostics divisions to General Electric ( GE ) fell through. White decided to revive these challenged divisions instead, investing in research and development, streamlining operations, and reorganizing products and services into a new diagnostics division. In August 2016 it began launching a family of next-generation instruments, informatics and services with common software and hardware platforms designed to be easy to use and more efficient, which White called "a game-changer for the industry."
Among other acquisitions, in 2010 Abbott paid $6.2 billion for the pharmaceuticals unit of Belgium-based Solvay, expanding its presence in emerging markets. The same year, a plan was announced to purchase a unit of Piramal Healthcare for $3.8 billion, which would make Abbott the biggest pharmaceutical company in India.
The success of the company's acquisitions may largely depend on an ability to anticipate consumers' medical needs, understand where the practice of medicine is headed, and aggressively position the company to benefit through internal and external investment.
"It's not just about acquiring companies," White said. "It's about what you do with them. How can you do more with that business? How can you make it better? How can it improve your existing operations?
"We've developed a very disciplined integration process through which we learn how best to bring new assets into Abbott and help them expand and reach their potential, faster and better than they could have before."
All of this and more were just preliminaries to spinning off half the company, for which Abbott took a 2012 third-quarter charge of $478 million. AbbVie was officially listed on the New York Stock Exchange on Jan. 2, 2013.
"What makes White such a savvy deal-maker?" asked Jim Cramer on his "Mad Money" show on CNBC in November 2017. "He has a real talent for anticipating consumers' future medical needs and then aggressively positioning his company to benefit from them. Within four years of becoming CEO, Abbott released Humira, which would go on to treat forms of arthritis, plaque psoriasis and Crohn's disease, among other ailments. In 2016, now part of AbbVie, it made $16.1 billion in sales, making it the best-selling drug in the world. But White had the foresight to spin off this part of his company ahead of the explosion of the debate about drug prices."
But guiding a global enterprise through massive change can result in mistakes, and Abbott's biggest occurred in the midst of the drama leading to the split. In October 2012, Abbott was fined $500 million for marketing Depakote, a brand of valproic acid, the world's most widely prescribed anti-epileptic drug, for conditions not approved by the Food and Drug Administration. As part of a settlement that cost it a total of $1.5 billion, the company agreed to strengthen its internal controls.
The New Abbott
After separating from AbbVie in January 2013, the new Abbott emerged with a focus on not only diagnostic products and services, but medical devices, nutritional lines and branded generic medicines. The latter is the Established Pharmaceuticals Division, which sells to developing markets, where a brand name may be trusted more than an unknown, due to high quality and efficacy standards, but which doesn't have the high costs of R&D-based pharma. The division now offers more than 1,500 products, with 400 in development. In 2014, it acquired CFR Pharmaceuticals for $2.9 billion, more than doubling its Latin American branded-generics pharmaceutical presence.
Abbott is also the world leader in adult nutritional products, including Ensure and ZonePerfect, as well as the U.S. leader in baby nutrition with Similac and other lines, and for special dietary needs with Glucerna and Juven.
The company is also a leader in diabetes care, introducing a revolutionary continuous glucose monitoring device, FreeStyleLibre, in September.
In 2017, the company purchased St. Jude Medicine for $25 billion in cash and stock, establishing Abbott as a leader in the medical device arena. It also closed Alere for $5.3 billion, which made it the leader in the $7 billion point-of-care diagnostics market.
"We've reinvented the company multiple times over the past 20 years," White said. "It's a continuous process of shaping the company for the future. We work very deliberately to ensure that we remain relevant and current to the people we serve and to the changes taking place in our environment. We're in several different businesses today than we were decades ago, and they were all chosen specifically for their relevance to where the science was going, where demographic and socioeconomic factors were going, and where our customers were going. And that's why we're still growing strong and our stock is at an all-time high."
Today, Abbott employs 94,000 workers in over 150 countries. In 2016, its revenue was $20.9 billion and net income was $1.4 billion.
White's Keys
CEO and chairman of Abbott Laboratories, a global leader in medical devices, diagnostics, nutritional products and branded generic medicines.
Overcame: The failed sale of the challenged diagnostics businesses, which he turned around by investing in innovation and becoming a highly profitable, consistent grower for the company.
Lesson: Envision a long-term big goal and work out the detailed steps to get there, even if it means defying the industry's consensus.
"You need to continually ask yourself, 'Is there a better way?' Because the answer is always yes, even though exactly how might not yet be apparent."
MORE ABOUT LEADERS & SUCCESS :
Pam Nicholson Drives Global Growth For Enterprise Holdings
Taco Bell's Founder Changed America's Fast-Food Menu
Meet The Man Hired To Take On Amazon
Phil Knight Cleared Hurdles To Make Nike A Merchandising Champion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company. But he turned it down because it meant moving to Japan; his wife wanted to open a children's bookstore in the U.S. White said he is a big believer in work-life balance and was confident that other opportunities for advancement would come his way. Abbott acquired Kos Pharmaceuticals, a maker of cardiovascular drugs, for $3.7 billion in cash, but a deal to sell its core laboratory and point-of-care diagnostics divisions to General Electric ( GE ) fell through. | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company. The New Abbott After separating from AbbVie in January 2013, the new Abbott emerged with a focus on not only diagnostic products and services, but medical devices, nutritional lines and branded generic medicines. In 2017, the company purchased St. Jude Medicine for $25 billion in cash and stock, establishing Abbott as a leader in the medical device arena. | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company. It seemed crazy to many, but White perceived that developing new drugs had a completely different business rhythm than what the new Abbott would now focus on: devices, diagnostics, nutritional products and branded generic drugs. White was hired by Abbott, based in the north Chicago suburb of Abbott Park, Ill., in 1984 as a director of sales in diagnostics, and four years later he was offered a chance to head the division's growing Asia-Pacific region - a prestigious position for a 33-year-old. | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company. It seemed crazy to many, but White perceived that developing new drugs had a completely different business rhythm than what the new Abbott would now focus on: devices, diagnostics, nutritional products and branded generic drugs. "It's not just about acquiring companies," White said. |
33371.0 | 2018-01-10 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2018 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-january-11-2018-2018-01-10 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2018. A cash dividend payment of $0.28 per share is scheduled to be paid on February 15, 2018. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 5.66% increase over prior dividend payment.
The previous trading day's last sale of ABT was $58.92, representing a -1.14% decrease from the 52 week high of $59.60 and a 50.11% increase over the 52 week low of $39.25.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and TiGenix ( TIG ). ABT's current earnings per share, an indicator of a company's profitability, is $1.27. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 13.5%, compared to an industry average of 11.9%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
First Trust Nasdaq Pharmaceuticals ETF ( FTXH )
iShares U.S. Healthcare ETF ( IYH )
Vanguard Health Care ETF ( VHT )
Vanguard Div Appreciation ETF ( VIG )
AdvisorShares Vice ETF ( ACT ).
The top-performing ETF of this group is VIG with an increase of 11.59% over the last 100 days. FTXH has the highest percent weighting of ABT at 8.4%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2017 as 13.5%, compared to an industry average of 11.9%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) AdvisorShares Vice ETF ( ACT ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2018. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) AdvisorShares Vice ETF ( ACT ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 11, 2018. The previous trading day's last sale of ABT was $58.92, representing a -1.14% decrease from the 52 week high of $59.60 and a 50.11% increase over the 52 week low of $39.25. |
33372.0 | 2018-01-09 00:00:00 UTC | Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-patterson-companies-abbvie-and-abbott-laboratories-2018-01-09 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc will pay its quarterly dividend of $0.26 on 1/26/18, AbbVie Inc will pay its quarterly dividend of $0.71 on 2/15/18, and Abbott Laboratories will pay its quarterly dividend of $0.28 on 2/15/18. As a percentage of PDCO's recent stock price of $37.61, this dividend works out to approximately 0.69%, so look for shares of Patterson Companies Inc to trade 0.69% lower - all else being equal - when PDCO shares open for trading on 1/11/18. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal.
Below are dividend history charts for PDCO, ABBV, and ABT, showing historical dividends prior to the most recent ones declared.
Patterson Companies Inc (Symbol: PDCO) :
AbbVie Inc (Symbol: ABBV) :
Abbott Laboratories (Symbol: ABT) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.77% for Patterson Companies Inc, 2.85% for AbbVie Inc, and 1.90% for Abbott Laboratories.
In Tuesday trading, Patterson Companies Inc shares are currently down about 0.5%, AbbVie Inc shares are trading flat, and Abbott Laboratories shares are up about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal. Below are dividend history charts for PDCO, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc (Symbol: PDCO) : AbbVie Inc (Symbol: ABBV) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc (Symbol: PDCO) : AbbVie Inc (Symbol: ABBV) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal. Below are dividend history charts for PDCO, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. |
33373.0 | 2018-01-07 00:00:00 UTC | 2 Top Dividend Stocks to Buy in 2018 | ABT | https://www.nasdaq.com/articles/2-top-dividend-stocks-buy-2018-2018-01-07 | nan | nan | Dividend stocks are a critical part of a well-structured portfolio because of their ability to generate passive sources of income, or alternatively, compound returns on capital via a dividend reinvestment plan . Picking top dividend stocks , though, is anything but a straightforward process.
The good news is that the best dividend stocks have historically shared a few underlying qualities that make them stand out from the crowd. The key traits that most elite income stocks have in common are stable and growing free cash flows, a strong track record of regular increases to the dividend, and a positive long-term outlook.
So what's the best space to uncover the most compelling dividend plays right now? In my view, the biopharmaceutical industry arguably occupies the top spot when it comes to dividend stocks. Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. Read on to learn more.
Top of its class
AbbVie is a solid dividend stock to buy (or continue holding) for a few reasons. First off, the drugmaker has grown its dividend at the fastest pace among large cap pharmas since being carved out of Abbott Laboratories in 2013. Its modest trailing payout ratio of 60.4% also implies that further increases are feasible moving forward -- especially since the company's free cash flow is forecast to grow at industry-leading levels in the next two to three years. AbbVie, for what it's worth, is living up to its status as a dividend aristocrat, bestowed upon it by Abbott.
While top-flight dividend programs are unusual in the pharma space because of the enormous costs associated with clinical trials, AbbVie has managed to find a nice balance between maintaining its upper-tier dividend and investing in its vast clinical pipeline. In fact, AbbVie's late-stage clinical pipeline was pegged as the most valuable within its peer group last year, according to EvaluatePharma.
That's especially good news for the company's longer-term growth prospects. AbbVie, after all, is still heavily reliant on the anti-inflammatory megablockbuster, Humira, for the bulk of its sales. As the company's diverse oncology pipeline matures, however, AbbVie's revenue stream should start to better reflect its status as a top dog in the clinic. Fortunately, AbbVie now has until the end of 2022 to complete its ongoing pivot to oncology, thanks to the global patent resolution with Amgen over Humira's intellectual property portfolio last year.
AbbVie is arguably worth buying because of its generous dividend yield of 2.94%, rapidly growing footprint in the high-value oncology market, and the substantially lower risk of copycat versions of Humira breaking into the all-important U.S. market this year.
Amgen's dividend is set to rise
Amgen's $39 billion overseas cash stockpile is among the largest within the biopharmaceutical arena. So it wasn't surprising to hear that the company announced a sizable hike to its dividend last month -- once the tax reform legislation appeared to be a slam dunk. As a result, Amgen now sports a slightly above-average (for a pharma stock) forward-looking yield of 3.04%.
Perhaps the best part about Amgen's juicy dividend, though, is that the drugmaker's trailing payout ratio of 40.2% is close to the bottom of its blue chip biotech and big pharma peer groups. So with plenty of repatriated cash to play with moving forward and stable free cash flow, Amgen could boost its dividend yet again within the next twelve months.
The downside is that Amgen's cardiovascular drug, Repatha, has so far failed to live up to expectations, and the biotech's bid to build a thriving biosimilar business has also gotten off to a painfully slow start.
On the bright side, Repatha's recent label expansion as a preventative treatment for cardiovascular disease should light a fire under its commercial trajectory this year. The U.S. biosimilar market is also just getting on its proverbial feet from a regulatory standpoint. And when all the legal and regulatory kinks are worked out, Amgen should benefit immensely from this high-value space.
In all, Amgen should entice dividend investors this year due to its upper-echelon yield that appears set to edge even higher in the years to come.
10 stocks we like better than Amgen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Amgen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The key traits that most elite income stocks have in common are stable and growing free cash flows, a strong track record of regular increases to the dividend, and a positive long-term outlook. Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. Its modest trailing payout ratio of 60.4% also implies that further increases are feasible moving forward -- especially since the company's free cash flow is forecast to grow at industry-leading levels in the next two to three years. | The key traits that most elite income stocks have in common are stable and growing free cash flows, a strong track record of regular increases to the dividend, and a positive long-term outlook. Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. So with plenty of repatriated cash to play with moving forward and stable free cash flow, Amgen could boost its dividend yet again within the next twelve months. | Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. While top-flight dividend programs are unusual in the pharma space because of the enormous costs associated with clinical trials, AbbVie has managed to find a nice balance between maintaining its upper-tier dividend and investing in its vast clinical pipeline. AbbVie is arguably worth buying because of its generous dividend yield of 2.94%, rapidly growing footprint in the high-value oncology market, and the substantially lower risk of copycat versions of Humira breaking into the all-important U.S. market this year. | In my view, the biopharmaceutical industry arguably occupies the top spot when it comes to dividend stocks. AbbVie is arguably worth buying because of its generous dividend yield of 2.94%, rapidly growing footprint in the high-value oncology market, and the substantially lower risk of copycat versions of Humira breaking into the all-important U.S. market this year. So with plenty of repatriated cash to play with moving forward and stable free cash flow, Amgen could boost its dividend yet again within the next twelve months. |
33374.0 | 2018-01-05 00:00:00 UTC | A Look At Johnson & Johnson's Medical Devices Segment | ABT | https://www.nasdaq.com/articles/look-johnson-johnsons-medical-devices-segment-2018-01-05 | nan | nan | Johnson & Johnson's ( JNJ ) Medical Devices segment accounts for 35% of the company's value, according to our estimates. Most of the company's value can be attributed to its Pharmaceuticals business. In this note, we focus on the company's Medical Devices segment and its future implications for JNJ. Take a look at our interactive dashboard of JNJ's business , which shows how its Medical Devices segment will perform in the coming years, compared to the company's other segments. Below we explain in more detail.
How Does Medical Devices Compare To JNJ's Other Segments?
Medical Devices Revenue Composition
Key Factors To Future Growth
Changing dynamics in the women's health market - with the rise of sub-specialties, particularly in gynecology - should result in a larger addressable market for the company.
Minimally invasive surgery (MIS) procedures reduce hospital-acquired infections. As a result, we expect higher demand for MIS surgical procedures.
An overall increase in global healthcare demand due to an aging population, increasing healthcare spending and income in emerging markets, availability of treatment, and overall population growth.
However, pricing pressure has grown in recent years due to a number of players competing in the market. This is likely to continue and keep the segment's growth in check.
Also, there are high regulatory standards with which to comply for the medical devices segment. Earlier this week, the US FDA issued a class I recall on JNJ's heart device, due to a faulty valve.
We have a $125 price estimate for Johnson & Johnson, which is around 10% below the current market price.
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In this note, we focus on the company's Medical Devices segment and its future implications for JNJ. However, pricing pressure has grown in recent years due to a number of players competing in the market. Earlier this week, the US FDA issued a class I recall on JNJ's heart device, due to a faulty valve. | Johnson & Johnson's ( JNJ ) Medical Devices segment accounts for 35% of the company's value, according to our estimates. An overall increase in global healthcare demand due to an aging population, increasing healthcare spending and income in emerging markets, availability of treatment, and overall population growth. See More at Trefis |View Interactive Institutional Research(Powered by Trefis) Get Trefis Technology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & Johnson's ( JNJ ) Medical Devices segment accounts for 35% of the company's value, according to our estimates. Take a look at our interactive dashboard of JNJ's business , which shows how its Medical Devices segment will perform in the coming years, compared to the company's other segments. Medical Devices Revenue Composition Key Factors To Future Growth Changing dynamics in the women's health market - with the rise of sub-specialties, particularly in gynecology - should result in a larger addressable market for the company. | Johnson & Johnson's ( JNJ ) Medical Devices segment accounts for 35% of the company's value, according to our estimates. In this note, we focus on the company's Medical Devices segment and its future implications for JNJ. Take a look at our interactive dashboard of JNJ's business , which shows how its Medical Devices segment will perform in the coming years, compared to the company's other segments. |
33375.0 | 2018-01-04 00:00:00 UTC | This News Explains Why DexCom Is Dropping Today | ABT | https://www.nasdaq.com/articles/news-explains-why-dexcom-dropping-today-2018-01-04 | nan | nan | What happened
Shares of DexCom (NASDAQ: DXCM) , a medical device company focused on blood glucose sensing , fell as much as 12% in early morning trading on Thursday. Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid.
So what
Dexcom's stock has been under a lot of selling pressure ever since Abbott won FDA approval for the FreeStyle Libre System in late 2017. The reason is that the Libre system does not need to be calibrated and is significantly cheaper than Dexcom's system. Those benefits have investors fearing that Dexcom's days of hyper growth are over.
Today's news only adds to those fears since DexCom's system was the only continuous glucose monitoring device that had previously secured Medicare coverage .
Given the update, it isn't hard to figure out why shares are nose-diving today.
Now what
Does this news mean that DexCom's investors should be running for the hills? I don't think so for a few reasons:
Abbott's Libre system requires action on the user's part to get a reading. Dexcom's sensors, on the other hand, communicate directly with a smartphone or Apple watch. This makes the device far more user-friendly.
DexCom only recently gained Medicare coverage, so this hasn't been a driving force behind the company's growth up to this point.
DexCom has several exciting products in development that should enhance its competitive position once launched.
DexCom has been successfully competing against the FreeStyle Libre system in Europe for years.
Worldwide usage of continuous glucose monitoring devices, in general, still remains quite low. That provides both companies with plenty of room for expansion.
Overall, today's update certainly isn't good news for DexCom's investors but isn't the end of the world either. Risk-loving investors might want to view today's drop as a chance to get in at a discount.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid. What happened Shares of DexCom (NASDAQ: DXCM) , a medical device company focused on blood glucose sensing , fell as much as 12% in early morning trading on Thursday. Today's news only adds to those fears since DexCom's system was the only continuous glucose monitoring device that had previously secured Medicare coverage . | Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid. Today's news only adds to those fears since DexCom's system was the only continuous glucose monitoring device that had previously secured Medicare coverage . I don't think so for a few reasons: Abbott's Libre system requires action on the user's part to get a reading. | Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid. Today's news only adds to those fears since DexCom's system was the only continuous glucose monitoring device that had previously secured Medicare coverage . Overall, today's update certainly isn't good news for DexCom's investors but isn't the end of the world either. | Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid. Overall, today's update certainly isn't good news for DexCom's investors but isn't the end of the world either. The Motley Fool has no position in any of the stocks mentioned. |
33376.0 | 2018-01-03 00:00:00 UTC | Abbott Boosts Diagnostics Arm With Alinity H-Series Launch | ABT | https://www.nasdaq.com/articles/abbott-boosts-diagnostics-arm-with-alinity-h-series-launch-2018-01-03 | nan | nan | AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing.
Per management, the Alinity h-series solution is 20% faster per m 2 in comparison to the integrated hematology systems presently available. Moreover, with a throughput of 133 complete blood counts (CBCs) per m 2 , the Alinity h-series provides a cost and time efficient diagnostic testing experience for laboratories.
Notably, the Alinity portfolio covers clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics along with Abbott's AlinIQ.
Recent Developments in Diagnostics
This Illinois-based global medical device company recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust to gain traction in the rapidly growing diagnostics market. Per NWLP, the alliance, which presently covers 6% of the pathology market in the U.K., is expected to carry out 26 million tests per year.
Continuing with the slew of developments, in June 2017, the company received CE Mark for Alinity hq, which has become the fifth new diagnostic system to be launched in Europe along with the ongoing rollout of four instruments in the areas of immunoassay, clinical chemistry, blood screening and point-of-care.
Interestingly, Abbott raked in 18.7% of total revenues from the diagnostics segment in the last-reported third quarter. The latest development is expected to help the company gain further traction in this space.
Market Prospects
We believe an ageing population, unhealthy lifestyle and rising awareness and expenditure in healthcare will continue to drive the diagnostics market. Going by a report by MarketsAndMarkets, theglobal marketfor molecular diagnostics is projected to reach a value of $10.12 billion by 2021, at a CAGR of 9.1%. Thus, in view of Abbott's current developments in the space, we expect top-line contributions to boost from the diagnostics segment.
However, the diagnostics market is dominated by well-established players like Quest Diagnostics DGX and QIAGEN N.V. QGEN .
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the past three months, the company's share price has outperformed the broader industry . The stock has gained 8.2%, higher than the broader industry's gain of 1.7%. The company has also surpassed the 5.7% gain of the S&P 500 market.
Zacks Rank and Key Pick
Abbott carries a Zacks Rank #3 (Hold).
A better-ranked medical stock is Walgreens Boots Alliance, Inc. WBA , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Walgreens Boots has a long-term expected earnings growth rate of 10.1%. The stock has gained 3.2% year to date.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Qiagen N.V. (QGEN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the Alinity portfolio covers clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics along with Abbott's AlinIQ. | AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked medical stock is Walgreens Boots Alliance, Inc. WBA , carrying a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Recent Developments in Diagnostics This Illinois-based global medical device company recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust to gain traction in the rapidly growing diagnostics market. | AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. The latest development is expected to help the company gain further traction in this space. |
33377.0 | 2018-01-03 00:00:00 UTC | Why This Is the Perfect Level to Buy Celgene Corporation Stock | ABT | https://www.nasdaq.com/articles/why-perfect-level-buy-celgene-corporation-stock-2018-01-03 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ: CELG ) is one of the first companies to come to mind. However, October was not kind to the CELG stock price. Shares fell more than 35% from the highs. After a slow yet steady bounce, is now the time to buy Celgene?
In fact, it might just be .
Decaying sentiment and negative analyst commentary wore on the CELG stock price. But it wasn't until mid-October until things really went sour.
Celgene pulled the plug on two treatments for Crohn's disease. I | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ: CELG ) is one of the first companies to come to mind. Decaying sentiment and negative analyst commentary wore on the CELG stock price. Celgene pulled the plug on two treatments for Crohn's disease. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ: CELG ) is one of the first companies to come to mind. However, October was not kind to the CELG stock price. Decaying sentiment and negative analyst commentary wore on the CELG stock price. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ: CELG ) is one of the first companies to come to mind. Decaying sentiment and negative analyst commentary wore on the CELG stock price. But it wasn't until mid-October until things really went sour. | However, October was not kind to the CELG stock price. Shares fell more than 35% from the highs. After a slow yet steady bounce, is now the time to buy Celgene? |
33378.0 | 2018-01-02 00:00:00 UTC | US Stocks Higher as Oil Prices Hold at Two-Year Highs, Manufacturing Activity Rises | ABT | https://www.nasdaq.com/articles/us-stocks-higher-oil-prices-hold-two-year-highs-manufacturing-activity-rises-2018-01-02 | nan | nan | US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations.
Some eight of the 11 sectors making up the S&P 500 Index were trading in positive territory at the time of writing, with the consumer discretionary segment leading the gainers, up by 1.4%, health care up by 1.2%, technology up by 1.1% and materials 1.1% higher, respectively.
In economic news, the final December manufacturing purchasing managers index (PMI), which provides a numerical indication of manufacturing activity in the US, rose to 55.1 in December, according to research company IHS Markit which produces the gauge, up from 53.9 in November. This beat analysts' expectations for 55. Readings above 50 signal expansion in the index while those below denote contraction.
Oil prices were fractionally lower, with West Texas Intermediate crude oil and Brent crude down by 0.3% and 0.7%, respectively, but both touched levels last seen in November 2014 earlier in the day after a crackdown on protesters in Iran rattled investors aware of the potential impact of instability in the oil-rich Middle East on future pricing.
In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. Netflix ( NFLX ) was up by 4.4% after Macquarie upgraded it to outperform from neutral and raised its price target to $220 from $200 per share.
The Dow Jones Industrial Average (DJIA) was 0.12% higher, the Standard & Poor's 500 was up by 0.54% and the Nasdaq was up by 1.16% at the time writing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations. Some eight of the 11 sectors making up the S&P 500 Index were trading in positive territory at the time of writing, with the consumer discretionary segment leading the gainers, up by 1.4%, health care up by 1.2%, technology up by 1.1% and materials 1.1% higher, respectively. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations. | In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations. In economic news, the final December manufacturing purchasing managers index (PMI), which provides a numerical indication of manufacturing activity in the US, rose to 55.1 in December, according to research company IHS Markit which produces the gauge, up from 53.9 in November. | In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations. Some eight of the 11 sectors making up the S&P 500 Index were trading in positive territory at the time of writing, with the consumer discretionary segment leading the gainers, up by 1.4%, health care up by 1.2%, technology up by 1.1% and materials 1.1% higher, respectively. |
33379.0 | 2017-12-29 00:00:00 UTC | AbbVie Inc Dividend at Risk Amid Patent Protection Problems | ABT | https://www.nasdaq.com/articles/abbvie-inc-dividend-risk-amid-patent-protection-problems-2017-12-29 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is firing on all cylinders right now. ABBV stock is one of the Dividend Aristocrats, a group of 51 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases.
AbbVie is one of 203 dividend stocks in the healthcare sector. You can see all 203 dividend-paying healthcare stocks here .
So far in 2017, AbbVie is one of the best-performing healthcare stocks. AbbVie stock has returned an impressive 50% year-to-date.
The company is growing earnings at a double-digit clip, thanks to the huge success of its flagship product Humira.
This article will discuss AbbVie's business model, growth potential, and expected future returns.
Business Overview for ABBV
AbbVie is a global pharmaceutical giant. It has a $149 billion market capitalization, and sells its products in more than 170 countries across the world.
AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ).
AbbVie operates one main business segment-pharmaceuticals. It focuses on a few key treatment areas , including immunology, oncology, and women's health.
The company has seen excellent growth since it was spun off from Abbott.
Source: 2017 AbbVie Strategic Update , page 5
From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira.
Last year was another strong one for the company. Humira revenue increased 16% in 2016 , to $16 billion. Thanks to Humira, AbbVie's revenue and adjusted earnings-per-share increased 13% and 12%, respectively, for the year.
Growth Prospects
AbbVie has continued to post strong operating results in 2017, and has potential for growth moving forward.
In the third quarter , total revenue increased 8.8%, to $7 billion. Growth was due largely to Humira, which increased sales by 15% for the quarter. Adjusted earnings-per-share rose 17%, an excellent earnings growth rate.
For 2017, AbbVie expects earnings-per-share in the range of $5.53 to $5.55. At the midpoint of guidance, management expects 15% earnings growth this year.
Humira is a multi-purpose drug that is used to treat a variety of conditions, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and more.
Humira is the company's most important growth driver, but this stands to change. AbbVie began losing patent protection on Humira in the U.S. in 2016, and it is scheduled to go off patent in Europe in 2018.
Source: 2017 AbbVie Strategic Update , page 11
This is a significant risk for AbbVie, since Humira itself represents two-thirds of the company's revenue. AbbVie management believes Humira will continue growing at a high rate through 2020. After that, the company expects new products to take the lead.
AbbVie expects Humira will still generate approximately $18 billion of revenue by 2020. Beyond 2020, the company expects to generate $25-$30 billion from its suite of new drug launches to more than offset any Humira declines.
The company expects to launch 20 new products or indications by 2020. It also is preparing to cut costs, which should result in expanding operating margins by 1% to 2% per year.
Combined, these growth catalysts are expected to result in double-digit adjusted earnings growth through the end of the decade.
Competitive Advantages & Recession Performance
The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection.
To build its pipeline, AbbVie has accelerated research and development spending, to prepare for the loss of Humira. R&D expense in the past few years is below:
2014 research-and-development expense of $3.3 billion
2015 research-and-development expense of $4.3 billion
2016 research-and-development expense of $4.4 billion
Fortunately, this spending is starting to show positive results, as AbbVie has a robust pipeline.
Source: 2017 AbbVie Strategic Update , page 15
It is unclear how AbbVie itself performed during the Great Recession, as it was still part of Abbott Laboratories. However, it stands to reason the company would hold up fairly well during the next recession.
Prescription drugs and medical supplies are necessities, with stable demand. Consumers often cannot choose to go without healthcare, even when the economy is in a downturn. As a result, investors can reasonably assume AbbVie's profits would experience a modest decline during a recession.
Valuation & Expected Returns
At the midpoint of AbbVie's earnings guidance for 2017, the stock is currently trading for a price-to-earnings ratio of 17.
AbbVie stock is valued considerably below the S&P 500 Index average price-to-earnings ratio of approximately 25. However, the stock is valued at a significant premium to its historical average in the past five years (10-year data is not available, as AbbVie was not a publicly-traded company until 2013).
Source: Value Line
In the past five years, AbbVie has traded for a price-to-earnings ratio of 14.9. This means the stock is valued at a premium of approximately 14% to its five-year average valuation.
It could be argued AbbVie stock deserves a higher valuation than it currently holds, given its high-quality business and strong growth prospects. Still, with a high reliance on Humira and a valuation that is 14% above its average level, AbbVie appears to be fairly valued.
This means going forward, AbbVie's returns will be the result of earnings growth and dividends. The good news is, there is still the opportunity to generate satisfactory returns, because the company is still growing earnings and dividends.
A breakdown of potential future returns is as follows:
3%-5% revenue growth
1% margin expansion
2% share repurchases
3% dividend yield
In this forecast, AbbVie's total shareholder returns would reach 9% to 11% each year, not including any impact from a rising or falling price-to-earnings multiple.
Even with a relatively modest forecast of low-to-mid single digit revenue growth, there is a reasonable chance AbbVie's total annualized returns could reach double-digits.
Final Thoughts On AbbVie Stock
AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. It is also a shareholder-friendly company, which returns excess cash flow to investors through stock buybacks and dividends.
The only flaw for AbbVie is its valuation. The stock is up 50% year-to-date, which has elevated its price-to-earnings multiple, and also lowered its dividend yield. As a result, investors might want to wait for a lower price before buying the stock, but AbbVie remains a strong holding for dividend growth.
Please send any feedback, corrections, or questions to ben@suredividend.com.
Compare Brokers
The post AbbVie Inc Dividend at Risk Amid Patent Protection Problems appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Humira is a multi-purpose drug that is used to treat a variety of conditions, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and more. Even with a relatively modest forecast of low-to-mid single digit revenue growth, there is a reasonable chance AbbVie's total annualized returns could reach double-digits. | AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Source: 2017 AbbVie Strategic Update , page 5 From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira. R&D expense in the past few years is below: 2014 research-and-development expense of $3.3 billion 2015 research-and-development expense of $4.3 billion 2016 research-and-development expense of $4.4 billion Fortunately, this spending is starting to show positive results, as AbbVie has a robust pipeline. | AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Source: 2017 AbbVie Strategic Update , page 5 From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira. Source: 2017 AbbVie Strategic Update , page 11 This is a significant risk for AbbVie, since Humira itself represents two-thirds of the company's revenue. | AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Last year was another strong one for the company. AbbVie expects Humira will still generate approximately $18 billion of revenue by 2020. |
33380.0 | 2017-12-27 00:00:00 UTC | iShares Russell 1000 Value ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-russell-1000-value-etf-experiences-big-inflow-2017-12-27 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $93.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 330,200,000 to 330,950,000). Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $93.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 330,200,000 to 330,950,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $93.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 330,200,000 to 330,950,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51. |
33381.0 | 2017-12-23 00:00:00 UTC | Here's How AbbVie Inc. Crushed It in 2017 | ABT | https://www.nasdaq.com/articles/heres-how-abbvie-inc-crushed-it-2017-2017-12-23 | nan | nan | It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. Shares of the Abbott spinoff have gained 56.5% this year as investors cheered a handful of important developments. As the year draws to a close, let's look back at a few ways AbbVie crushed it.
What biosimilar competition?
AbbVie investors can thank the company's legal team for the lion's share of this stock's gain in 2017. Key patents protecting Humira's exclusivity in the U.S. have expired, but it looks like supplemental patents will keep biosimilar competition at bay much longer than previously anticipated. That's a pretty big deal because AbbVie depends on the rheumatoid arthritis drug for about two-thirds of total revenue.
AbbVie Inc. CEO Richard Gonzalez gave investors plenty to smile about in 2017. Image source: AbbVie Inc.
Humira might be aging, but sales are as vibrant as ever, rising 16% on year in the third quarter to a stunning $18.8 billion annualized run rate. AbbVie CEO Richard Gonzalez gave investors a lot to smile about in September when Amgen (NASDAQ: AMGN) agreed to license Humira intellectual property from AbbVie, beginning next year in the EU and not until 2023 in the vital U.S. market.
Amgen's biosimilar version of Humira, Amjevita, earned FDA approval over a year ago and had been expected to begin pinching U.S. Humira sales in 2018. Now that Amgen has agreed to stand down, Gonzalez expects Humira sales to approach $21 billion in 2020. That's a lot better than the contraction we were expecting at the beginning of the year, and it's probably why Gonzalez has the most genuine smile in biopharma.
Rival bested
AbbVie may have added a few chapters to Humira's growth story, but its sales can't grow forever. This year, AbbVie hit another home run with an experimental psoriasis drug that could go a long way to offset the impending losses.
Stelara is a popular psoriasis drug that Johnson & Johnson (NYSE: JNJ) launched around eight years ago and finished the third quarter on pace to achieve $4.5 billion in sales this year. In a pair of head-to-head trials, 21% and 30% of psoriasis patients receiving Stelara achieved completely clear skin after one year of treatment.
Stelara's performance was pretty good, but it couldn't hold a candle to risankizumab. After a year of treatment, AbbVie's candidate completely cleared skin for 56% and 60% of psoriasis patients randomized to receive it. New drug launches can be unpredictable, but it isn't unreasonable to expect risankizumab to outperform Stelara in the commercial setting, as well.
Leukemia better run
Imbruvica has been crushing it for AbbVie since it became the first chemotherapy-free option for newly diagnosed leukemia patients. Third-quarter sales of the drug, which AbbVie markets in partnership with Johnson & Johnson, bounded 37% higher to a $2.8 billion run rate.
While Imbruvica tears up the charts as a first-line treatment for the most common form of leukemia, a more recently launched drug is poised to dominate the space for previously treated patients. AbbVie saved one of the most thrilling clinical trial readouts of 2017 for a scientific conference this December. A combination of Venclexta, which AbbVie markets in partnership with Roche (NASDAQOTH: RHHBY) , and Rituxan showed a huge survival benefit over Rituxan plus a standard treatment.
Two years after beginning treatment, 84.9% of patients given the Venclexta combo hadn't shown signs of disease progression, versus just 36.3% among those given standard treatment. With data this good, Gonzalez's assertion that annual Venclexta sales will reach $7 billion isn't as crazy as it sounded over a year ago.
Still a buy?
Even when a company's operations are firing on all cylinders, shares purchased at excessively high prices tend to deliver subpar returns. Although I liked AbbVie much better at the beginning of the year when it was trading at around 11 times 2017 earnings expectations, there's still a chance the stock could outperform over the long run.
Right now the shares trade at about 17.6 times this year's earnings estimates, which is a bit less than the average stock in the S&P 500 (which trades at about 19.8 times forward estimates). AbbVie's accomplishments this year paved a path forward that's far better than average, though. Wall Street consensus growth estimates for AbbVie's bottom line suggest an outstanding 15.2% annual growth rate over the next five years. Put it together, and I'd say there's a good chance AbbVie will continue to outperform over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Dec. 4, 2017
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Image source: AbbVie Inc. Humira might be aging, but sales are as vibrant as ever, rising 16% on year in the third quarter to a stunning $18.8 billion annualized run rate. While Imbruvica tears up the charts as a first-line treatment for the most common form of leukemia, a more recently launched drug is poised to dominate the space for previously treated patients. With data this good, Gonzalez's assertion that annual Venclexta sales will reach $7 billion isn't as crazy as it sounded over a year ago. | AbbVie Inc. CEO Richard Gonzalez gave investors plenty to smile about in 2017. AbbVie CEO Richard Gonzalez gave investors a lot to smile about in September when Amgen (NASDAQ: AMGN) agreed to license Humira intellectual property from AbbVie, beginning next year in the EU and not until 2023 in the vital U.S. market. In a pair of head-to-head trials, 21% and 30% of psoriasis patients receiving Stelara achieved completely clear skin after one year of treatment. | AbbVie CEO Richard Gonzalez gave investors a lot to smile about in September when Amgen (NASDAQ: AMGN) agreed to license Humira intellectual property from AbbVie, beginning next year in the EU and not until 2023 in the vital U.S. market. Stelara is a popular psoriasis drug that Johnson & Johnson (NYSE: JNJ) launched around eight years ago and finished the third quarter on pace to achieve $4.5 billion in sales this year. Although I liked AbbVie much better at the beginning of the year when it was trading at around 11 times 2017 earnings expectations, there's still a chance the stock could outperform over the long run. | Amgen's biosimilar version of Humira, Amjevita, earned FDA approval over a year ago and had been expected to begin pinching U.S. Humira sales in 2018. Stelara is a popular psoriasis drug that Johnson & Johnson (NYSE: JNJ) launched around eight years ago and finished the third quarter on pace to achieve $4.5 billion in sales this year. That's right -- they think these 10 stocks are even better buys. |
33382.0 | 2017-12-22 00:00:00 UTC | The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-fedex-abbott-biogen-and-marathon-petroleum-2017 | nan | nan | For Immediate Release
Chicago, IL - Dec 22, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Thursday's Analyst Blog:
Top Research Reports for Pfizer, FedEx and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, FedEx and Abbott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Pfizer 's shares have underperformed the peer group so far this year (the stock is up +12.2% over this period vs. a +16.1% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals.
However, Pfizer continues to face headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nonetheless, the Zacks analyst thinks new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance.
The company also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Pfizer's growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer.
(You can read the full research report on Pfizer here >>> ).
Shares of Buy-rated FedEx have outperformed the Zacks Air Freight and Cargo industry and rival United Parcel Service on a year-to-date basis. The company has gained 34.8% while the industry it belongs to and UPS have rallied 14% and 3.2%, respectively, in the same period. Ushering in further good news, FedEx also outperformed in the second quarter of fiscal 2018 driven by increased package volumes during the current holiday season.
Growth was witnessed across all the major segments of the company. In fact, the strong growth of e-commerce is a huge positive for the company. Meanwhile, FedEx is on track to deliver a strong performance in the ongoing holiday season. Efforts to reward its shareholders through dividend payments and share buybacks are also encouraging. High costs are, however, hurting the bottom line.
(You can read the full research report on FedEx here >>> ).
Abbott 's shares have gained +8.6% over the last three months, outperforming the Zacks Medical Products industry, which has gained +3.1% over the same period Post promising third-quarter results by Abbott, the Zacks analyst is optimistic about the strong and consistent EPD and Medical Devices performance. However, the ongoing sluggish trend in the Nutrition business is a downside. However, the company continues to benefit from the recently completed St. Jude Medical buyout.
Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also economic problems in Venezuela are likely to remain unresolved.
(You can read the full research report on Abbott here >>> ).
Other noteworthy reports we are featuring today include Biogen and Marathon Petroleum.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Marathon Petroleum Corporation (MPC): Free Stock Analysis Report
FedEx Corporation (FDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. You can see all of today's research reports here >>> Pfizer 's shares have underperformed the peer group so far this year (the stock is up +12.2% over this period vs. a +16.1% increase for the Zacks Large-Cap Pharmaceuticals industry). | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Here are highlights from Thursday's Analyst Blog: Top Research Reports for Pfizer, FedEx and Abbott The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Here are highlights from Thursday's Analyst Blog: Top Research Reports for Pfizer, FedEx and Abbott The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Abbott 's shares have gained +8.6% over the last three months, outperforming the Zacks Medical Products industry, which has gained +3.1% over the same period Post promising third-quarter results by Abbott, the Zacks analyst is optimistic about the strong and consistent EPD and Medical Devices performance. |
33383.0 | 2017-12-21 00:00:00 UTC | Abbott (ABT) at a 52-Week High: What's Driving the Stock? | ABT | https://www.nasdaq.com/articles/abbott-abt-at-a-52-week-high%3A-whats-driving-the-stock-2017-12-21 | nan | nan | Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. This represents a strong year-to-date return of approximately 48.4%, higher than the S&P 500's 20.2%. The stock has a Zacks Rank #3 (Hold).
Taking the stable stock performance into consideration, we expect Abbott to scale higher in the quarters ahead. The company also has a trailing four-quarter average positive earnings surprise of 4.5%. Its positive long-term growth of 10.7% holds promise as well.
For the majority of the last three months, the company's share price has considerably outperformed the broader industry . The stock has rallied 8.6% over the last three months, beating the industry's gain of just 3.3%.
Factors Driving the Stock
Alere Acquisition : Abbott's successful closure of the Alere acquisition after a prolonged legal battle has instilled confidence in investors. The acquisition closed in October 2017 under amended financial terms in favor of Abbott. Taking the attractive prospects of Point-of-care testing within the in vitro diagnostics market into consideration, Abbott is highly optimistic about the Alere integration. According to the company, the Alere buyout will significantly expand its diagnostics presence. Moreover, Abbott expects Alere to contribute around $475 million to its top line in 2017.
Recent FDA Approvals : Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received FDA approval. Also, it received approval for MR-conditional labeling for Ellipse ICD.
Developing Diabetes Business : There have been a slew of developments within the Diabetics business. We are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System's recent reimbursement approval in the U.K. Plus, the company recently announced receipt of Health Canada License for the same. In May 2017, the company received full or partial reimbursement from the French Health Ministry for the product.
Solid Emerging Market Performance : Abbott's emerging market performance has been promising, courtesy of the latest strategic developments. Notably, the company has been witnessing double-digit growth in Brazil, Russia, India, and China of late.
Key Picks
A few better-ranked medical stocks are athenahealth, Inc. ATHN , Align Technology, Inc. ALGN and Luminex Corporation LMNX . Notably, athenahealth, Align Technology and Luminex sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has a long-term expected earnings growth rate of 22.3%. The stock has rallied roughly 27.3% over a year.
Align Technology has a long-term expected earnings growth rate of 28.9%. The stock has gained 137.9% in a year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 2.9% in the past three months.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Luminex Corporation (LMNX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Taking the attractive prospects of Point-of-care testing within the in vitro diagnostics market into consideration, Abbott is highly optimistic about the Alere integration. | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. Key Picks A few better-ranked medical stocks are athenahealth, Inc. ATHN , Align Technology, Inc. ALGN and Luminex Corporation LMNX . | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. Factors Driving the Stock Alere Acquisition : Abbott's successful closure of the Alere acquisition after a prolonged legal battle has instilled confidence in investors. | Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, its FreeStyle Libre Flash received FDA approval. |
33384.0 | 2017-12-19 00:00:00 UTC | Why 2017 Was a Year to Remember for Johnson & Johnson | ABT | https://www.nasdaq.com/articles/why-2017-was-year-remember-johnson-johnson-2017-12-19 | nan | nan | With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share price is up close to 24% year to date. J&J stock is at an all-time high. Johnson & Johnson shareholders have even more to like about 2017, with the dividend payout also at an all-time high.
Why has 2017 been such a year to remember for Johnson & Johnson. Here are the top three reasons.
1. Acquisitions
Two major acquisitions changed the dynamics for Johnson & Johnson in 2017. The first was J&J's purchase of Abbott Medical Optics from Abbott Labs for $4.3 billion. This deal was completed in February, and brought a lineup of cataract surgery, laser refractive surgery and consumer eye health products into J&J's fold to join the company's successful Acuvue contact lens business. Largely as a result of this acquisition, J&J's medical device segment posted solid sales growth in 2017.
The bigger deal, however, was Johnson & Johnson's buyout of Actelion for $30 billion, which closed in June. Some observers thought that J&J overpaid for the Swiss drugmaker (including me). However, Actelion was expected to give a shot in the arm to J&J's pharmaceutical segment -- and it did .
Thanks to the Actelion buyout, Johnson & Johnson now has a solid pulmonary hypertension franchise. Three pulmonary hypertension drugs picked up from Actelion should generate additional revenue of more than $1.5 billion for J&J in 2017 and even more next year with a full 12 months of sales included.
2. Protecting Remicade
A big question among Johnson & Johnson shareholders for 2017 was how autoimmune disease drug Remicade, would fare against biosimilar competition from Pfizer (NYSE: PFE) . With 2017 drawing to a close, we now know the answer to that question: Pretty good. While Remicade sales slipped more than 9% year over year in the first nine months of 2017, it could have been much worse.
Remicade remains a very important component of Johnson & Johnson's lineup. It's J&J's top-selling product by far, generating nearly 10% of the company's total revenue in 2016. Even with the sales decline this year, the drug will still represent close to 9% of total revenue.
Pfizer, however, isn't a happy camper. During the big pharma company's third-quarter conference call, Pfizer CEO Ian Read said that Johnson & Johnson's "exclusionary contracting of Remicade" has unfairly limited the uptake of Pfizer's Remicade biosimilar, Inflectra. As a result, Pfizer sued J&J for alleged violation of antitrust laws.
3. Momentum for key drugs
Several other drugs in addition to Remicade experienced sales declines in 2017. The good news, though, was that strong momentum continued for several key drugs.
Stelara helped offset Remicade's sales drop to a large extent. The psoriasis and psoriatic arthritis drug is on track to generate sales approaching $4 billion this year. Sales continued to grow strongly for Invega Sustenna also. The schizophrenia drug should make around $2.5 billion in 2017.
Johnson & Johnson's strongest sales growth this year, however, came from its oncology lineup. Multiple myeloma drug Darzalex should become a blockbuster in its first full year on the market in 2017. Imbruvica, which won two new FDA approvals this year for treating marginal zone lymphoma and chronic graft versus host disease, is on pace to make close to $2 billion in 2017.
Looking to 2018
Expect these same factors to be important for Johnson & Johnson in 2018 also. The acquisitions of Abbott Medical Optics and Actelion will help fuel growth next year. Corporate tax reform in the U.S. could spur J&J to make even more deals.
The company will continue to face competition for Remicade. But unless the courts force J&J to change its practices, its contracting approaches should help control sales losses to a manageable level. At the same time, Stelara, Invega Sustenna, Darzalex, and Imbruvica should enjoy sustained momentum.
Johnson & Johnson should also get help from new products next year. The company won U.S. regulatory approval in June for psoriasis drug Tremfya. J&J filed for approval in October for promising prostate cancer drug apalutamide.
I wouldn't count on Johnson & Johnson having another year of 24% or higher gains. After all, that has only happened twice this century so far. Still, my view is that 2018 will again be a solid year for J&J.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three pulmonary hypertension drugs picked up from Actelion should generate additional revenue of more than $1.5 billion for J&J in 2017 and even more next year with a full 12 months of sales included. Imbruvica, which won two new FDA approvals this year for treating marginal zone lymphoma and chronic graft versus host disease, is on pace to make close to $2 billion in 2017. But unless the courts force J&J to change its practices, its contracting approaches should help control sales losses to a manageable level. | The bigger deal, however, was Johnson & Johnson's buyout of Actelion for $30 billion, which closed in June. Thanks to the Actelion buyout, Johnson & Johnson now has a solid pulmonary hypertension franchise. Three pulmonary hypertension drugs picked up from Actelion should generate additional revenue of more than $1.5 billion for J&J in 2017 and even more next year with a full 12 months of sales included. | Protecting Remicade A big question among Johnson & Johnson shareholders for 2017 was how autoimmune disease drug Remicade, would fare against biosimilar competition from Pfizer (NYSE: PFE) . Johnson & Johnson's strongest sales growth this year, however, came from its oncology lineup. Johnson & Johnson should also get help from new products next year. | Three pulmonary hypertension drugs picked up from Actelion should generate additional revenue of more than $1.5 billion for J&J in 2017 and even more next year with a full 12 months of sales included. Johnson & Johnson should also get help from new products next year. The Motley Fool owns shares of and recommends Johnson & Johnson. |
33385.0 | 2017-12-17 00:00:00 UTC | 3 Top Dividend Aristocrats to Buy for 2018 | ABT | https://www.nasdaq.com/articles/3-top-dividend-aristocrats-buy-2018-2017-12-17 | nan | nan | It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends for 25 or more years in a row. But some Dividend Aristocrats are better than others.
Several of the nearly 50 Dividend Aristocrats look like good picks as the new year approaches. Which are the best? I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. Here's why these are three top Dividend Aristocrats to buy for 2018.
Abbott Labs
Abbott Labs' track record of 45 consecutive years of dividend increases easily landed the healthcare company on the list of Dividend Aristocrats. The company's dividend currently yields a respectable 1.94%. However, it's not the dividend that interests me the most with Abbott.
2017 has been a tremendous year for Abbott, with the stock gaining over 40%. Revenue and earnings soared, thanks primarily to what I view as a really smart acquisition. In January, Abbott closed on its $23.6 billion buyout of St. Jude Medical. This acquisition positioned the company as an even more formidable competitor in the cardiovascular market.
That wasn't the only major deal for the company this year. Abbott completed its acquisition of Alere in October. This purchase established Abbott Labs as the leader in point of care testing, which is the fastest-growing segment of the $50 billion global in vitro diagnostics market.
Acquisitions aren't the only reason I like Abbott stock, though. The company won FDA approval in September for its FreeStyle Libre Flash Glucose Monitoring System, the first approved continuous glucose monitoring system that doesn't require a finger-stick blood sample. The potential for this system is so great that I recently picked Abbott as the best diabetes stock on the market .
AbbVie
There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. AbbVie claims a more appealing dividend than its parent, with a yield of 2.96%.
The drugmaker also enjoyed its best year ever in 2017, with its stock soaring more than 50%. AbbVie benefited greatly from an agreement with Amgen that keeps a biosimilar rival to top-selling Humira off the U.S. market until early 2023.
With Humira's position more secure, AbbVie now projects sales for the drug of close to $21 billion by 2020. The company also has time for its current products and pipeline programs to contribute more revenue. AbbVie's sales for cancer drug Imbruvica are expected to double over the next three years. New hepatitis C drug Mavyret should become the company's next blockbuster.
AbbVie also claims a strong pipeline. The pharma company expects tremendous success from several candidates, particularly cancer drug Rova-T, autoimmune-disease drug upadacitinib, and endometriosis drug elagolix. Big current winners like Humira and Imbruvica combined with a promising pipeline and an attractive dividend make AbbVie the best big pharma stock of all, in my view.
General Dynamics
General Dynamics has increased its dividend for 26 consecutive years -- just over the threshold for joining the Dividend Aristocrats club. The defense contractor's dividend now yields 1.68%. General Dynamics is in the best position of any of the three companies mentioned to increase its dividend in the future, though, with a low payout ratio of 31%.
2017 hasn't been the greatest of times for General Dynamics shareholders. The stock is up by a double-digit percentage so far this year, but shares have dropped over the past couple of months with the company's mixed results in the third quarter.
I think 2018 could be better for General Dynamics. Corporate tax reform in the U.S. holds the potential to boost spending, which could benefit the company's Gulfstream business jet business. It could also spur General Dynamics to make some strategic acquisitions that could fuel growth.
General Dynamics stock, like other defense stocks, is cyclical in nature. However, with potential hot spots such as North Korea and the Middle East, I suspect U.S. military spending won't slow down anytime soon. That's good news for General Dynamics.
Best pick?
I own shares of one of these Dividend Aristocrats and think it's the best of the group. Which stock is it? AbbVie.
Don't take my word for it, though. Just look at the numbers. As we already saw, AbbVie has the highest dividend yield of the three. It also has the most attractive valuation, with shares currently trading at less than 15 times expected earnings. In addition, AbbVie should have the greatest growth prospects over the next few years. Add all this up, and I think you'll agree with me that AbbVie stands out as the best investing option among these three solid Dividend Aristocrats.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. This purchase established Abbott Labs as the leader in point of care testing, which is the fastest-growing segment of the $50 billion global in vitro diagnostics market. The stock is up by a double-digit percentage so far this year, but shares have dropped over the past couple of months with the company's mixed results in the third quarter. | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. Abbott Labs Abbott Labs' track record of 45 consecutive years of dividend increases easily landed the healthcare company on the list of Dividend Aristocrats. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. Abbott Labs Abbott Labs' track record of 45 consecutive years of dividend increases easily landed the healthcare company on the list of Dividend Aristocrats. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. Acquisitions aren't the only reason I like Abbott stock, though. Which stock is it? |
33386.0 | 2017-12-15 00:00:00 UTC | Health Care Sector Update for 12/15/2017: SGRY,ABT,GLYC,ECYT,TTPH,CASC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12152017-sgryabtglycecytttphcasc-2017-12-15 | nan | nan | Top Health Care Stocks
JNJ +0.13%
PFE +1.85%
ABT +1.40%
MRK +0.13%
AMGN +1.10%
Health care stocks were starting to struggle somewhat Friday afternoon, increasingly lagging the broader markets, including a slightly more than 0.6% gain for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up more than 1.4% as a group while the Nasdaq Biotechnology index ( NBI ) raced nearly 1.0% higher today.
Among health care stocks moving on news:
+ Surgery Partners ( SGRY ) climbed over 14% on Friday, reaching a session high of $11.15 a share, after the specialty hospitals operator authorized a new stock buyback program for up to $50 million of its common stock.
In other sector news:
+ Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. The upcoming dividend, including the added $0.015 per share, is payable Feb. 15 to shareholders of record on Jan. 12.
+ GlycoMimetics ( GLYC ) advanced as much as 6% after the glycomimetic drugmaker was tapped to join the Nasdaq Biotechnology Index early next week. Endocyte ( ECYT ), Tetraphase Pharmaceuticals (TTPH) and Cascadian Therapeutics (CASC) also were selected in the annual reclassification of the capitalization-weighted index.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: + Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. Shares of health care companies in the S&P 500 were up more than 1.4% as a group while the Nasdaq Biotechnology index ( NBI ) raced nearly 1.0% higher today. Endocyte ( ECYT ), Tetraphase Pharmaceuticals (TTPH) and Cascadian Therapeutics (CASC) also were selected in the annual reclassification of the capitalization-weighted index. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news: + Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. Health care stocks were starting to struggle somewhat Friday afternoon, increasingly lagging the broader markets, including a slightly more than 0.6% gain for the NYSE Health Care Index in recent trading. | In other sector news: + Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. Health care stocks were starting to struggle somewhat Friday afternoon, increasingly lagging the broader markets, including a slightly more than 0.6% gain for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up more than 1.4% as a group while the Nasdaq Biotechnology index ( NBI ) raced nearly 1.0% higher today. | In other sector news: + Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. Top Health Care Stocks Health care stocks were starting to struggle somewhat Friday afternoon, increasingly lagging the broader markets, including a slightly more than 0.6% gain for the NYSE Health Care Index in recent trading. |
33387.0 | 2017-12-14 00:00:00 UTC | Medtronic a Top Ranked SAFE Dividend Stock With 2.2% Yield (MDT) | ABT | https://www.nasdaq.com/articles/medtronic-top-ranked-safe-dividend-stock-22-yield-mdt-2017-12-14 | nan | nan | Medtronic PLC (Symbol: MDT) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
According to the ETF Finder at ETF Channel , Medtronic PLC is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.01% of the SPDR S&P Dividend ETF ( SDY ), which holds $167,898,987 worth of MDT shares.
Medtronic PLC (Symbol: MDT) made the "Dividend Channel S.A.F.E. 25" list because of these qualities: S . Solid return - hefty yield and strong DividendRank characteristics; A. Accelerating amount - consistent dividend increases over time; F . Flawless history - never a missed or lowered dividend; E. Enduring - at least two decades of dividend payments.
The annualized dividend paid by Medtronic PLC is $1.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 12/28/2017. Below is a long-term dividend history chart for MDT, which the report stressed as being of key importance.
MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ).
Top 25 S.A.F.E. Dividend Stocks Increasing Payments For Decades »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ). 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report. Below is a long-term dividend history chart for MDT, which the report stressed as being of key importance. | MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ). Medtronic PLC (Symbol: MDT) has been named to the Dividend Channel ''S.A.F.E. Medtronic PLC (Symbol: MDT) made the "Dividend Channel S.A.F.E. | MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ). 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report. According to the ETF Finder at ETF Channel , Medtronic PLC is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.01% of the SPDR S&P Dividend ETF ( SDY ), which holds $167,898,987 worth of MDT shares. | MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ). Medtronic PLC (Symbol: MDT) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report. |
33388.0 | 2017-12-13 00:00:00 UTC | Analysts Take Action on Health Care Stocks | ABT | https://www.nasdaq.com/articles/analysts-take-action-health-care-stocks-2017-12-13 | nan | nan | Analysts took action on some healthcare stocks yesterday, Dec. 12.
BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform.
As reported by thefly.com, Joanne Wuensch, analyst at BMO Capital, "is placing the stock on her Top Picks list, noting that 2018 will be the year of execution with several product launches ahead and acquisitions of Alere and St. June in the past."
The analyst maintains the target price of $65 per share of Abbott labs, which is a 16.7% upside from the current market value per share.
The analyst says, adds thefly.com, that "the company stands to benefit from easier comps and shifting foreign exchange environment" in the first six months of 2018 as well.
Abbott Labs has an average target price of $61.88 per share and a recommendation rating of 2 out of a total of 5.
The U.S. health care stock has a market capitalization of $96.85 billion, a price-book (P/B) ratio of 3.02 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.73 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 43.85 versus an industry median of 30.77.
For the 52-weeks through Dec. 12, Abbott labs gained 43% on the New York Stock Exchange and is trading about 1.8% below the 52-week high of $56.69. The 52-week low is $37.90.
The forward P/E ratio is 19.92 versus an industry median of 25.06. When the forward P/E ratio is multiplied by the EPS of $2.83 - as forecasted by analysts for full fiscal 2018 - it yields to a value of $56.37 per share. For full fiscal 2017, analysts expect Abbott Labs will report EPS of $2.50.
Abbott Labs has a forward annual dividend of $1.06 for a yield of 1.94%.
Citigroup Inc. ( C ) confirmed its buy rating on shares of Aetna Inc. ( AET ) and its price target of $197 per unit.
As reported by the StreetInsider.com, Ralph Giacobbe, analyst at Citigroup, "notes the removal of AET from the Citi Focus List, as the company's valuation is no longer trading on standalone fundamentals following the pending deal with CVS."
Aetna Inc. has an average target price of $192.76 per share, which is a 6.3% upside from the current share price of $181.33.
The recommendation rating is 2.4 out of 5.
The U.S. managed health care company has a market capitalization of $59.13 billion, a price-book (P/B) ratio of 3.80 versus an industry median of 2.89, a price-sales (P/S) ratio of 1.01 versus an industry median of 0.58 and a price-earnings (P/E) ratio of 33.66 versus an industry median of 19.90.
For the 52-weeks through Dec. 12, Aetna Inc. gained 43% on the New York Stock Exchange. The 52-week range is $116.04 to $192.37.
The forward P/E ratio is 18.08 versus an industry median of 15.85.
For full fiscal 2017 and 2018, analysts forecast Aetna will report EPS of $9.74 and $10.04.
Aetna has a forward annual dividend of $2 for a yield of 1.09%.
Medtronic PLC ( MDT ) has been upgraded by Argus to a buy rating from a previous rating of hold. The firm has set a price target of $95 per share.
As reported by thefly.com, John Eade, analyst at Argus, "sees better opportunities ahead for the stock, having generated synergies from its acquisition of Covidien and its work on improving operating margins."
For the next two years, the analyst sets its goal of growth at nearly 10% and adds "that the stock valuation of about 16-times expected 2019 earnings is well below the average multiple of 21-times for its peers."
Medtronic PLC has an average target price of $89.92 per share, which is 9.7% higher than the current share price of $82 and has a recommendation rating of 2.3 out of a total of 5.
The stock has a market capitalization of $110.99 billion, a price-book (P/B) ratio of 2.16 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.80 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 22.47 versus an industry median of 30.77.
For the 52-weeks through Dec. 12, the medical device company gained 12% on the New York Stock Exchange and is trading about 9.4% below the 52-week high of $89.72. The 52-week low is $69.35.
The forward P/E ratio is 17.27 versus an industry median of 25.06.
Analysts forecast 3.7% growth in EPS to $4.77 in full fiscal 2018 and 8.4% growth in EPS to $5.17 in full fiscal 2019.
Medtronic PLC has a forward annual dividend of $1.84 for a yield of 2.26%.
Guggenheim started covering shares of Mylan N.V. ( MYL ) with a buy rating, according to a research note dispatched by the financial services firm on Dec. 12.
Guggenheim set a price target of $59 per share of Mylan N.V.
As reported by thefly.com, Rohit Vanjani - analyst at Guggenheim - told "investors the biosimilars pipeline is a differentiating factor and believes copies of Herceptin and Neulasta as potential nearer-term catalysts". The Fly adds that Rohit Vanjani is also positive on diversified revenues of Mylan and on the strong company's pipeline of Abbreviated New Drug Applications which are still at the U.S. Food and Drug Administration.
Mylan has an average target price of $43.65 per share, which is a 9.8% upside from the current share price of $39.77.
The recommendation rating is 2.1 out of 5.
Mylan has a market capitalization of $21.08 billion, a price-book (P/B) ratio of 1.58 versus an industry median of 2.86, a price-sales (P/S) ratio of 1.76 versus an industry median of 2.79 and a price-earnings (P/E) ratio of 24.08 versus an industry median of 25.41.
For the 52-weeks through December 12, Mylan gained 4% on the Nasdaq Stock Exchange. The 52 Week Range is $29.39 - $45.87.
The forward PE ratio is 7.38 versus an industry median of 19.53.
For full fiscal 2017 and 2018 analysts forecast Mylan will report an EPS of $4.54 and $5.34.
Disclosure: No positions in any stock mentioned in this article.
Warning! GuruFocus has detected 3 Warning Sign with CTL. Click here to check it out.
CTL 15-Year Financial Data
The intrinsic value of CTL
Peter Lynch Chart of CTL
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform. As reported by thefly.com, Joanne Wuensch, analyst at BMO Capital, "is placing the stock on her Top Picks list, noting that 2018 will be the year of execution with several product launches ahead and acquisitions of Alere and St. June in the past." As reported by the StreetInsider.com, Ralph Giacobbe, analyst at Citigroup, "notes the removal of AET from the Citi Focus List, as the company's valuation is no longer trading on standalone fundamentals following the pending deal with CVS." | BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform. The U.S. health care stock has a market capitalization of $96.85 billion, a price-book (P/B) ratio of 3.02 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.73 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 43.85 versus an industry median of 30.77. The U.S. managed health care company has a market capitalization of $59.13 billion, a price-book (P/B) ratio of 3.80 versus an industry median of 2.89, a price-sales (P/S) ratio of 1.01 versus an industry median of 0.58 and a price-earnings (P/E) ratio of 33.66 versus an industry median of 19.90. | BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform. The U.S. health care stock has a market capitalization of $96.85 billion, a price-book (P/B) ratio of 3.02 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.73 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 43.85 versus an industry median of 30.77. The stock has a market capitalization of $110.99 billion, a price-book (P/B) ratio of 2.16 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.80 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 22.47 versus an industry median of 30.77. | BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform. Abbott Labs has an average target price of $61.88 per share and a recommendation rating of 2 out of a total of 5. When the forward P/E ratio is multiplied by the EPS of $2.83 - as forecasted by analysts for full fiscal 2018 - it yields to a value of $56.37 per share. |
33389.0 | 2017-12-13 00:00:00 UTC | Intersect ENT (XENT) SINUVA Implant Receives FDA Approval | ABT | https://www.nasdaq.com/articles/intersect-ent-xent-sinuva-implant-receives-fda-approval-2017-12-13 | nan | nan | Intersect ENT, Inc . XENT received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients.
SINUVA is an exclusive approach to treat recurrent nasal polyp disease in patients who have undergone ethmoid sinus surgery. Per management, approximately 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects.
Intersect ENT expects SINUVA to be costlier than other products in the portfolio. However, higher price will not dent the company's gross margins in the upcoming fourth quarter. It has a long-term expected earnings growth rate of 25%.
Notably, nasal polyps are inflammations along the lining of nasal passage or sinus resulting in congestion, infections and low sense of smell. SINUVA is Intersect ENT's fourth commercial product, which is likely to be introduced to physicians across the country in the following months.
Shares Shine Bright
Year to date, Intersect ENT has had a solid run on the bourses, trading above the market at large. The company returned 163.2% comparing favorably with the industry 's rally of only 23.2%. Also, the current return is higher than the S&P 500 index's increase of 21.7% over the same time frame. The stock has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Market Trends Buoy Optimism
Introduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market. Per a report by Persistence Market Research, the Center of Disease Control and Prevention (CDC) has revealed that 11.7 million people in the United States get diagnosed with chronic sinusitis on a regular basis.
Considering the solid prospects of the market, we believe that Intersect ENT will gain strong market traction in the upcoming days. A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY .
Our Take
Intersect ENT's fourth-quarter operating expenses are likely to rise, thanks to the one-time expenses related to the SINUVA launch, production of demo units and costs related to market-access infrastructure.
Among latest developments, PROPEL Contour is expected to be an important driver for Intersect ENT. Products like PROPEL and PROPEL mini are drug-eluting implants for patients suffering from chronic sinusitis. It offers products and therapies for ear, nose and throat surgeons to improve treatment of patients with chronic diseases.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intersect ENT, Inc. (XENT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY . Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. Shares Shine Bright Year to date, Intersect ENT has had a solid run on the bourses, trading above the market at large. | A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY . Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. | A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY . Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. Market Trends Buoy Optimism Introduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY . Intersect ENT, Inc . |
33390.0 | 2017-12-13 00:00:00 UTC | Abbott Laboratories Clears Key Benchmark, Hitting 80-Plus RS Rating | ABT | https://www.nasdaq.com/articles/abbott-laboratories-clears-key-benchmark-hitting-80-plus-rs-rating-2017-12-13 | nan | nan | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before.
[ibd-display-video id=2881825 width=50 float=left autostart=true] IBD's unique rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the top-performing stocks tend to have an RS Rating of at least 80 as they begin their biggest runs.
See How IBD Helps You Make More Money In Stocks
Abbott Laboratories is building a flat base with a 56.79 entry . See if the stock can clear the breakout price in volume at least 40% higher than normal.
While the company's bottom line growth dropped in the company's most recent performance report from 13% to 12%, sales rose 29%, up from 24% in the previous report.
Abbott Laboratories holds the No. 1 rank among its peers in the Medical-Diversified industry group. Johnson & Johnson ( JNJ ) and () are also among the group's highest-rated stocks.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before. History shows that the top-performing stocks tend to have an RS Rating of at least 80 as they begin their biggest runs. See How IBD Helps You Make More Money In Stocks Abbott Laboratories is building a flat base with a 56.79 entry . | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before. IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before. IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database. IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? |
33391.0 | 2017-12-09 00:00:00 UTC | Abbott Labs to announce dividend increase | ABT | https://www.nasdaq.com/articles/abbott-labs-announce-dividend-increase-2017-12-09 | nan | nan | What's Happening
Healthcare company Abbott Labs ( ABT ) has a lengthy 44-year streak of dividend increases that it will likely extend this week. The stock has trended steadily higher through the year, and shares are currently up 39.3% on the year.
Technical Analysis
ABT was recently trading at $54.40, down $2.29 from its 12-month high and $16.50 above its 12-month low. Technical indicators for ABT are bullish and the stock is in a strong upward trend. The stock has recent support above $53.50 and recent resistance below $56.70. Of the 21 analysts who cover the stock, 12 rate it a "strong buy", two rate it a "buy", and seven rate it a "hold". DG gets a score of 75 from InvestorsObserver's Stock Score Report.
Analyst's Thoughts
Abbott is a true dividend aristocrat, with a nice 44-year streak of increases. The stock has a low 42.6% payout ratio, so the company can easily afford to extend its streak of annual increases. ABT currently has a yield of 1.95%, and pays a $0.265 quarterly distribution. Look for the payment to rise to around $0.28, which would translate to a 5.6% increase. Look for the announcement this week, with the stock trading ex-dividend mid-January.
Stock Only Trade
If you're looking to establish a long stock position in ABT, consider buying the stock under $54.50. Sell if it falls below $49.00 or take profits if it gets to $62.50.
Bullish Trade
If you want to set up a bullish hedged trade on ABT, consider a February 44/49 bull-put credit spread for a 25-cent credit. That's a potential 5.3% return (27.4% annualized*) and the stock would have to fall 9.5% to cause a problem.
Bearish Trade
If you want to take a bearish stance on ABT at this time, consider a February 60/65 bear-call credit spread for a 25-cent credit. That's a potential 5.3% return (27.4% annualized*) and the stock would have to rise 10.8% to cause a problem.
Covered Call Trade
If you like the stock, but wish to lower your cost basis on a new position, you may want to consider a February $55.00 covered call. Buy ABT shares (typically 100 shares, scale as appropriate), while selling the February $55.00 call for a debit of $52.90 per share. The trade has a target assigned return of 4.0%, and a target annualized return of 21.0% (for comparison purposes only).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Originally published on InvestorsObserver.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What's Happening Healthcare company Abbott Labs ( ABT ) has a lengthy 44-year streak of dividend increases that it will likely extend this week. Technical Analysis ABT was recently trading at $54.40, down $2.29 from its 12-month high and $16.50 above its 12-month low. Technical indicators for ABT are bullish and the stock is in a strong upward trend. | What's Happening Healthcare company Abbott Labs ( ABT ) has a lengthy 44-year streak of dividend increases that it will likely extend this week. Technical Analysis ABT was recently trading at $54.40, down $2.29 from its 12-month high and $16.50 above its 12-month low. Technical indicators for ABT are bullish and the stock is in a strong upward trend. | Stock Only Trade If you're looking to establish a long stock position in ABT, consider buying the stock under $54.50. Bullish Trade If you want to set up a bullish hedged trade on ABT, consider a February 44/49 bull-put credit spread for a 25-cent credit. What's Happening Healthcare company Abbott Labs ( ABT ) has a lengthy 44-year streak of dividend increases that it will likely extend this week. | What's Happening Healthcare company Abbott Labs ( ABT ) has a lengthy 44-year streak of dividend increases that it will likely extend this week. Technical Analysis ABT was recently trading at $54.40, down $2.29 from its 12-month high and $16.50 above its 12-month low. Technical indicators for ABT are bullish and the stock is in a strong upward trend. |
33392.0 | 2017-12-08 00:00:00 UTC | Abbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of Shares | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-chairman-and-ceo-miles-d-white-sold-151-million-shares-2017-12-08 | nan | nan | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share. The total sale was $15.1 million.
Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Abbott Laboratories has a market cap of $95.11 billion; its shares were traded at around $54.64 with a P/E ratio of 42.99 and P/S ratio of 3.65. The dividend yield of Abbott Laboratories stocks is 1.95%. Abbott Laboratories had annual average EBITDA growth of 0.70% over the past five years. GuruFocus rated Abbott Laboratories the business predictability rank of 2-star .
CEO Recent Trades:
Chairman and CEO Miles D White sold 10,644 shares of ABT stock on 12/06/2017 at the average price of $54.94. The price of the stock has decreased by 0.55% since.
Chairman and CEO Miles D White sold 71,530 shares of ABT stock on 12/06/2017 at the average price of $54.83. The price of the stock has decreased by 0.35% since.
Chairman and CEO Miles D White sold 49,203 shares of ABT stock on 12/06/2017 at the average price of $54.7. The price of the stock has decreased by 0.11% since.
Chairman and CEO Miles D White sold 121,737 shares of ABT stock on 12/06/2017 at the average price of $54.5. The price of the stock has increased by 0.26% since.
Chairman and CEO Miles D White sold 276,886 shares of ABT stock on 12/06/2017 at the average price of $54.41. The price of the stock has increased by 0.42% since.
Directors and Officers Recent Trades:
Senior Vice President Sharon J Bracken sold 2,188 shares of ABT stock on 11/30/2017 at the average price of $56.12. The price of the stock has decreased by 2.64% since.
Senior Vice President Alejandro D Wellisch sold 2,153 shares of ABT stock on 11/22/2017 at the average price of $55.86. The price of the stock has decreased by 2.18% since.
Executive Vice President Brian J Blaser sold 23,866 shares of ABT stock on 11/17/2017 at the average price of $55.55. The price of the stock has decreased by 1.64% since.
Executive Vice President Daniel Gesua Sive Salvadori sold 71,157 shares of ABT stock on 11/14/2017 at the average price of $55. The price of the stock has decreased by 0.65% since.
click here
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Directors and Officers Recent Trades: Senior Vice President Sharon J Bracken sold 2,188 shares of ABT stock on 11/30/2017 at the average price of $56.12. Senior Vice President Alejandro D Wellisch sold 2,153 shares of ABT stock on 11/22/2017 at the average price of $55.86. Executive Vice President Daniel Gesua Sive Salvadori sold 71,157 shares of ABT stock on 11/14/2017 at the average price of $55. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share. CEO Recent Trades: Chairman and CEO Miles D White sold 10,644 shares of ABT stock on 12/06/2017 at the average price of $54.94. Directors and Officers Recent Trades: Senior Vice President Sharon J Bracken sold 2,188 shares of ABT stock on 11/30/2017 at the average price of $56.12. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share. CEO Recent Trades: Chairman and CEO Miles D White sold 10,644 shares of ABT stock on 12/06/2017 at the average price of $54.94. Chairman and CEO Miles D White sold 71,530 shares of ABT stock on 12/06/2017 at the average price of $54.83. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share. CEO Recent Trades: Chairman and CEO Miles D White sold 10,644 shares of ABT stock on 12/06/2017 at the average price of $54.94. Chairman and CEO Miles D White sold 71,530 shares of ABT stock on 12/06/2017 at the average price of $54.83. |
33393.0 | 2017-11-29 00:00:00 UTC | Health Care Sector Update for 11/29/2017: JNJ, PFE, ABT, MRK, AMGN, KOOL, CAPR, RXII | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11292017-jnj-pfe-abt-mrk-amgn-kool-capr-rxii-2017-11-29 | nan | nan | Top Health Care Stocks:
JNJ: +0.1%
PFE: -0.1%
ABT: +0.3%
MRK: +0.2%
AMGN: +0.1%
Health care shares were mostly higher in pre-market trading Wednesday.
In sector news, Capricor Therapeutics ( CAPR ) shares rallied 27% after the company said that the US Food and Drug Administration has approved its investigational new drug application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. The randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. The primary efficacy endpoint of the trial will be the relative change in the mid-level dimension of the performance of the upper limb test from baseline to month 12. The trial is expected to enroll approximately 84 patients and be conducted at 10-12 US sites. It plans to initiate it in Q1 of 2018.
In other sector news,
(+) RXII (+19.4%) Data show RXI-231 has potential to reduce pigmentation
(-) KOOL (-8.3%) Plans registered public offering of shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Capricor Therapeutics ( CAPR ) shares rallied 27% after the company said that the US Food and Drug Administration has approved its investigational new drug application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. The randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. The primary efficacy endpoint of the trial will be the relative change in the mid-level dimension of the performance of the upper limb test from baseline to month 12. | In sector news, Capricor Therapeutics ( CAPR ) shares rallied 27% after the company said that the US Food and Drug Administration has approved its investigational new drug application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. In other sector news, (+) RXII (+19.4%) Data show RXI-231 has potential to reduce pigmentation (-) KOOL (-8.3%) Plans registered public offering of shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Capricor Therapeutics ( CAPR ) shares rallied 27% after the company said that the US Food and Drug Administration has approved its investigational new drug application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. The randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. In other sector news, (+) RXII (+19.4%) Data show RXI-231 has potential to reduce pigmentation (-) KOOL (-8.3%) Plans registered public offering of shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: Health care shares were mostly higher in pre-market trading Wednesday. In other sector news, (+) RXII (+19.4%) Data show RXI-231 has potential to reduce pigmentation (-) KOOL (-8.3%) Plans registered public offering of shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33394.0 | 2017-11-29 00:00:00 UTC | Boston Scientific Again Delays Heart Valve; Can It Catch Up To Rivals? | ABT | https://www.nasdaq.com/articles/boston-scientific-again-delays-heart-valve-can-it-catch-rivals-2017-11-29 | nan | nan | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ).
[ibd-display-video id=2986986 width=50 float=left autostart=true] By the closing bell on the stock market today , Boston fell 1.7% to finish at 25.95. Abbott lost 0.8% to close at 55.58 while Medtronic dipped 0.4% to end the day at 82.11.
Earlier this year, Boston voluntarily recalled the Lotus and Lotus Edge Aortic Valve Systems, citing an issue with the locking mechanism. It had planned to relaunch Lotus Edge in Europe in the first quarter of 2018 and file an application with the Food and Drug Administration in January.
Late Tuesday, Boston said it would again delay those plans.
"While we are disappointed in this delay to our timelines, we are working carefully to analyze and implement necessary modifications to pass our rigorous internal quality standards," Chief Executive Mike Mahoney said in a prepared statement.
Although it didn't provide a timeline for when it plans to relaunch in Europe and file in the U.S., Boston said it doesn't expect the delay to have a material impact on fourth-quarter and 2017 guidance. It will provide an update during its fourth-quarter earnings conference call on Feb. 1.
Boston's Lotus Edge is a system for replacing a diseased heart value without using open-heart surgery. Abbott and Medtronic also make these devices, called transcatheter aortic heart valve replacements, or TAVR.
IBD'S TAKE:Boston has an IBD Composite Rating of 84, meaning it outperforms more than eight in 10 stocks in terms of key growth metrics. But it still lags top leaders with best-possible CRs of 99. Get the names of those leaders by visiting IBD Stock Checkup .
Canaccord analyst Jason Mills lowered his worldwide transcatheter aortic heart valve replacement sales model for Boston in 2018, 2019, 2020 and 2021 by $70 million, $114 million, $67 million and $9 million, respectively. He also cut his price target to 35 from 36, but kept his buy rating.
Needham analyst Mike Matson estimates the transcatheter aortic heart valve replacement market grew 22% in the third quarter, down from 24% in the prior quarter.
For 2017, he expects the market to have grown 25% to $3.4 billion worldwide and 28% year over year to $1.7 billion in the U.S. Next year, Matson calls for the market to grow 18% to $4.1 billion worldwide and 20% in the U.S. to $2 billion.
"Boston was expected to be third to market in the U.S. with Lotus Edge," he said. "We think this is still possible, but note that Abbott's Portico TAVR pivotal trial enrollment is completed and we think it could be launched in the U.S. by late 2019."
Matson kept his buy rating and 32 price target on Boston stock.
RELATED:
Medtronic Surges After Topping Quarterly Earnings Views
How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales
How Electricity Could Replace Opioids In Treating Chronic Pain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ). It had planned to relaunch Lotus Edge in Europe in the first quarter of 2018 and file an application with the Food and Drug Administration in January. "While we are disappointed in this delay to our timelines, we are working carefully to analyze and implement necessary modifications to pass our rigorous internal quality standards," Chief Executive Mike Mahoney said in a prepared statement. | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ). Abbott and Medtronic also make these devices, called transcatheter aortic heart valve replacements, or TAVR. Canaccord analyst Jason Mills lowered his worldwide transcatheter aortic heart valve replacement sales model for Boston in 2018, 2019, 2020 and 2021 by $70 million, $114 million, $67 million and $9 million, respectively. | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ). Canaccord analyst Jason Mills lowered his worldwide transcatheter aortic heart valve replacement sales model for Boston in 2018, 2019, 2020 and 2021 by $70 million, $114 million, $67 million and $9 million, respectively. Medtronic Surges After Topping Quarterly Earnings Views How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales How Electricity Could Replace Opioids In Treating Chronic Pain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ). Although it didn't provide a timeline for when it plans to relaunch in Europe and file in the U.S., Boston said it doesn't expect the delay to have a material impact on fourth-quarter and 2017 guidance. Abbott and Medtronic also make these devices, called transcatheter aortic heart valve replacements, or TAVR. |
33395.0 | 2017-11-28 00:00:00 UTC | Health Care Sector Update for 11/28/2017: JNJ, PFE, ABT, MRK, AMGN, EARS, EGLT, AZN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11282017-jnj-pfe-abt-mrk-amgn-ears-eglt-azn-2017-11-28 | nan | nan | Top Health Care Stocks:
JNJ: +0.3%
PFE: -0.5%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly inactive in pre-market trading Tuesday.
In sector news, Auris Medical ( EARS ) shares fell 55% after the company said Tuesday that a phase 3 clinical trial on AM-111 for the treatment of sudden deafness failed to meet its primary endpoint of a statistically significant improvement in hearing from baseline to day 28 compared to placebo for either active treatment groups. Based on the finding, the company has concluded that the very similar design of the currently ongoing ASSENT trial is no longer adequate for testing AM-111. Therefore, the ASSENT trial will be terminated early.
In other sector news,
(+) EGLT (+9.2%) Study of abuse-deterrent oxycodone meets endpoint in pain reduction
(-) AZN (-0.2%) European Medicines Agency accepts variation to Tagrisso drug application
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trading Tuesday. In sector news, Auris Medical ( EARS ) shares fell 55% after the company said Tuesday that a phase 3 clinical trial on AM-111 for the treatment of sudden deafness failed to meet its primary endpoint of a statistically significant improvement in hearing from baseline to day 28 compared to placebo for either active treatment groups. Based on the finding, the company has concluded that the very similar design of the currently ongoing ASSENT trial is no longer adequate for testing AM-111. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trading Tuesday. In other sector news, (+) EGLT (+9.2%) Study of abuse-deterrent oxycodone meets endpoint in pain reduction (-) AZN (-0.2%) European Medicines Agency accepts variation to Tagrisso drug application The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trading Tuesday. In sector news, Auris Medical ( EARS ) shares fell 55% after the company said Tuesday that a phase 3 clinical trial on AM-111 for the treatment of sudden deafness failed to meet its primary endpoint of a statistically significant improvement in hearing from baseline to day 28 compared to placebo for either active treatment groups. In other sector news, (+) EGLT (+9.2%) Study of abuse-deterrent oxycodone meets endpoint in pain reduction (-) AZN (-0.2%) European Medicines Agency accepts variation to Tagrisso drug application The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trading Tuesday. Top Health Care Stocks: In sector news, Auris Medical ( EARS ) shares fell 55% after the company said Tuesday that a phase 3 clinical trial on AM-111 for the treatment of sudden deafness failed to meet its primary endpoint of a statistically significant improvement in hearing from baseline to day 28 compared to placebo for either active treatment groups. |
33396.0 | 2017-11-27 00:00:00 UTC | 3 Top Diabetes Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/3-top-diabetes-stocks-buy-now-2017-11-27 | nan | nan | Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs associated with diabetes are projected to increase by more than 50% by 2030.
But where there's a problem, there's also an opportunity. Healthcare companies continue to develop innovative new approaches to treating and managing diabetes. This innovation in turn creates value for investors.
At least 15 publicly traded companies have current products addressing diabetes either on the market or in development. A few of these stocks hold the potential to generate market-beating returns for investors. I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Here's why these are three top diabetes stocks to buy now.
Abbott Labs
Abbott Labs claims a market cap of close to $98 billion. The company's primary focus in the past has been on branded generic drugs, diagnostic systems and tests, nutritional products, and cardiovascular and neuromodulation medical devices. Abbott's diabetes care unit revenue wasn't even listed separately in the company's financial statements.
However, diabetes should be much more important to Abbott in the future. In September, the U.S. Food and Drug Administration (FDA) approved the company's FreeStyle Libre Flash Glucose Monitoring System. It's the first continuous glucose monitoring (CGM) system approved by the FDA that doesn't require a finger-stick blood sample.
As you might imagine, the potential for the FreeStyle Libre system is huge. DexCom (NASDAQ: DXCM) has been the leader in of the fast-growing CGM market so far. FDA approval for Abbott's FreeStyle Libre system caused DexCom stock to plummet because of the threat from Abbott. Although DexCom is developing its own no-finger-stick device, it's about a year away from being able to market the product. That gives Abbott a nice head start.
Abbott was already enjoying a fantastic year even before the FDA decision. The stock is up more than 40% year to date, driven in large part by the company's acquisition earlier this year of St. Jude Medical. This acquisition made Abbott an even more formidable force in the medical device market.
There's also a lot for investors to like about Abbott's dividend. Its yield currently stands at 1.91%. Abbott has increased its dividend for 45 consecutive years and has paid a dividend every quarter since 1924.
Becton, Dickinson and Company
Becton, Dickinson and Company's market cap of nearly $52 billion makes it the smallest of these three top diabetes stocks. However, the company will grow close in size to the other two on the list once it finalizes a planned $24 billion acquisition of C. R. Bard, Inc. (NYSE: BCR) .
Around 13% of Becton, Dickinson and Company's total revenue stems from its diabetes care segment. BD's diabetes products include insulin pumps, insulin syringes, pen needles, and sharps containment. Sales for its diabetes care segment is growing by low-single-digit percentages, held back in part because of austerity measures in some European countries.
The addition of C. R. Bard will provide a big boost to BD's revenue and earnings. However, Bard focuses on vascular, urology, and oncology products. BD's diabetes care unit won't be impacted much, if any, by the deal.
BD stock has been a big winner so far in 2017, with shares jumping close to 40% year to date. In addition, the company pays a dividend, which currently yields 1.33%. Like Abbott, both BD and C. R. Bard are Dividend Aristocrats , with BD increasing its dividend every year since 1972.
Johnson & Johnson
Johnson & Johnson is the giant of the group, with a market cap of over $370 billion. J&J's diabetes care unit is a big business on track to generate sales of around $1.6 billion in 2017, but that's only a small sliver of the company's total revenue. However, the company's pharmaceutical segment markets diabetes drug Invokana, which should add another $1.1 billion or so to J&J's total diabetes-related revenue this year.
There's an asterisk needed with Johnson & Johnson, though. Were it not for Invokana, J&J might not be classified as a diabetes stock for much longer. The company announced that it was exiting the insulin pump business. J&J is also evaluating strategic options for its other diabetes care businesses. These options include selling the units and forming partnerships or joint ventures with other companies.
Still, J&J certainly qualifies as a diabetes stock now. And it should be a good one to own over the long run, albeit more because of its pharmaceutical lineup than its diabetes care products. Cancer drugs Darzalex and Imbruvica combined with autoimmune-disease drug Stelara are enjoying strong sales growth. The acquisition of Swiss drugmaker Actelion earlier this year has added a successful pulmonary hypertension franchise to the company's roster. J&J also has one of the best drug pipelines in the biopharmaceutical industry , with promising candidates including prostate cancer drug apalutamide.
Don't forget Johnson & Johnson's dividend, either. Its dividend yields 2.37% right now. J&J is also a Dividend Aristocrat and has raised its dividend for an impressive 55 years in a row.
Best pick?
I don't think investors would go wrong by buying any or all of these diabetes stocks. All three pay great dividends, and all three have decent growth prospects. If I could only pick one of them, though, I'd go with Abbott.
Wall Street analysts project higher earnings growth over the next five years for Abbott than they do for BD or J&J. I suspect they're right. The acquisition of St. Jude Medical was a smart move for Abbott, in my view. I'm also excited about the potential for the FreeStyle Libre CGM system. If you're looking for a growth stock with a solid dividend that's also going to significantly impact how diabetes is managed, I think Abbott Labs is the best option.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 6, 2017
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool recommends Becton Dickinson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. The company's primary focus in the past has been on branded generic drugs, diagnostic systems and tests, nutritional products, and cardiovascular and neuromodulation medical devices. Sales for its diabetes care segment is growing by low-single-digit percentages, held back in part because of austerity measures in some European countries. | I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. In September, the U.S. Food and Drug Administration (FDA) approved the company's FreeStyle Libre Flash Glucose Monitoring System. BD's diabetes products include insulin pumps, insulin syringes, pen needles, and sharps containment. | I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Becton, Dickinson and Company Becton, Dickinson and Company's market cap of nearly $52 billion makes it the smallest of these three top diabetes stocks. If you're looking for a growth stock with a solid dividend that's also going to significantly impact how diabetes is managed, I think Abbott Labs is the best option. | I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Like Abbott, both BD and C. R. Bard are Dividend Aristocrats , with BD increasing its dividend every year since 1972. However, the company's pharmaceutical segment markets diabetes drug Invokana, which should add another $1.1 billion or so to J&J's total diabetes-related revenue this year. |
33397.0 | 2017-11-24 00:00:00 UTC | Health Care Sector Update for 11/24/2017: JNJ, PFE, ABT, MRK, AMGN, TEVA, NKTR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-11242017-jnj-pfe-abt-mrk-amgn-teva-nktr-2017-11-24 | nan | nan | Top Health Care Stocks:
JNJ: flat
PFE: flat
ABT: +0.02%
MRK: flat
AMGN: flat
Health care shares were mostly flat in pre-market trading Friday.
In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. The report did not say where it obtained the information.
In other sector news,
(-) NKTR (-6.1%) Says Bayer product containing inhalation system fails to meet endpoint.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. In other sector news, (-) NKTR (-6.1%) Says Bayer product containing inhalation system fails to meet endpoint. Unauthorized reproduction is strictly prohibited. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. | MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trading Friday. In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: JNJ: flat PFE: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trading Friday. In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. |
33398.0 | 2017-11-22 00:00:00 UTC | Global In Vitro Diagnostic Market Booms: Stocks in Focus | ABT | https://www.nasdaq.com/articles/global-in-vitro-diagnostic-market-booms%3A-stocks-in-focus-2017-11-22 | nan | nan | The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA approved Oncomine Dx Target Test) clearly point toward the rapid emergence of in vitro diagnostics (IVD) in the MedTech space.
The recent EvaluateMedTech World Preview indicates that while worldwide MedTech sales are expected to witness CAGR of 5.1% to $522 billion by 2022, steering ahead of cardiology, IVD will rake in annual sales of $69.6 billion at a CAGR of 5.9%.
The above data is just a small indicator of the vast scope for growth of the IVD market. For investors keen on MedTech, the most important fact is that IVD's benefits are not limited to any particular country or geographic territory. With the emergence of complex and transmittable diseases worldwide, this part of the MedTech space is currently in the spotlight.
IVD in a Nutshell
If we go by FDA's definition, in vitro diagnostics are, "tests that can detect diseases, conditions, or infections. Some tests are used in laboratory or other health professional settings and other tests are for consumers to use at home."
Growth Factors
Rapid occurrence of infectious diseases worldwide, increasing burden of killer bugs like cancer, cardiovascular diseases, stroke and other heart diseases, and diabetes in developing and developed nations as well as growing cognizance of early cancer screening, detection, and prevention have made IVD indispensable in the healthcare space.
Growing investment from both government and private players in the form of reimbursement coverage and speedy patent approvals are also driving demand.
These apart, per a report by Research and Markets, increasing geriatric population, rising per capita GDP and per capita healthcare expenditure are acting as major growth catalysts. Per the report, owing to suitable demographical changes and rising disposable income coupled with improving basic infrastructure, developing regions are gradually becoming happy hunting grounds for this business.
Geographic Distribution
So far, North America has the lead in the in vitro diagnostic market. Per Coherent Markets Insights' data, it is the highest contributing region with projected market share of 46.7% by 2024 (at CAGR of 5.4% between 2016 and 2024). Favorable demography and regulatory policies along with increasing healthcare spending have aided growth of the IVD business in this geography.
However, increasing instances of lifestyle oriented diseases, improving government funding and growing awareness of new technologies have fueled demand for IVD in emerging economies.
According to a recent report by Research and Market, China is the fastest growing among the top 10 IVD country markets. It is likely to expand more than threefold by 2022 from 2016.
On the other hand, the revenue of the Indian IVD market has grown at a CAGR of 20% having increased from $0.64 billion in 2012 to $1.6 billion in 2017 (data by Goldstein Research).
Segmental Contribution
Per a MedGadget report, apart from geographic distribution, the global in vitro diagnostic market has been segmented on the basis of application, type, end user and usability. Application wise, diabetes, infectious diseases, oncology, nephrology, autoimmune diseases and cardiology are generating huge revenues across the globe.
From the point of view of end user, hospitals, laboratory, point of care testing are the leading users. In terms of usability, disposable IVD devices and re-usable IVD devices are widely used across the globe.
Key Players
Roche remains the top player in the IVD market with expected sales of $12.8 billion in 2022. Key IVD developments at Roche include the Cobas range of tests, the latest one being Cobas Zika (the first commercially available test for the detection of the Zika virus RNA in samples of human plasma).
On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. In this regard, the company noted that, point-of-care testing is a $7 billion segment of the in vitro diagnostics market and is growing rapidly.
Among the other bigwigs, Becton Dickinson & Company BDX deserves a mention. The company is striving to get approval for the commercialization of its innovative products in the fast-growing infectious diseases testing market. Its BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancer.
Wall Street's Next Amazon
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Per the report, owing to suitable demographical changes and rising disposable income coupled with improving basic infrastructure, developing regions are gradually becoming happy hunting grounds for this business. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA approved Oncomine Dx Target Test) clearly point toward the rapid emergence of in vitro diagnostics (IVD) in the MedTech space. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA approved Oncomine Dx Target Test) clearly point toward the rapid emergence of in vitro diagnostics (IVD) in the MedTech space. | On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA approved Oncomine Dx Target Test) clearly point toward the rapid emergence of in vitro diagnostics (IVD) in the MedTech space. |
33399.0 | 2017-11-22 00:00:00 UTC | DexCom-Lily Partnership to Boost CGM Platform, Customer Base | ABT | https://www.nasdaq.com/articles/dexcom-lily-partnership-to-boost-cgm-platform-customer-base-2017-11-22 | nan | nan | DexCom, Inc.DXCM recently announced the signing of a development agreement with Eli Lilly and Company LLY . Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added to Lilly's Connected Diabetes Ecosystem.
Through the integration of CGM with Lily's smart insulin delivery devices, DexCom aims to provide a holistic approach to diabetes management for its customers. Notably,clinical trials are expected to begin by the end of 2017.
DexCom's FDA-cleared CGM system - the DexCom G4 Platinum - is contributing significantly to the top line. DexCom G4 Platinum is the most innovative CGM system in the market. In June, DexCom had announced the FDA approval of the DexCom G5 mobile app for Android devices.
Moreover, DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product use. In September 2017, DexCom announced a tie-up with leading wearables brand Fitbit to develop and market products to help people better manage diabetes and get a clearer picture of their overall health. The first planned initiative is to bring DexCom CGM data to Fitbit's new smartwatch, Fitbit Ionic. The companies aim to make the smartwatch available in 2018 and will continue to explore ways to develop tools to improve diabetes management.
We believe the glucose monitoring market represents significant commercial opportunity for DexCom. Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is projected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%. Also, the International Diabetes Federation (IDF) estimates that by 2035, the worldwide incidence of people suffering from diabetes will reach 592 million.
Recently, management at DexCom confirmed that the company is well poised to congregate the unmet demand in the global diabetic space, especially when it comes to CGM. DexCom's increased patient convenience, enhanced connectivity, data analytics, and lower cost platforms fortify the company's foothold in the global diabetic space.
However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. In this space, Abbott recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States.
Share Price Performance
DexCom has been gaining investor confidence on consistently positive results. Over the last month, the company's share price outperformed the broader industry . The stock has gained 23.1%, as compared with the broader industry's 1%. The company has also outperformed the 0.9% gain of the S&P 500 market.
Zacks Rank & Key Pick
DexCom carries a Zacks Rank #3 (Hold).
A better-ranked medical stock is PetMed Express, Inc. PETS , with a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 80.9% in a year.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Through the integration of CGM with Lily's smart insulin delivery devices, DexCom aims to provide a holistic approach to diabetes management for its customers. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added to Lilly's Connected Diabetes Ecosystem. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added to Lilly's Connected Diabetes Ecosystem. | However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom, Inc.DXCM recently announced the signing of a development agreement with Eli Lilly and Company LLY . |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.